

# Activated ATF6 $\alpha$ is a hepatic tumour driver restricting immunosurveillance

<https://doi.org/10.1038/s41586-025-10036-8>

Received: 5 October 2023

Accepted: 10 December 2025

Published online: 4 February 2026

Open access

 Check for updates

Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality and there are limited therapies<sup>1</sup>. Although endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR transducer ATF6 $\alpha$  remains unclear<sup>2</sup>. Here we demonstrate the function of ATF6 $\alpha$  as an ER-stress-inducing tumour driver and metabolic master regulator restricting cancer immunosurveillance for HCC, in contrast to its well-characterized role as an adaptive response to ER stress<sup>3</sup>. ATF6 $\alpha$  activation in human HCC is significantly correlated with an aggressive tumour phenotype, characterized by reduced patient survival, enhanced tumour progression and local immunosuppression. Hepatocyte-specific ATF6 $\alpha$  activation in mice induced progressive hepatitis with ER stress, immunosuppression and hepatocyte proliferation. Concomitantly, activated ATF6 $\alpha$  increased glycolysis and directly repressed the gluconeogenic enzyme FBP1 by binding to gene regulatory elements. Restoring FBP1 expression limited ATF6 $\alpha$ -activation-related pathologies. Prolonged ATF6 $\alpha$  activation in hepatocytes triggered hepatocarcinogenesis, intratumoural T cell infiltration and nutrient-deprived immune exhaustion. Immune checkpoint blockade (ICB)<sup>4</sup> restored immunosurveillance and reduced HCC. Consistently, patients with HCC who achieved a complete response to immunotherapy displayed significantly increased ATF6 $\alpha$  activation compared with those with a weaker response. Targeting *Atf6* through germline ablation, hepatocyte-specific ablation or therapeutic hepatocyte delivery of antisense oligonucleotides dampened HCC in preclinical liver cancer models. Thus, prolonged ATF6 $\alpha$  activation drives ER stress, leading to glycolysis-dependent immunosuppression in liver cancer and sensitizing to ICB. Our findings suggest that persistently activated ATF6 $\alpha$  is a tumour driver, a potential stratification marker for ICB response and a therapeutic target for HCC.

HCC accounts for 80–85% of primary liver cancers<sup>1</sup> and derives mostly from malignant, transformed hepatocytes in chronic hepatitis<sup>5,6</sup>. Despite advances in immunotherapies that improved survival, the complex genetic, metabolic and inflammatory interactions remain a barrier towards effective treatment. HCC-infiltrating lymphocytes express exhaustion markers (such as PD-1, CTLA-4) leading to poor prognosis<sup>7,8</sup>. Improving T-cell-mediated tumour surveillance with ICB (atezolizumab) and VEGF blockade (bevacizumab) is the standard of care for unresectable HCC<sup>4,9–11</sup>. Metabolic reprogramming, including glucose deprivation in HCC and intratumoural hypoxia, was proposed to reduce anti-tumour therapy efficacy and enhance malignancy<sup>12</sup>. Thus, new strategies are needed to overcome metabolism-related tumour escape and immunosuppression.


ER stress and UPR activation represent negative prognostic factors in cancer<sup>2,13</sup> and are implicated in liver diseases<sup>14</sup>. The UPR encompasses three ER transmembrane proteins with downstream signalling cascades: (1) PKR-like ER kinase (PERK); (2) inositol-requiring enzyme 1 alpha (IRE1 $\alpha$ ); and (3) activating transcription factor 6 alpha (ATF6 $\alpha$ ), which is cleaved to generate an N-terminal p50 fragment (nATF6 $\alpha$ ) that enters the nucleus to activate ER chaperones and lipid synthesis

genes<sup>14,15</sup>. While PERK and IRE1 $\alpha$  may promote cancer hallmarks<sup>2</sup>, less is known about ATF6 $\alpha$ , of which the chronic activation in intestinal epithelial cells induces microbiota-dependent colon adenomas<sup>15</sup>. Here, in contrast to its characterized adaptive role in acute ER stress<sup>3,16</sup>, we describe ATF6 $\alpha$  as a tumour driver and master regulator of glucose metabolism contributing to immunosuppression, with implications for HCC therapy.

## ATF6 $\alpha$ activation marks aggressive HCC

Patient-derived liver sections showed nuclear ATF6 $\alpha$  expression (Supplementary Fig. 1a–d), suggesting ER stress and ATF6 $\alpha$  activation in chronic hepatitis. In 22 distinct human HCC datasets, *ATF6* mRNA (encoding ATF6 $\alpha$ ) and the human ATF6 $\alpha$ -activation signature derived from the Molecular Signatures Database (MSigDB)<sup>17</sup> were consistently and significantly increased in HCC compared with non-tumour livers (Fig. 1a and Supplementary Fig. 1e). The human ATF6 $\alpha$ -activation signature and UPR signature from MSigDB<sup>17</sup> were significantly associated with reduced patient survival in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) dataset

A list of authors and their affiliations appears at the end of the paper.



**Fig. 1** Hepatic ATF6α activation is prognostic in human HCC. **a**, Forest plot of the human ATF6α-activation signature in HCC versus non-tumour liver in 22 datasets. CI, confidence interval. **b,c**, Kaplan–Meier survival curves for TCGA-LIHC patients split by median enrichment of the human ATF6α-activation signature (**b**) or the Reactome\_Unfolded\_Protein\_Response\_UPR (**c**) MsigDB<sup>17</sup> human gene set. **d,e**, Representative ATF6α IHC identifying ATF6α<sup>low</sup> or ATF6α<sup>hi</sup> samples in human HCC TMAs (**d**) and ATF6α<sup>hi</sup> tumour grading (**e**; G1–G3)<sup>20</sup>. Scale bar, 200 μm (**d**). **f,g**, Representative immunoblot (**f**) and quantification (**g**) of ATF6α in non-tumour (NT) and tumour (T) lysates from patients with HCC. Vinculin was used as the loading control, run on a cATF6α blot. **h**, IHC analysis of active (nuclear) and inactive ATF6α in human HCC. Scale bar, 20 μm. **i**, The percentage of active ATF6α cells in non-tumour liver, tumour margin or tumour centre from patients with HCC. **j**, Human HCC TMAs with low or high ATF6α expression as determined using IHC (left) were selected for spatial transcriptomics from annotated 300-μm-diameter circular ROIs (right). Scale bars, 400 μm (left) and 100 μm (right). **IF**, immunofluorescence.

**k**, Principal component analysis (PCA) of spatial transcriptomics with low versus high ATF6α ROIs. **l**, Ingenuity pathway analysis (IPA) of differentially expressed genes in high versus low ATF6α ROIs. **m**, *t*-Distributed stochastic neighbour embedding (*t*-SNE) plot of liver cell types by IMC in ATF6α<sup>low</sup> versus ATF6α<sup>hi</sup> livers from patients with HCC. **n**, Representative IMC of ATF6α<sup>low</sup> and ATF6α<sup>hi</sup> HCC. ATF6α (red), E-cadherin (green) and nuclei (blue, left), and CD3<sup>+</sup> T cells (green), CD8<sup>+</sup> T cells (red) and nuclei (blue, right) are shown. Scale bar, 60 μm. **o,p**, *t*-SNE plots of the immune cell distribution (**o**) and CD8<sup>+</sup> T cell subset composition (**p**) in ATF6α<sup>low</sup> and ATF6α<sup>hi</sup> HCC, as determined using IMC. **q**, Immune neighbourhood analysis of CD8<sup>+</sup>, CD8<sup>+</sup>TCF1<sup>+</sup> and CD11c<sup>+</sup> cells in ATF6α<sup>low</sup> and ATF6α<sup>hi</sup> HCC. **r**, ATF6α target gene expression and the human ATF6α-activation signature sorted by response to anti-PD-1 monotherapy<sup>25</sup>. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. Sample sizes, biological replicates and statistical tests are described in the Methods and Source data.

(Fig. 1b,c). ATF6α activation appeared to be the primary UPR driver and was uniquely associated with HCC compared with various cancers; other canonical UPR components did not correlate with survival probability in TCGA-LIHC and the human ATF6α-activation signature was not associated with reduced survival in other TCGA cancer datasets

(Fig. 1b,c and Supplementary Fig. 1f,g). Patient-derived HCC samples<sup>18,19</sup> stratified by the human ATF6α-activation signature were enriched in hepatic progenitor transformation, poor prognosis, cell cycle, oncogenesis hallmarks and lower scores of metabolism-related signatures (Extended Data Fig. 1a–c).

Immunohistochemical scoring of human HCC tissue microarray (TMA) revealed that, among the 74.6% ATF6 $\alpha$ -positive samples, those with high versus low ATF6 $\alpha$  activation were associated with high-grade (G3) HCC<sup>20</sup> (Fig. 1d,e and Extended Data Fig. 1d). Evaluation of the Chinese Human Proteome Project<sup>21</sup> corroborated that tumour samples of subgroup SIII of patients with HCC, characterized by low overall survival and poor prognosis after first-line surgery, exhibited increased expression of ATF6 $\alpha$  targets and glycolysis-related proteins, coupled with significantly reduced FBPI expression, and enrichment of proteins linked to proliferation, immunosuppression and metastasis (Extended Data Fig. 1e,f). Immunoblotting of protein lysates from patients with HCC showed preferential accumulation of cleaved ATF6 $\alpha$  (cATF6 $\alpha$ , C terminal, inactive; nATF6 $\alpha$ , N terminal, active) in tumours (Fig. 1f,g). Whereas nATF6 $\alpha$  localized to hepatocyte nuclei at the tumour margin of patients with non-virus-associated HCC, inactive, cytoplasmic ATF6 $\alpha$  remained unchanged (Fig. 1h,i and Extended Data Fig. 1g,h).

### ATF6 $\alpha$ activation is a tumour driver

Using spatial transcriptomics, we sequenced regions of interest (ROIs) based on immunohistochemistry (IHC)-stained human HCC serial sections for high and low ATF6 $\alpha$  expression (Fig. 1j–l and Extended Data Fig. 1i–l). The ATF6 $\alpha$ -specific chaperone *HSP90B1* and cancer-related genes were significantly increased in transcriptionally distinct ATF6 $\alpha$ <sup>hi</sup> versus ATF6 $\alpha$ <sup>low</sup> regions (Fig. 1k and Extended Data Fig. 1j,k). High ATF6 $\alpha$  expression was associated with PD-1–PD-L1, CTLA-4 signalling, hypoxia, cell cycle progression and glycolysis, the latter of which was linked to downregulated *FBPI*; the low expression of *FBPI* was correlated with an aggressive HCC subtype (T-SIII; Extended Data Fig. 1e,f) and reduced survival of patients with HCC (Fig. 1l and Extended Data Fig. 1k–m). Reduced FBPI in stressed hepatocytes and HCC progenitor cells acts as a metabolic switch: reversing senescence, supporting proliferation and promoting DNA-damage-induced mutations in MASH-HCC<sup>22</sup>.

Imaging mass cytometry (IMC) demonstrated altered site-specific (that is, non-tumour, tumour margin, tumour) cellular composition, including parenchymal, stromal and immune cells, particularly within samples from patients with HCC exhibiting high ATF6 $\alpha$  activation (Fig. 1m and Supplementary Fig. 2). ATF6 $\alpha$ <sup>hi</sup> versus ATF6 $\alpha$ <sup>low</sup> tumour regions presented increased CD8<sup>+</sup> T cell infiltration and other immune cell abundance (for example, CD11c<sup>+</sup> cells), where the percentage of CD8<sup>+</sup>PD-1<sup>+</sup> T cells and CD8<sup>+</sup>PD-1<sup>+</sup>TIM3<sup>+</sup> terminally exhausted T cells was significantly higher (Fig. 1n–p and Supplementary Fig. 2f). Neighbourhood analysis of CD8<sup>+</sup> T cells revealed expanded CD8<sup>+</sup> T cells clustering within a hub comprising CD11c<sup>+</sup> dendritic cells (DCs) and CD4<sup>+</sup> T cells in ATF6 $\alpha$ <sup>hi</sup> tumours, reminiscent of recently reported hepatic niches locally promoting CD8<sup>+</sup> T cell responses<sup>23,24</sup>. Preferential colocalization of CD11c<sup>+</sup> DCs with CD8<sup>+</sup> T cells and FOXP3<sup>+</sup>CD4<sup>+</sup> regulatory T (T<sub>reg</sub>) cells in ATF6 $\alpha$ <sup>hi</sup> HCC revealed increased immunosuppression, while the ICB-responsive CD8<sup>+</sup>TCF1<sup>+</sup> T cell subset hardly colocalized with T<sub>reg</sub> cells in ATF6 $\alpha$ <sup>hi</sup> HCC (Fig. 1q). As this may reveal mechanisms underlying sensitization of ATF6 $\alpha$ <sup>hi</sup> tumours to ICB, we investigated 83 samples from patients with advanced HCC receiving anti-PD-1 monotherapy<sup>25</sup> and found that those with a complete response had significantly higher expression of ATF6 $\alpha$  target genes and the human ATF6 $\alpha$ -activation signature (Fig. 1r).

### Hepatic ATF6 $\alpha$ activation induces injury

To investigate the role of ATF6 $\alpha$  activation in hepatocytes, we generated heterozygous transgenic mice with hepatocyte-specific Cre-inducible HA-tagged nATF6 $\alpha$  (*TG<sup>Alb-cre+</sup>*, *TG<sup>AAV-cre+</sup>*) and controls (*TG<sup>Alb-cre-</sup>*, *TG<sup>AAV-gfp</sup>*) (Extended Data Fig. 2a–c and Supplementary Table 1). *TG<sup>Alb-cre+</sup>* mice at 3 and 6 months of age exhibited hepatomegaly and liver damage, characterized by increased liver-to-body weight and serum alanine–aspartate


aminotransferases (ALT–AST), among others (Fig. 2a–c, Extended Data Fig. 2d–f and Supplementary Fig. 3a–d). Transmission electron microscopy (TEM) analysis demonstrated ER stress in 3-month-old *TG<sup>Alb-cre+</sup>* livers by notable swelling and disruption of the stacked ER lamellar sheet structure (Fig. 2d and Extended Data Fig. 2g), corroborated by increased mRNA and protein expression of ATF6 $\alpha$  and UPR targets (Fig. 2e–h and Extended Data Fig. 2h–j). Western blot and IHC analyses of ATF6 $\alpha$  (or HA tag) confirmed successful expression and nuclear translocation of activated nATF6 $\alpha$  (Fig. 2e, Extended Data Fig. 2a–c,i,k,l and Supplementary Fig. 3e,f), showing similar fold induction to nATF6 $\alpha$  levels in patients with hepatitis (Supplementary Fig. 1a–d). Hepatocyte ATF6 $\alpha$  activation increased liver cell proliferation (for example, Ki-67, PCNA, cyclin D1), DNA damage and cell death (for example,  $\gamma$ -H2AX, cleaved PARP (cl-PARP), cleaved caspase 3 (cl-CASP3)), HCC marker AFP, cancer stem cell marker CD44v6, oncogenic p62<sup>26</sup> and tumour suppressor p53-binding protein 1 (53BP1) (Fig. 2e,f and Extended Data Fig. 2i–l). RNA-sequencing (RNA-seq) followed by gene set enrichment analysis (GSEA)<sup>27</sup> revealed upregulated UPR, glycolysis, inflammation, cell fate (for example, cell cycle, division, death) and oncogenic signalling, but downregulated detoxification and respiration pathways (for example, oxidative phosphorylation), in transcriptionally distinct *TG<sup>Alb-cre+</sup>* versus *TG<sup>Alb-cre-</sup>* livers (Fig. 2g and Extended Data Fig. 2m). Paralleling with human HCC (Extended Data Fig. 1c), fatty acid metabolism was transcriptionally downregulated, whereas the expression of cholesterol biosynthesis and homeostasis proteins (for example, HMGCS1, CD36) was increased in the livers of *TG<sup>Alb-cre+</sup>* versus *TG<sup>Alb-cre-</sup>* mice (Fig. 2g,h). ATF6 $\alpha$  activation increased expression of glycolysis-related enzymes (for example, PKM, PGK1) but suppressed rate-limiting gluconeogenic enzymes, including FBPI, causing hepatic glycogen and glucose depletion in *TG<sup>Alb-cre+</sup>* mice compared with the control mice (Fig. 2f–i). At 6 months of age, glycolysis, immune cell infiltration and oncogenic pathways remained enriched in the livers of *TG<sup>Alb-cre+</sup>* mice (Supplementary Fig. 3g,h).

Chromatin binding of nATF6 $\alpha$  in livers from *TG<sup>Alb-cre+</sup>* mice was determined by CUT&RUN using antibodies detecting endogenous ATF6 $\alpha$  or exogenous HA-tagged nATF6 $\alpha$ , therefore identifying direct binding of nATF6 $\alpha$  to the promoter region of the tumour suppressor *FBPI*<sup>28</sup>. Strong binding to *Hspa5* (encoding BiP), an inducible target of ATF6 $\alpha$ , served as a positive control (Fig. 2j and Supplementary Fig. 4a,b). Assay for transposase-accessible chromatin using sequencing (ATAC-seq) analysis revealed reduced chromatin accessibility of the *Fbp1* promoter region in livers of *TG<sup>Alb-cre+</sup>* versus *TG<sup>Alb-cre-</sup>* mice (Fig. 2j (top) and Supplementary Fig. 4a,c), highlighting chromatin closure at the *Fbp1* locus after ATF6 $\alpha$  activation.

### FBPI counters nATF6 $\alpha$ -altered metabolism

Persistent ATF6 $\alpha$  activation rendered *TG<sup>Alb-cre+</sup>* mice more glucose tolerant, without affecting insulin tolerance, compared with *TG<sup>Alb-cre-</sup>* mice that had similar locomotion, respiration, and food and water intake (Supplementary Fig. 4d–i). ATF6 $\alpha$  activation by AAV8-cre transduction into hepatocytes induced hepatomegaly and liver injury after 2–3 weeks in *TG<sup>AAV-cre+</sup>* mice (Fig. 2k–m and Supplementary Fig. 4j–l). This was associated with ATF6 $\alpha$ -dependent ER stress and deficient protein *N*-glycosylation, the latter caused by lack of glycogen/glucose, essential substrates for proper glycoprotein folding<sup>29</sup>. Accordingly, FBPI levels were reduced in *TG<sup>AAV-cre+</sup>* versus *TG<sup>AAV-gfp</sup>* mice after overnight fasting (Fig. 2n, Extended Data Fig. 3a–d and Supplementary Fig. 4m–o).

Given the direct repression of FBPI by activated ATF6 $\alpha$ , we hypothesized that restoring FBPI could suppress glycolysis, reactivate gluconeogenesis and potentially prevent ATF6 $\alpha$ -activation-mediated liver injury (Fig. 2k–p). AAV8-induced hepatocyte FBPI reduced the liver-to-body weight, ALT–AST levels and glucose sensitivity without affecting gluconeogenesis or fasting insulin levels, while simultaneously limiting ATF6 $\alpha$ -dependent signalling (that is, reduced ER stress,



**Fig. 2 | Persistent ATF6 $\alpha$  activation in hepatocytes induces liver injury and glucose metabolic dysfunction through FBP1 repression.** **a**, Schematic and liver images of  $TG^{Alb-cre-/-}$  and  $TG^{Alb-cre+/+}$  mice euthanized aged 3 or 6 months. Scale bar, 1 cm. **b, c**, The liver-to-body weight (**b**) and serum ALT and AST levels (**c**) of 3- and 6-month-old  $TG^{Alb-cre-/-}$  and  $TG^{Alb-cre+/+}$  mice. **d**, Representative liver TEM images of  $TG^{Alb-cre-/-}$  and  $TG^{Alb-cre+/+}$  mice showing ER, mitochondria (M) and nucleus (N). Scale bar, 1  $\mu$ m. Quantification is shown in Extended Data Fig. 2g. **e**, Representative immunoblot of liver lysates from 3-month-old  $TG^{Alb-cre-/-}$  and  $TG^{Alb-cre+/+}$  mice. GAPDH was used as the loading control, run on a BiP blot. Quantification is shown in Extended Data Fig. 2i. **f**, Representative periodic acid–Schiff (PAS) staining and IHC for the indicated proteins in the livers of 3-month-old  $TG^{Alb-cre-/-}$  and  $TG^{Alb-cre+/+}$  mice. Scale bar, 200  $\mu$ m. Quantification is shown in Extended Data Fig. 2j. **g–i**, GSEA<sup>27</sup> of liver RNA-seq (**g**), volcano plot of liver proteomic analysis (**h**) and NMR-based liver metabolic analysis (**i**) of 3-month-old  $TG^{Alb-cre+/+}$  versus  $TG^{Alb-cre-/-}$  mice. EMT, epithelial-mesenchymal transition; FC, fold change; VIP score, variable importance score. **j**, CUT&RUN

and ATAC-seq analysis of livers from 3-month-old  $TG^{Alb-cre+/+}$  versus  $TG^{Alb-cre-/-}$  mice. Anti-IgG (control), anti-ATF6 $\alpha$  (endogenous ATF6 $\alpha$ ) or anti-HA (exogenous nATF6 $\alpha$ -HA) antibodies are indicated for CUT&RUN, while three JASPAR motifs aligning with the *Fbp1* promoter predicted to bind to ATF6 $\alpha$  motifs are shown. *Hspa5* was used as the positive control. *Rabepk* is the neighbouring gene. **k**, Schematic of AAV8-gfp-, AAV8-cre- or AAV8-cre/fbp1-injected mice euthanized 3 weeks after injection, with liver images of  $TG^{AAV-gfp}$  and  $TG^{AAV-cre/fbp1}$  mice. Scale bar, 1 cm. **l, m**, The liver-to-body weight (**l**) and serum ALT levels (**m**) of  $TG^{AAV-gfp}$ ,  $TG^{AAV-cre}$  and  $TG^{AAV-cre/fbp1}$  mice. **n**, Representative immunoblot of liver lysates from  $TG^{AAV-gfp}$ ,  $TG^{AAV-cre}$  and  $TG^{AAV-cre/fbp1}$  mice. Vinculin was used as the loading control, run on a TRAP $\alpha$  blot. Quantification is shown in Extended Data Fig. 3d. **o**, Representative PAS staining and IHC for indicated proteins in  $TG^{AAV-cre}$  and  $TG^{AAV-cre/fbp1}$  mouse livers. Scale bar, 200  $\mu$ m. Quantification is shown in Extended Data Fig. 3e. **p**, GSEA<sup>27</sup> of liver RNA-seq data from  $TG^{AAV-cre/fbp1}$  versus  $TG^{AAV-cre}$  mice. Sample sizes, biological replicates and statistical tests are described in the Methods and Source data.

UPR induction, TRAP $\alpha$  hypoglycosylation) in the livers of  $TG^{AAV-cre}$  mice (Fig. 2k–n and Extended Data Fig. 3a–d). FBPI re-expression in hepatocytes of  $TG^{AAV-cre}$  mice mitigated DNA damage, cell death and cell proliferation (Fig. 2o,p and Extended Data Fig. 3e–g).  $TG^{AAV-cre/fbp1}$  livers presented downregulated glycolysis and hypoxia in favour of oxidative phosphorylation (OXPHOS), reduced levels of taurine, known to promote glycolysis and metastasis in HCC<sup>30</sup>, increased glucose levels and reduced the uptake of <sup>13</sup>C-labelled lactate compared with  $TG^{AAV-cre}$  livers (Fig. 2o,p and Extended Data Fig. 3h–j).

Cytosolic and catalytically active FBPI is required for gluconeogenesis, whereas nuclear FBPI inhibits hypoxia-inducible factors, independent of its enzymatic properties<sup>31–33</sup>. Catalytically active FBPI, but not the inactive mutant (*Fbp1*<sup>E98A</sup>)<sup>28</sup>, restored glycogen, limited induction of ATF6 $\alpha$  targets in the liver, and reduced serum and liver lipid accumulation in  $TG^{AAV-cre}$  mice (Fig. 2o and Extended Data Fig. 3k–p). Decreased FBPI activity prevents gluconeogenesis and accelerates glycolytic flux<sup>31</sup>, thereby depleting glycogen/glucose needed for protein *N*-glycosylation and ER function, further perpetuating ER stress and ATF6 $\alpha$  activation (Extended Data Fig. 3q). Accordingly, FBPI re-expression promoted gluconeogenesis, increased liver hexose phosphate levels and prevented the ATF6 $\alpha$ -activation-driven increase in tricarboxylic-acid-cycle-related oncometabolites (Supplementary Fig. 5). Thus, metabolic reprogramming occurs through the repression of catalytically functional FBPI in livers of mice with activated ATF6 $\alpha$ .

### ATF6 $\alpha$ activation causes mouse liver cancer

Considering the progression of chronic hepatitis to HCC, hepatocyte-specific ATF6 $\alpha$  activation in  $TG^{Alb-cre+}$  mice reduced body-weight gain and lifespan compared with the  $TG^{Alb-cre-}$  controls due to spontaneous primary liver cancer (Fig. 3a–c). Hepatomegaly and liver injury persisted in 9- and 12-month-old  $TG^{Alb-cre+}$  mice (Fig. 3d,e and Extended Data Fig. 4a–d). Medical imaging detected tumour nodules in livers of 9-month-old  $TG^{Alb-cre+}$  mice, and subsequent dissection confirmed macroscopically visible liver tumours in 97.5% of them (Fig. 3f–h). Among the analysed tumours, 95% were HCC (AFP<sup>+</sup>, reduced intratumoural collagen type IV (COL IV), GS<sup>+</sup>, GP73<sup>+</sup>; nATF6 $\alpha$ -HA<sup>+</sup>), and the remainder were cholangiocarcinoma (CCA; AFP<sup>-</sup>, CK19<sup>+</sup>) (Fig. 3g). Prolonged ATF6 $\alpha$  activation caused primary liver cancer in all 12-month-old  $TG^{Alb-cre+}$  mice (Fig. 3h). Synteny analysis by array-based comparative genomic hybridization (aCGH) revealed that  $TG^{Alb-cre+}$  mice developed HCC with a comparable burden of chromosomal aberrations to human HCC (Fig. 3i and Extended Data Fig. 4e), and the extent of ATF6 $\alpha$  activation in their livers/tumours was similar to that in human and mouse HCC (Fig. 1f,g and Extended Data Fig. 4f–i).

To investigate whether postnatal ATF6 $\alpha$  activation (AAV8-cre) accelerates tumorigenesis, mice were subjected to diethylnitrosamine (DEN) and high-fat diet (HFD) feeding (DEN/HFD)<sup>34</sup>. Sustained ATF6 $\alpha$  activation with DEN/HFD expedited hepatomegaly and liver damage, without significantly affecting body-weight gain in  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  mice (Fig. 3j–l and Extended Data Fig. 5a–e). Whereas 80% of  $TG^{AAV-gfp}$  mice presented early tumour lesions, 100% of  $TG^{AAV-cre}$  mice exhibited liver tumours, significantly greater in number, surface area and AFP positivity (Fig. 3m–o and Extended Data Fig. 5f,g). Tumours from  $TG^{AAV-cre}$  mice presented increased nuclear localization of ATF6 $\alpha$ , together with elevated BiP and incompletely glycosylated TRAP $\alpha$  (Extended Data Fig. 5f–i). Non-tumour tissue showed an increase in apoptotic cells in  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  mice, while cleaved CASP3 and CHOP were significantly reduced in tumour versus non-tumour  $TG^{AAV-cre}$  liver (Extended Data Fig. 5j,k). In mouse livers with ATF6 $\alpha$  activation, CHOP may induce UPR-specific hepatocyte death and promote compensatory proliferation, while established tumour cells downregulate CHOP to evade such death<sup>35</sup>. Transcriptomic analysis of DEN/HFD-treated  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  livers showed increased ER stress, inflammation and oncogenic signalling, with downregulated *Fbp1*, especially

in tumour versus non-tumour  $TG^{AAV-cre}$  samples (Fig. 3p and Extended Data Fig. 5l,m).

A mouse-derived ATF6 $\alpha$ -activation signature was custom-generated by single-sample GSEA (ssGSEA)<sup>27</sup> with RNA-seq data from the livers of DEN/HFD-treated  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  mice to compare with human HCC (Fig. 3q). TCGA-LIHC samples sorted by high-to-low enrichment of the mouse-derived ATF6 $\alpha$ -activation signature correlated with the human ATF6 $\alpha$ -activation signature (Fig. 1), ER stress and UPR, *N*-glycosylation machinery, hypoxia, oncogenesis and immunosuppression (Fig. 3q). Consistent with the correlation between ATF6 $\alpha$  activation and an immune-exhausted profile in human liver cancer (Fig. 1), tumour-infiltrating CD8<sup>+</sup> T cells and PD-1<sup>+</sup> cells were significantly increased in DEN/HFD-treated  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  livers (Fig. 3r and Extended Data Fig. 5n).

In 15 datasets of patients with HCC, *FBPI* mRNA was inversely correlated with ATF6 $\alpha$ -activation signatures and significantly reduced in human HCC versus non-tumour liver (Fig. 3q and Extended Data Fig. 6a,b). Restoring hepatic FBPI expression in DEN/HFD-treated  $TG^{AAV-cre}$  mice significantly reduced ATF6 $\alpha$ -activation-driven HCC development, as shown by reduced liver-to-body weight, tumour number and size (Extended Data Fig. 6c–e). Although the number of CD8<sup>+</sup> T cells was similar between  $TG^{AAV-cre/fbp1}$  and  $TG^{AAV-cre}$  livers, FBPI expression blunted PD-1<sup>+</sup> cell accumulation in non-tumour and tumour tissue of  $TG^{AAV-cre}$  mice (Extended Data Fig. 6f,g). This suggests that CD8<sup>+</sup> T cells were present but less exhausted in the livers of  $TG^{AAV-cre/fbp1}$  versus  $TG^{AAV-cre}$  mice.

### Atf6 deletion reduces mouse HCC

*Atf6*-deleted (encoding ATF6 $\alpha$ ) mice (*Atf6*<sup>-/-</sup>) and control littermates (*Atf6*<sup>+/+</sup>) were injected with DEN and fed a HFD for 32 weeks (Fig. 4a). *Atf6* deletion reduced liver-to-body weight and ALT levels, without affecting body-weight gain (Extended Data Fig. 7a–c). Whereas all *Atf6*<sup>+/+</sup> mice developed steatotic tumours with ER stress, *Atf6* deletion mitigated lipid accumulation, ER stress and HCC incidence with reduced tumour numbers and size (Fig. 4b–e and Extended Data Fig. 7d–k). Liver IHC and intratumoural quantification revealed reduced tumour-cell proliferation, lipid peroxidation, as well as CD8<sup>+</sup> T cell and PD-1<sup>+</sup> cell infiltration in *Atf6*<sup>-/-</sup> versus *Atf6*<sup>+/+</sup> mice (Extended Data Fig. 7f,g), contrary to ATF6 $\alpha$  activation in human and mouse HCC displaying increased tumour-cell proliferation and increased CD8<sup>+</sup> T cell and PD-1<sup>+</sup> cell infiltration (Figs. 1 and 3 and Extended Data Figs. 1 and 5). *Atf6* deletion inhibited UPR activation, hypoglycosylation of TRAP $\alpha$  and maintained FBPI levels, therefore impeding pathogenic hepatic glycolysis, inflammation and oncogenic signalling (Fig. 4f and Extended Data Fig. 7i–m).

To investigate a cell-autonomous protective effect of *Atf6* deletion in HCC, hepatocyte-specific *Atf6*-knockout mice (*Atf6* <sup>$\Delta$ Hep</sup>; Supplementary Table 1) were challenged in various preclinical models. *Atf6* <sup>$\Delta$ Hep</sup> mice fed a choline-deficient HFD (CD-HFD)<sup>36</sup> for 58 weeks displayed significantly reduced liver-to-body weight, liver cancer incidence and tumour number compared with the control mice (Fig. 4g–j and Supplementary Fig. 6a,b). CD-HFD-fed *Atf6* <sup>$\Delta$ Hep</sup> mice had significantly higher liver *Fbp1* and reduced glycolysis pathway expression compared with *Atf6*<sup>R/f</sup> mice, as determined using RNA-seq, mirroring an increase in hepatic glucose content and restored glycogen (Fig. 4k,l and Supplementary Fig. 6c). CD8<sup>+</sup> T cells and PD-1<sup>+</sup> cells were significantly reduced in the livers of *Atf6* <sup>$\Delta$ Hep</sup> versus *Atf6*<sup>R/f</sup> mice (Supplementary Fig. 6d,e). These results were corroborated by Western diet (WD)-fed *Atf6* <sup>$\Delta$ Hep</sup> mice challenged with or without DEN. DEN/WD-treated *Atf6* <sup>$\Delta$ Hep</sup> mice displayed reduced tumour numbers compared with *Atf6*<sup>R/f</sup> mice (Supplementary Fig. 6f–j). Despite unaltered steatosis, WD-fed *Atf6* <sup>$\Delta$ Hep</sup> mice presented reduced hepatomegaly and tumour incidence with significantly smaller and fewer HCC nodules (Supplementary Fig. 6k–p).

In *MUP-uPA* mice that develop ER-stress-driven MASH-HCC<sup>37</sup> due to transiently high urokinase-type plasminogen activator (uPA, encoded by *Plau*) levels driven by the hepatocyte major urinary protein (MUP)

promoter and HFD feeding, *Atf6* deletion reduced the liver-to-body weight, liver injury and tumour burden without affecting body-weight gain (Fig. 4m–o and Supplementary Fig. 6q–s). *Atf6* deletion in *MUP-uPA* mice reduced ER chaperones BiP (encoded by *Hspa5*) and *Hsp90b1* expression, but did not affect *Ddit3*, *Atf4* or *Xbp1* mRNA levels (Supplementary Fig. 6t–v), indicating no compensatory activation of the other UPR branches.

### **Atf6 ASOs limit ER stress and reduce HCC**

Targeting ATF6 $\alpha$  activation was further investigated using non-toxic *N*-acetylgalactosamine (GalNac)-conjugated antisense oligonucleotides (ASOs) that are preferentially taken up by hepatocytes and have high therapeutic potential in HCC<sup>38</sup>. ASOs against *Atf6* (GalNac-ASO-*Atf6*) or a scrambled nucleotide sequence (GalNac-ASO-scramble) were assessed in the *MUP-uPA* preclinical model (Fig. 4p). Early on, *MUP-uPA* mice exhibit liver injury due to strong, transient ER stress<sup>37</sup> from 4 to 7 weeks of age that was abrogated by 85% knockdown of *Atf6* mRNA with hepatocyte-specific GalNac-ASO-*Atf6*, without affecting *uPA* levels (Fig. 4p–r and Extended Data Fig. 8a–g). GalNac-ASO-*Atf6* treatment in wild-type (WT) mice resulted in 89% *Atf6* mRNA knockdown with no observed adverse phenotype (Extended Data Fig. 8a–d). In *MUP-uPA* mice, reducing ATF6 $\alpha$  activation prevented hepatic glycogen depletion, reduced BiP protein, as well as lipid accumulation, cell proliferation and cell death (Fig. 4r and Extended Data Fig. 8e–i). Targeting ATF6 $\alpha$  protected against ER stress caused by *uPA* protein misfolding that activates all three UPR branches in *MUP-uPA* mice<sup>37</sup>.

At 30 weeks old, HFD-fed *MUP-uPA* mice display hepatocyte transformation and tumour progenitor cell development<sup>37</sup>, with nearly 90% of mice presenting macroscopically visible tumours (Extended Data Fig. 8j–m). GalNac-ASO-*Atf6* was administered to 30-week-old HFD-fed and tumour-bearing *MUP-uPA* mice until aged 40 weeks, when *MUP-uPA* mice exhibit steatohepatic HCC<sup>37</sup> and WT mice exhibit steatosis (Fig. 4s and Extended Data Fig. 8n). Hepatocyte-specific ATF6 $\alpha$  targeting decreased the liver-to-body weight and serum ALT in both steatohepatic *MUP-uPA* and steatotic WT mice (Extended Data Fig. 8o,p). Evaluated using *in situ* hybridization, GalNac-ASO-*Atf6* significantly reduced *Atf6* mRNA in hepatocytes and tumour cells of HFD-fed *MUP-uPA* mice by approximately 72% (Extended Data Fig. 8q,r). GalNac-ASO-*Atf6* downregulated *Atf6* without affecting *uPA* mRNA levels, downregulated ER stress, UPR and glycolysis targets, and significantly reduced the tumour burden in HFD-fed *MUP-uPA* mice (Fig. 4t,u and Extended Data Fig. 8s).

In another preclinical cancer model, hydrodynamic tail vein injection (HDTV) of mutant *NRAS*<sup>G12V</sup> plasmid accelerated tumour burden and depleted glycogen in livers of mice with activated ATF6 $\alpha$  (Supplementary Fig. 7a–e). Conversely, targeting *Atf6* by GalNac-ASO-*Atf6* compared with GalNac-ASO-scramble reduced the liver tumour size of *NRAS*<sup>G12V</sup>-injected WT mice, prevented glycogen depletion and reduced PD-1<sup>+</sup> cell abundance (Fig. 4v–x and Supplementary Fig. 7f–m). ATF6 $\alpha$  may therefore be a therapeutic target for initiated HCC, leading to reduced tumour progression and reactivation of the natural anti-liver cancer immune response.

### **Hepatocyte ATF6 $\alpha$ drives immunosuppression**

Transcriptional analyses were performed for immune-mediated cancer field (ICF) signatures<sup>39</sup>, defined by 172 genes for deregulated immune response associated with HCC. Livers of 3-month-old *TG*<sup>Alb-cre+</sup> mice already presented significantly higher ICF signature scores, related to immunosuppression<sup>39</sup>, TGF $\beta$ -activation and T<sub>reg</sub>-cell-signature enrichment, while restoring FBP1 expression limited many of the above-mentioned signatures (Fig. 5a and Extended Data Fig. 9a). In tumours from 171 patients with HCC<sup>19</sup>, the mouse-derived ATF6 $\alpha$ -activation signature was enriched in inflamed tumours,

particularly those of the immune-exhausted subclass (23%; Extended Data Fig. 9b). Higher scores for predicted ICB response, which included a novel 11-gene signature in frontline advanced HCC (IFNAP)<sup>25</sup>, were enriched in human ATF6 $\alpha$ <sup>hi</sup> HCCs (Fig. 1r and Extended Data Fig. 9b). Liver tumours of DEN/HFD-treated transgenic mice with activated ATF6 $\alpha$  had enriched oncogenic (for example, angiogenesis and E2F targets) and immunosuppressive (for example, ICF and TGF $\beta$  activation) signatures, in contrast to *Atf6*-knockout mice (Fig. 5a). ATF6 $\alpha$ -activation-driven metabolic dysregulation may therefore precede inflammation, both predisposing to hepatocarcinogenesis.


At the 6-month-old precancerous stage, chronically activated ATF6 $\alpha$  increased hepatic PD-L1 levels (Extended Data Fig. 9c), which is known to suppress T cell function<sup>40</sup>. A significant increase in liver-infiltrating immune cells was detected by flow cytometry, immunofluorescence and IHC analysis of *TG*<sup>Alb-cre+</sup> versus *TG*<sup>Alb-cre-</sup> livers (Fig. 5b–d and Extended Data Fig. 9d–h). Cells manifesting immunosuppression, including monocytic myeloid-derived suppressor cells (M-MDSCs), PD-1<sup>+</sup> T cells, and CD206<sup>+</sup> and PD-L1<sup>+</sup> macrophages, were significantly increased in *TG*<sup>Alb-cre+</sup> livers (Fig. 5c,d, Extended Data Fig. 9h,i and Supplementary Fig. 10a–c), consistent with human HCC (Fig. 1o–q). Overall, persistent, hepatocyte-specific ATF6 $\alpha$  activation promotes early-onset liver injury with progressive oncogenic signalling in an inflamed, immunosuppressive microenvironment.

### **Hepatocyte ATF6 $\alpha$ limits T cell function**

To elucidate how hepatocyte-specific ATF6 $\alpha$  activation impacts neighbouring immune cells, we performed single-cell RNA-seq (scRNA-seq) analysis of sorted CD45<sup>+</sup> leukocytes, which were more abundant and enriched in innate immune cell populations in *TG*<sup>Alb-cre+</sup> than in *TG*<sup>Alb-cre-</sup> livers (Extended Data Fig. 9j,k and Supplementary Fig. 8a). Subclustering of CD8<sup>+</sup> T cells revealed increased effector and exhausted CD8<sup>+</sup> T cells in *TG*<sup>Alb-cre+</sup> livers (Fig. 5e and Extended Data Fig. 9l), consistent with human HCC (Fig. 1p,q) and transcriptomic characterization (Fig. 5a). This indicates an accelerated recruitment or local proliferation of naive CD8<sup>+</sup> T cells concomitant with exhausted and immunosuppressive features (Fig. 5f,g and Supplementary Fig. 8b). As anti-tumour immunosurveillance relies on glycolysis and OXPHOS as energy sources in cytotoxic T cells<sup>6</sup>, we predicted the glucose-deprived liver microenvironment generated by hepatocyte-specific ATF6 $\alpha$  activation hampers surrounding CD8<sup>+</sup> T cell function. In contrast to other metabolic pathways, glycolysis and OXPHOS pathway activity were reduced in CD8<sup>+</sup> T cells from *TG*<sup>Alb-cre+</sup> versus *TG*<sup>Alb-cre-</sup> livers (Fig. 5h and Supplementary Fig. 8c). CD4<sup>+</sup> T cell distribution and metabolic pathway expression were similar between *TG*<sup>Alb-cre+</sup> and *TG*<sup>Alb-cre-</sup> livers (Supplementary Fig. 8d–g). *TG*<sup>Alb-cre+</sup> livers demonstrated substantial repopulation of myeloid cells to compensate for the loss of Kupffer cells, commonly found in hepatitis<sup>41</sup> (Supplementary Fig. 8h–j). Glucose-related metabolism in myeloid cells remained relatively unchanged between *TG*<sup>Alb-cre+</sup> and *TG*<sup>Alb-cre-</sup> livers (Supplementary Fig. 8k), suggesting that the glucose-deprived microenvironment predominantly affected glucose-sensitive CD8<sup>+</sup> T cells<sup>42</sup>.

We next addressed whether activated ATF6 $\alpha$  sufficed to induce a cell non-autonomous immunosuppressive environment. Activated ATF6 $\alpha$  expression in mouse FL83B hepatocytes (FL83B<sup>TG</sup>) significantly increased glucose consumption, lactate production, glycolysis and glycolytic capacity compared with FL83B<sup>WT</sup> hepatocytes (Extended Data Fig. 10a–e). By contrast, *Atf6*-deleted FL83B hepatocytes (FL83B<sup>KO</sup>) displayed significantly reduced lactate production (Extended Data Fig. 10e,f). Primary hepatocytes with activated ATF6 $\alpha$  from chow-fed *TG*<sup>Alb-cre+</sup> mice compared with *TG*<sup>Alb-cre-</sup> mice had significantly upregulated glycolysis-related genes, while hepatocytes collected from CD-HFD-fed *Atf6* <sup>$\Delta$ Hep</sup> compared with *Atf6*<sup>fl/fl</sup> mice showed the opposite (Extended Data Fig. 10g,h).

In an *in vitro* co-culture system, HLE or Colo800 cell lines with stable nATF6 $\alpha$  expression demonstrated resistance to MART-1-specific




**Fig. 3 | Prolonged ATF6 $\alpha$  activation induces spontaneous, primary liver cancer in mice. a, b**, Kaplan-Meier survival (a) and body-weight (b) curves of  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. **c**, Schematic of  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice euthanized aged 9 and 12 months, the latter including liver images; the arrowheads indicate tumours. Scale bar, 1 cm. **d, e**, The liver-to-body weight (d) and serum ALT/AST levels (e) of 9- or 12-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. **f**, Representative fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) (left; coronal and sagittal images from left to right) and magnetic resonance tomography (MRT) (right; axial images) of 9-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. H, heart; K, kidney. The red asterisks denote tumour nodules/lesions. **g**, Representative haematoxylin and eosin (H&E) staining and IHC analysis of the indicated proteins in tumour or non-tumour liver from 9-month-old  $TG^{Alb-cre+}$  mice. Scale bar, 200  $\mu m$ . **h**, The tumour incidence in 9- and 12-month-old  $TG^{Alb-cre+}$  and  $TG^{Alb-cre-}$  mice. **i**, Synteny analysis for chromosomal gains (blue) and losses (red) in 12-month-old  $TG^{Alb-cre+}$  mice (MI-19) and human HCC (HI-22).

The outer circle represents mouse (M) and human (H) chromosomes. **j**, Schematic and liver images of  $nAtf6^{fl/+}$  mice intraperitoneally (i.p.) injected with DEN, followed by AAV8-gfp or AAV8-cre injection and HFD feeding. The arrowheads indicate tumours. Scale bar, 1 cm. **k-o**, The liver-to-body weight (k), serum ALT levels (l), tumour number (m) and area (n;  $cm^2$ ) per liver, and the tumour incidence (o) of DEN/HFD-treated  $TG^{AAV-gfp}$  and  $TG^{AAV-cre}$  mice. **p**, Liver RNA-seq analysis of DEN/HFD-treated  $TG^{AAV-cre}$  versus  $TG^{AAV-gfp}$  mice. **q**, Human gene sets expressed in TCGA-LIHC HCC samples were sorted by high to low enrichment of the mouse-derived ATF6 $\alpha$ -activation signature. IC, information coefficient; RNS, reactive nitrogen species; ROS, reactive oxygen species. **r**, Representative liver IHC for CD8<sup>+</sup> and PD-1<sup>+</sup> in  $TG^{AAV-gfp}$  and  $TG^{AAV-cre}$  HCC samples. Scale bar, 200  $\mu m$ . Quantification is shown in Extended Data Fig. 5n. The sample sizes, biological replicates and statistical tests are described in the Methods and Source data.

T-cell-mediated killing (Extended Data Fig. 10i-n), corroborating that ATF6 $\alpha$  activation induces immunosuppression. Inhibiting lactate dehydrogenase activity with galloflavin or lactate efflux with AZD3965 restored the killing efficiency of Colo800<sup>TG</sup> cells by

MART-1-specific T cells (Extended Data Fig. 10m,n). Indeed, untreated Colo800<sup>TG</sup> cells exhibited higher glucose consumption and lactate production compared with Colo800<sup>WT</sup> cells (Extended Data Fig. 10o-r). Thus, hepatocyte-specific ATF6 $\alpha$  activation metabolically restricts



**Fig. 4 | Prophylactic or therapeutic *Atf6* targeting reduces HCC.** **a**, Schematic and liver images of DEN/HFD-treated *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice. Scale bar, 1 cm. **b, c**, The tumour incidence (**b**), number (**c**; left) and area (**c**; right, cm<sup>2</sup>) of DEN/HFD-treated *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice. **d**, Representative liver H&E staining of DEN/HFD-treated *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice. Scale bar, 3 mm. **e**, Representative liver TEM images of DEN/HFD-treated *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice. Scale bar, 1 μm. Quantification is shown in Extended Data Fig. 7h. Gly, glycogen. **f**, GSEA<sup>27</sup> of liver tumour RNA-seq data from DEN/HFD-treated *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice. **g**, Schematic and liver images of CD-HFD-fed *Atf6*<sup>fl/fl</sup> and *Atf6*<sup>ΔHep</sup> mice. Scale bar, 1 cm. **h, i**, The tumour incidence (**h**), number and area (**i**; cm<sup>2</sup>) of CD-HFD-fed *Atf6*<sup>fl/fl</sup> and *Atf6*<sup>ΔHep</sup> mice. **j**, Representative liver H&E staining of CD-HFD-fed *Atf6*<sup>fl/fl</sup> and *Atf6*<sup>ΔHep</sup> mice. Scale bar, 3 mm. **k**, Volcano plot of liver RNA-seq data from *Atf6*<sup>ΔHep</sup> versus *Atf6*<sup>fl/fl</sup> mice. **l**, Liquid chromatography–mass spectrometry (LC–MS) analysis of hepatic glucose in *Atf6*<sup>fl/fl</sup> and *Atf6*<sup>ΔHep</sup> mice. **m**, Schematic and liver images of *Atf6*<sup>+/+</sup> and *Atf6*<sup>-/-</sup> mice crossed with MUP-uPA mice and fed a HFD. Scale bar, 1 cm. **n**, The tumour number (left) and area (right; cm<sup>2</sup>) of *Atf6*<sup>+/+</sup>:MUP-uPA and *Atf6*<sup>-/-</sup>:MUP-uPA mice. **o**, Representative liver H&E staining of HFD-fed *Atf6*<sup>+/+</sup>:MUP-uPA and *Atf6*<sup>-/-</sup>:MUP-uPA mice. Scale bar, 3 mm.

**p**, Schematic and liver images of MUP-uPA mice administered GalNac-ASO-scramble or GalNac-ASO-*Atf6*. Scale bar, 1 cm. **q**, Representative liver TEM images of ASO-scramble- or ASO-*Atf6*-treated MUP-uPA mice. Scale bar, 500 nm. Quantification is shown in Extended Data Fig. 8f. C, collagen. **r**, Representative liver PAS staining and IHC for BiP and CHOP in ASO-scramble- or ASO-*Atf6*-treated MUP-uPA mice. Scale bar, 200 μm. Quantification is shown in Extended Data Fig. 8e. **s**, Schematic and liver images of HFD-fed MUP-uPA mice administered GalNac-ASO-scramble or GalNac-ASO-*Atf6*. Scale bar, 1 cm. **t**, The tumour number (left) and area (right) of 30-week-old untreated or 40-week-old ASO-scramble- or ASO-*Atf6*-treated MUP-uPA mice. **u**, Representative liver H&E staining of ASO-scramble- or ASO-*Atf6*-treated MUP-uPA mice. Scale bar, 3 mm. **v**, Schematic and liver images of GalNac-ASO-scramble- or GalNac-ASO-*Atf6*-treated C57BL/6J + *NRAS*<sup>G12V</sup> mice. Scale bar, 1 cm. **w**, Tumour area (cm<sup>2</sup>) of ASO-scramble- or ASO-*Atf6*-treated C57BL/6J + *NRAS*<sup>G12V</sup> mice. **x**, Representative liver H&E staining of ASO-scramble- or ASO-*Atf6*-treated C57BL/6J + *NRAS*<sup>G12V</sup> mice. Scale bar, 3 mm. The sample sizes, biological replicates and statistical tests are described in the Methods and Source data.

T-cell-mediated anti-tumour immunosurveillance, probably through lactate production (among others) in a cell non-autonomous manner.

### ATF6 $\alpha$ activation sensitizes HCC to ICB

With prognostic potential for guiding HCC immunotherapy, ATF6 $\alpha$  activation promotes immunosuppressive features (MDSCs, CD8<sup>+</sup>PD-1<sup>+</sup>, CD8<sup>+</sup>PD-1<sup>+</sup>TIM3<sup>+</sup> T cells)<sup>7</sup> and an ICB-responsive tumour microenvironment characterized by: (1) hub-like immune niches (CD8<sup>+</sup> T cells clustered with CD11c<sup>+</sup> DCs and CD4<sup>+</sup> T cells) and (2) spatial segregation of ICB-responsive CD8<sup>+</sup>TCF1<sup>+</sup> T cells from immunosuppressive T<sub>reg</sub> cells<sup>23,24</sup>.

Anti-PD-1 neutralizing antibody was therapeutically administered to 9-month-old *TG<sup>Alb-cre+</sup>* mice, all presenting spontaneous liver cancer (Fig. 5i). Anti-PD-1 treatment in *TG<sup>Alb-cre+</sup>* mice reduced tumour number and size (Fig. 5j), as well as liver-to-body weight (Extended Data Fig. 11a). IHC analysis revealed increased CD8<sup>+</sup> T cell accumulation in both non-tumour liver and tumours of anti-PD-1-treated compared with anti-IgG-treated *TG<sup>Alb-cre+</sup>* mice, with no change in ER stress markers or HCC marker AFP (Fig. 5k and Extended Data Fig. 11b–d). Multiplexed ion beam imaging (MIBI) analysis for multiparametric analysis of distinct proteins at the single-cell level<sup>43</sup> in situ revealed that anti-PD-1 treatment significantly increased LDH expression, one of the crucial enzymes in aerobic glycolysis<sup>44</sup>, in CD8<sup>+</sup> tumour-infiltrating lymphocytes (TILs) (Fig. 5l and Extended Data Fig. 11e).

In an oncogene-induced HCC model, HDTV<sub>i</sub> of *MYC:TP53<sup>KO</sup>* caused tumour formation within 6 weeks in C57BL/6J mice, without significantly altering *Atf6* or *Hspa5* mRNA expression in tumour versus non-tumour tissue (Extended Data Fig. 11f). Anti-PD-1 monotherapy did not significantly reduce tumour burden unless *MYC:TP53<sup>KO</sup>* mice were subjected to AAV8-mediated hepatocyte-specific ATF6 $\alpha$  activation, which was observed 5 days after injection by HA-positive IHC (Extended Data Fig. 11g–m). Anti-PD-1 treatment of *MYC:TP53<sup>KO</sup>TG<sup>AAV-cre</sup>* mice reduced the liver-to-body weight, tumour number and area (Extended Data Fig. 11l,m). CD8<sup>+</sup> T cells and PD-1<sup>+</sup> cells were increased after anti-PD-1 monotherapy in tumours that also displayed collagen IV loss but increased HNF4 $\alpha$  positivity, typical of HCC (Extended Data Fig. 11n–p). Ultimately, immunotherapy prolonged the survival of *MYC:TP53<sup>KO</sup>* mice with activated hepatocyte ATF6 $\alpha$  (Extended Data Fig. 11q). Similar results were obtained from HDTV<sub>i</sub> of mutant *KRAS<sup>G12D</sup>:TP53<sup>KO</sup>* in *TG<sup>AAV-cre</sup>* mice (Supplementary Fig. 9a–k), in which a metabolic flux assay and scRNA-seq analysis revealed an increased glycolytic capacity in CD8<sup>+</sup> TILs isolated from anti-PD-1- versus anti-IgG-treated liver tumours (Supplementary Fig. 9l–r).

Finally, *TG<sup>Alb-cre+</sup>* and *Pdcd1<sup>-/-</sup>* mice were crossed to genetically knock-out PD-1 (*TG:Pdcd1<sup>-/-</sup>*) (Fig. 5m and Extended Data Fig. 12a). PD-1 deletion resulted in elevated T cell proliferation, dampened T cell apoptosis and potentially reduced differentiation into T<sub>reg</sub> cells<sup>45</sup>. Compared with *TG<sup>Alb-cre+</sup>* mice, 9-month-old *TG:Pdcd1<sup>-/-</sup>* mice presented significantly fewer and smaller tumours (Fig. 5n), reduced liver-to-body weight, but similar liver damage and hepatic metabolic readouts (Extended Data Fig. 12b–f). The levels of activated ATF6 $\alpha$  (HA) and associated BiP, as well as DNA-damage-associated marker  $\gamma$ -H2AX, were unchanged, while Ki-67 levels were reduced and the number of TNF-producing foci was increased in the livers of *TG:Pdcd1<sup>-/-</sup>* versus *TG<sup>Alb-cre+</sup>* mice (Extended Data Fig. 12f–i).

The number of tumour-infiltrating CD8<sup>+</sup> T cells in *TG:Pdcd1<sup>-/-</sup>* livers increased, suggesting improved anti-tumour immunosurveillance due to *Pdcd1* deletion (Fig. 5o and Extended Data Fig. 12j). The proportion of cytokine-secreting T cells (CD8<sup>+</sup> and CD4<sup>+</sup> T cells, natural killer T cells) was higher in *TG:Pdcd1<sup>-/-</sup>* versus *TG<sup>Alb-cre+</sup>* livers (Extended Data Fig. 12k–m and Supplementary Fig. 10d). A greater proportion of effector T cells (CD8<sup>+</sup>CD44<sup>+</sup>CD62L<sup>-</sup>) and a reduced proportion of naive (CD8<sup>+</sup>CD44<sup>-</sup>CD62L<sup>+</sup>) as well as CD8<sup>+</sup>PD-1<sup>+</sup> T cells, was identified in *TG:Pdcd1<sup>-/-</sup>* compared with *TG<sup>Alb-cre+</sup>* livers (Extended Data Fig. 12n–p


and Supplementary Fig. 10e). MIBI revealed that CD8<sup>+</sup> TILs derived from hepatic tumours of *TG:Pdcd1<sup>-/-</sup>* mice displayed increased LDH expression, revealing improved CD8<sup>+</sup> T cell glycolysis (Extended Data Fig. 12q,r). Ultimately, PD-1 deletion significantly improved the survival rates of *TG<sup>Alb-cre+</sup>* mice (Fig. 5p). These data suggest that activated ATF6 $\alpha$  sensitizes less-responsive liver cancer to immunotherapy by transforming tumours to hot or altered-immunosuppressed states<sup>46</sup>.

### Discussion

Here we introduce chronically activated ATF6 $\alpha$  as a hepatic tumour driver with cell-autonomous and cell-non-autonomous functionalities, driving hepatocyte transformation and glucose-metabolism-dependent microenvironmental immunosuppression, respectively. Our data reveal the importance of post-translational ATF6 $\alpha$  processing to derive an activated nuclear form that perpetuates ER stress, causing liver injury accompanied by inflammation, immunosuppression, metabolic dysregulation and cell fate alterations (Extended Data Fig. 12s). We acknowledge the distinction between human data focused on advanced HCC to identify molecular signatures, including ATF6 $\alpha$  linked to disease progression and therapy response, and preclinical mouse studies examining early hepatocarcinogenesis to identify mechanisms of HCC initiation rather than reversing established disease. Preclinical mouse models (such as HFD-fed *MUP-uPA*) partly recapitulate human advanced HCC and their potential to respond to therapy, which remains a limitation of this study. Nevertheless, our findings reveal causal pathways that may inform preventive strategies and have clinical use in guiding patient stratification to optimize existing treatment approaches.

Activated ATF6 $\alpha$  was detected in chronic hepatitis and persisted in HCC in which it further correlated with poor prognosis, involving chronic UPR, hepatocyte transformation, failed immune surveillance and immunosuppression. The notable disparity in prolonged ATF6 $\alpha$ -mediated liver UPR observed in this study, as compared to its well-established role in short-term studies or supraphysiological acute responses<sup>3,16</sup>, represents a paradigm shift and underscores the distinct function of activated ATF6 $\alpha$  in acute versus chronic diseases, as shown in the colon<sup>15</sup>. Either absence of or excessive UPR signaling may promote pathogenesis and impact therapeutic strategies<sup>47</sup>. Although activated ATF6 $\alpha$  is a key driver, contributing roles of IRE1 $\alpha$  and PERK UPR pathways in MASH-HCC<sup>48</sup> and liver cancer cannot be excluded.

It is plausible that ATF6 $\alpha$ -mediated UPR undergoes a transition from its adaptive function in acute diseases to a state of resistant UPR in chronic diseases with a persistent insult (for example, high caloric diet, chronic virus infection). Constitutive ATF6 $\alpha$  activation appears to be necessary and sufficient to drive tumour development and progression, due to cell-autonomous and non-autonomous functions. We provide additional substantiation for this concept by demonstrating that ATF6 $\alpha$ -activated hepatocytes exhibit elevated glycolysis, a reduction in crucial nutrients and an augmented release of lactate into the microenvironment that restricts T cell function. ATF6 $\alpha$  target genes comprise chaperones from the glucose-regulated protein family, suggesting a pivotal role for ATF6 $\alpha$ -mediated UPR in monitoring glucose fluctuations and maintaining glucose and glycosylation precursor levels within the liver. Reduced ATF6 $\alpha$  N-glycosylation feeds forward toward ATF6 $\alpha$  activation<sup>49</sup>. ATF6 $\alpha$  activation depletes glycogen/glucose, further impairing glycoprotein folding to induce UPR activation and FBPI repression; a mechanism rescued by restored FBPI expression. Note that mice have limited liver glycogen reserves and may depend more on gluconeogenesis than humans, which maintain glucose levels by glycogenolysis<sup>50</sup>. Nevertheless, FBPI repression by ATF6 $\alpha$  is central to hepatocyte metabolism, whereby ATF6 $\alpha$  activation and low FBPI levels lead to HCC with aggressive phenotypes characterized by glycolysis, proliferation and immunosuppression. Consequently, this



**Fig. 5 | Hepatic ATF6 $\alpha$  activation metabolically restricts anti-tumour immunosurveillance.** **a**, Analysis of pro-tumorigenic ICF, TGF $\beta$ , immune cell or oncogenic signatures in 3-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice (Fig. 2a), 3-month-old  $TG^{AAV-cre}$  and  $TG^{AAV-cre/fbp1}$  mice (Fig. 2k), 30-week-old DEN/HFD-treated  $TG^{AAV-gfp}$  and  $TG^{AAV-cre}$  mice (Fig. 3j) and 38-week-old DEN/HFD-treated  $Atf6^{+/+}$  and  $Atf6^{-/-}$  mice (Fig. 4a). Additional data from refs. 51,52. NS, not significant. **b,c**, Fluorescence-activated cell sorting (FACS) analysis of the proportion of CD8 $^{+}$  T cells (**b**) and CD4 $^{+}$ PD-1 $^{+}$  and CD8 $^{+}$ PD-1 $^{+}$  T cells (**c**) in the livers of 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. **d**, Representative liver immunofluorescence for PD-1, CD8 and CD4 in lymphocytes (left) and F4/80, CD206 and PD-L1 in macrophages (right) in 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. The arrowheads indicate double-stained cells. Scale bar, 50  $\mu$ m. Quantification is shown in Extended Data Fig. 9i. **e,f**, scRNA-seq UMAP (**e**) and trajectory analysis (**f**; left) of subclustered CD8 $^{+}$  T cells from the livers of 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice, with pseudotime ordering predicting CD8 $^{+}$  T cell development by subtype (**f**; right). **g,h**, Pseudotime-ordered CD8 $^{+}$  T cells (**g**; bottom) with state-wise density distribution (**g**; top), and pseudotime-

based metabolic pathway activity of CD8 $^{+}$  T cells (**h**) from livers of 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice. **i**, Schematic and liver images of anti-IgG and anti-PD-1-treated  $TG^{Alb-cre+}$  mice. Scale bar, 1 cm. **j**, The tumour number (left) and area (right; cm $^2$ ) of anti-IgG and anti-PD-1-treated  $TG^{Alb-cre+}$  mice. **k**, Representative liver H&E staining (scale bar, 3 mm) and IHC for CD8 or PD-1 (scale bar, 200  $\mu$ m) in anti-IgG and anti-PD-1-treated  $TG^{Alb-cre+}$  mice. Quantification is shown in Extended Data Fig. 11b. **l**, Kernel density estimation (KDE) plot for LDH expression in TILs from the livers of anti-IgG and PD-1-treated  $TG^{Alb-cre+}$  mice. **m**, The breeding strategy and liver images of 9-month-old  $TG:Pdcd1^{-/-}$  mice. Scale bar, 1 cm. **n**, The tumour number (left) and area (right; cm $^2$ ) of 9-month-old  $TG:Pdcd1^{-/-}$  mice. **o**, Representative liver H&E staining (scale bar, 3 mm) and IHC analysis of CD8 or PD-1 (scale bar, 200  $\mu$ m) in 9-month-old  $TG:Pdcd1^{-/-}$  mice. Quantification is shown in Extended Data Fig. 12j. **p**, Kaplan-Meier survival curves of  $TG^{Alb-cre+}$  ( $n = 43$ ) and  $TG:Pdcd1^{-/-}$  mice ( $n = 53$ ). The sample sizes, biological replicates and statistical tests are described in the Methods and Source data.

environment fosters a unique tumour immune microenvironment of T cell exhaustion, weakening natural immunosurveillance, rendering it highly responsive to ICB.

Genetic inhibition or targeting of PD-1 in mice with hepatic ATF6 $\alpha$  activation reduced tumour burden. Accordingly, higher expression of ATF6 $\alpha$  target genes in human liver tumours was found in complete responders to ICB monotherapy and the induction of ATF6 $\alpha$  activation in preclinical liver cancer models significantly improved response to anti-PD-1 therapy. Therapeutically limiting hepatocyte ATF6 $\alpha$  activation reduced cell-autonomous oncogenesis and increased naturally existing immunosurveillance. Together, ATF6 $\alpha$  activation in HCC may serve both as (1) a promising candidate for targeted suppression in liver cancer; and (2) a potential stratification marker in human HCC, indicating increased likelihood of response to ICB therapy.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-025-10036-8>.

- Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA* **71**, 209–249 (2021).
- Urrea, H., Dufey, E., Avril, T., Chevet, E. & Hetz, C. Endoplasmic reticulum stress and the hallmarks of cancer. *Trends Cancer* **2**, 252–262 (2016).
- Wu, J. et al. ATF6 $\alpha$  optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. *Dev. Cell* **13**, 351–364 (2007).
- Finn, R. S. et al. Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. *Lancet Oncol.* **26**, 214–226 (2025).
- Ringelhan, M., Pfister, D., O'Connor, T., Pikarsky, E. & Heikenwalder, M. The immunology of hepatocellular carcinoma. *Nat. Immunol.* **19**, 222–232 (2018).
- Li, X. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. *Nat. Rev. Cancer* **21**, 541–557 (2021).
- Shalapour, S. et al. Inflammation-induced IgA<sup>+</sup> cells dismantle anti-liver cancer immunity. *Nature* **551**, 340–345 (2017).
- Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. *Nat. Rev. Clin. Oncol.* **19**, 151–172 (2022).
- Llovet, J. M. et al. Hepatocellular carcinoma. *Nat. Rev. Dis. Primers* **7**, 6 (2021).
- Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. *Nat. Rev. Clin. Oncol.* **15**, 599–616 (2018).
- Abou-Alfa Ghassan, K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *NEJM Evid.* **1**, EVID0a2100070 (2022).
- Xia, S., Pan, Y., Liang, Y., Xu, J. & Cai, X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. *eBioMedicine* **51**, 102610 (2020).
- Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat. Rev. Cancer* **14**, 581–597 (2014).
- Lebeaupein, C. et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. *J. Hepatol.* **69**, 927–947 (2018).
- Coleman, O. I. et al. Activated ATF6 induces intestinal dysbiosis and innate immune response to promote colorectal tumorigenesis. *Gastroenterology* **155**, 1539–1552 (2018).
- Rutkowski, D. T. et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. *Dev. Cell* **15**, 829–840 (2008).
- Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* **1**, 417–425 (2015).
- Villanueva, A. et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. *Hepatology* **61**, 1945–1956 (2015).
- Montironi, C. et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. *Gut* **72**, 129 (2023).
- Martins-Filho, S. N., Paiva, C., Azevedo, R. S. & Alves, V. A. F. Histological grading of hepatocellular carcinoma—a systematic review of literature. *Front. Med.* **4**, 193 (2017).
- Jiang, Y. et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. *Nature* **567**, 257–261 (2019).
- Gu, L. et al. FBP1 controls liver cancer evolution from senescent MASH hepatocytes. *Nature* **637**, 461–469 (2025).
- English, K. et al. A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs. *Nat. Commun.* **15**, 1261 (2024).
- Magen, A. et al. Intratumoral dendritic cell–CD4<sup>+</sup> T helper cell niches enable CD8<sup>+</sup> T cell differentiation following PD-1 blockade in hepatocellular carcinoma. *Nat. Med.* **29**, 1389–1399 (2023).
- Haber, P. K. et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. *Gastroenterology* **164**, 72–88 (2023).
- Umemura, A. et al. p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. *Cancer Cell* **29**, 935–948 (2016).

- Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550 (2005).
- Li, F. et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. *Nat. Cell Biol.* **22**, 728–739 (2020).
- Freeze, H. H., Boyce, M., Zachara, N. E., Hart, G. W. & Schnaar, R. L. in *Essentials of Glycobiology* (eds Varki, A. et al.) 53–66 (Cold Spring Harbor Laboratory Press, 2022).
- Lin, Y. H. et al. Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. *Hepatology* **67**, 188–203 (2018).
- Gu, L. et al. Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness. *Cell Metab.* **35**, 1009–1021 (2023).
- Hirata, H. et al. Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. *Cancer Res.* **76**, 3265–3276 (2016).
- Li, B. et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. *Nature* **513**, 251–255 (2014).
- Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* **140**, 197–208 (2010).
- Liu, K., Zhao, C., Adajar, R. C., DeZwaan-McCabe, D. & Rutkowski, D. T. A beneficial adaptive role for CHOP in driving cell fate selection during ER stress. *EMBO Rep.* **25**, 228–253 (2024).
- Wolf, M. J. et al. Metabolic activation of intrahepatic CD8<sup>+</sup> T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell* **26**, 549–564 (2014).
- Nakagawa, H. et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. *Cancer Cell* **26**, 331–343 (2014).
- Kim, Y. et al. Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular cancer models. *Mol. Ther.* **27**, 1547–1557 (2019).
- Moeini, A. et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. *Gastroenterology* **157**, 1383–1397 (2019).
- Daassi, D., Mahoney, K. M. & Freeman, G. J. The importance of exosomal PDL1 in tumour immune evasion. *Nat. Rev. Immunol.* **20**, 209–215 (2020).
- Tran, S. et al. Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. *Immunity* **53**, 627–640 (2020).
- Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. *Cell* **162**, 1217–1228 (2015).
- Hartmann, F. J. et al. Single-cell metabolic profiling of human cytotoxic T cells. *Nat. Biotechnol.* **39**, 186–197 (2021).
- Sharma, D., Singh, M. & Rani, R. Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. *Semin. Cancer Biol.* **87**, 184–195 (2022).
- Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. *Nature* **541**, 321–330 (2017).
- Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat. Rev. Drug Discov.* **18**, 197–218 (2019).
- Grandjean, J. M. D. & Wiseman, R. L. Small molecule strategies to harness the unfolded protein response: where do we go from here? *J. Biol. Chem.* **295**, 15692–15711 (2020).
- Hazari, Y., Chevet, E., Bailly-Maitre, B. & Hetz, C. ER stress signaling at the interphase between MASH and HCC. *Hepatology* **83**, 387–408 (2026).
- Hong, M. et al. Underglycosylation of ATF6 as a novel sensing mechanism for activation of the unfolded protein response. *J. Biol. Chem.* **279**, 11354–11363 (2004).
- Bruce, C. R. et al. Translating glucose tolerance data from mice to humans: Insights from stable isotope labelled glucose tolerance tests. *Mol. Metab.* **53**, 101281 (2021).
- Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. *Cell* **175**, 984–997.e924 (2018).
- Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. *Cell Rep.* **18**, 248–262 (2017).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

Xin Li<sup>1,2,69</sup>, Cynthia Lebeaupein<sup>3,69,82</sup>, Aikaterini Kadianaki<sup>1,2</sup>, Clementine Druelle-Cedano<sup>3</sup>, Niklas Vesper<sup>4,5</sup>, Charlotte Rennert<sup>4</sup>, Júlia Huguet-Pradell<sup>6,7</sup>, Borja Gomez Ramos<sup>8,9,10</sup>, Chaofan Fan<sup>1,2</sup>, Robert Stefan Pieczyk<sup>11,12</sup>, Laimdota Zizmare<sup>13,14</sup>, Pierluigi Ramadori<sup>11,15</sup>, Luqing Li<sup>1</sup>, Lukas Frick<sup>16</sup>, Menjie Qiu<sup>15</sup>, Cangang Zhang<sup>17</sup>, Luiza Martins Nascentes Melo<sup>18,19</sup>, Vikas Prakash Ranvir<sup>1,2</sup>, Peng Shen<sup>12</sup>, Johannes Hanselmann<sup>15</sup>, Jan Kosla<sup>1</sup>, Mirian Fernández-Vaquero<sup>1,2</sup>, Mihael Vucur<sup>20</sup>, Praveen Baskaran<sup>21</sup>, Xuanwen Bao<sup>22</sup>, Olivia I. Coleman<sup>23</sup>, Yingyue Tang<sup>24</sup>, Miray Cetin<sup>2,25</sup>, Zhouji Chen<sup>3</sup>, Insook Jang<sup>3</sup>, Stefania Del Prete<sup>26</sup>, Mohammad Rahbari<sup>1</sup>, Peng Zhang<sup>27</sup>, Timothy V. Pham<sup>28</sup>, Yushan Hou<sup>29</sup>, Aihua Sun<sup>29</sup>, Li Gu<sup>30,31,32</sup>, Laura C. Kim<sup>33,34</sup>, Ulrike Rothermel<sup>1</sup>, Danijela Heide<sup>1</sup>, Adnan Ali<sup>1</sup>, Suchira Gallage<sup>15</sup>, Nana Talvard-Balland<sup>35</sup>, Marta Piqué-Gil<sup>16</sup>, Albert Gris-Oliver<sup>6</sup>,

Alessio Bevilacqua<sup>36</sup>, Lisa Schlicker<sup>37</sup>, Alec Duffey<sup>3</sup>, Kristian Unger<sup>1,11,12,38,39,40,41</sup>, Marta Szydłowska<sup>1</sup>, Jenny Hetzer<sup>1</sup>, Duncan T. Odom<sup>26</sup>, Tim Machauer<sup>1</sup>, Daniele Buccì<sup>13</sup>, Pooja Sant<sup>42</sup>, Jun-Hoe Lee<sup>21</sup>, Jonas Rösler<sup>43</sup>, Sven W. Meckelmann<sup>43</sup>, Johannes Schreck<sup>24</sup>, Sue Murray<sup>44</sup>, M. Celeste Simon<sup>33,34</sup>, Sven Nahnsen<sup>14,21,45</sup>, Almut Schulze<sup>37</sup>, Ping-Chih Ho<sup>36,46</sup>, Manfred Jugold<sup>47</sup>, Kai Breuhahn<sup>24</sup>, Jan-Philipp Mallm<sup>42</sup>, Peter Schirmacher<sup>24</sup>, Susanne Roth<sup>15,48,49</sup>, Nuh Rahbari<sup>1,48</sup>, Darjus F. Tschaharganeh<sup>24</sup>, Stephanie Roessler<sup>24</sup>, Benjamin Goepfert<sup>50,51</sup>, Bertram Bengsch<sup>4,52</sup>, Geoffroy Andrieux<sup>53</sup>, Melanie Boerries<sup>53,54</sup>, Nisar P. Malek<sup>15,55</sup>, Marco Prinz<sup>2,56,57,58</sup>, Achim Weber<sup>59,60</sup>, Robert Zeiser<sup>35</sup>, Pablo Tamayo<sup>28,61</sup>, Peter Bronsner<sup>62,63</sup>, Konrad Kurowski<sup>62,63</sup>, Robert Thimme<sup>4</sup>, Detian Yuan<sup>27</sup>, Rafael Carretero<sup>64</sup>, Tom Luedde<sup>20</sup>, Roser Pinyol<sup>6</sup>, Felix J. Hartmann<sup>25</sup>, Michael Karin<sup>3,30</sup>, Alpaslan Tasdogan<sup>18,19</sup>, Christoph Trautwein<sup>13,14,15,65</sup>, Moritz Mall<sup>8,9,10</sup>, Maik Hofmann<sup>4</sup>, Josef M. Llovet<sup>6,7,66</sup>, Dirk Haller<sup>23,67,68</sup>, Randal J. Kaufman<sup>3,70,69</sup> & Mathias Heikenwälder<sup>1,14,15,68,70,69</sup>

<sup>1</sup>Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>2</sup>Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. <sup>3</sup>Center for Metabolic and Liver Disease, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. <sup>4</sup>Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>5</sup>Faculty of Biology, University of Freiburg, Freiburg, Germany. <sup>6</sup>Liver Cancer Translational Research Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. <sup>7</sup>Mount Sinai Liver Cancer Program, Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>8</sup>Division of Cell Fate Engineering and Disease Modeling, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. <sup>9</sup>HITBR Hector Institute for Translational Brain Research, Heidelberg, Germany. <sup>10</sup>Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. <sup>11</sup>Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. <sup>12</sup>Bavarian Cancer Research Center (BZKF), Munich, Germany. <sup>13</sup>Werner Siemens Imaging Center (WSIC), Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany. <sup>14</sup>Cluster of Excellence IFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. <sup>15</sup>M3-Research Center for Malignome, Metabolome and Microbiome, Institute for Interdisciplinary Research on Cancer Metabolism and Chronic Inflammation, Faculty of Medicine, University of Tübingen, Tübingen, Germany. <sup>16</sup>Institute of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. <sup>17</sup>Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, China. <sup>18</sup>Department of Dermatology, University Hospital Essen, Essen, Germany. <sup>19</sup>German Cancer Consortium (DKTK) Partner Site, Essen, Germany. <sup>20</sup>Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty at Heinrich-Heine-University, Düsseldorf, Germany. <sup>21</sup>Quantitative Biology Center (QBiC), Eberhard Karls University Tübingen, Tübingen, Germany. <sup>22</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. <sup>23</sup>Chair of Nutrition and Immunology, Technische Universität München, Freising, Germany. <sup>24</sup>Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. <sup>25</sup>Systems Immunology and Single-Cell Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>26</sup>Division of Regulatory Genomics and Cancer Evolution, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>27</sup>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, CheeLoo College of Medicine, Shandong University, Jinan, China. <sup>28</sup>Center for Novel Therapeutics and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. <sup>29</sup>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for

Protein Sciences (Beijing), Institute of Lifeomics, Beijing, China. <sup>30</sup>Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA. <sup>31</sup>Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. <sup>32</sup>Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China. <sup>33</sup>Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. <sup>34</sup>Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA, USA. <sup>35</sup>Department of Hematology and Oncology, Freiburg University Medical Centre, Freiburg, Germany. <sup>36</sup>Department of Oncology, University of Lausanne, Epalinges, Switzerland. <sup>37</sup>Division of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>38</sup>German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>39</sup>Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany. <sup>40</sup>Research Unit Translational Metabolic Oncology (TMO), Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany. <sup>41</sup>German Center for Diabetes Research (DZD), Neuherberg, Germany. <sup>42</sup>Single-Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>43</sup>Applied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany. <sup>44</sup>Ionis Pharmaceuticals, Carlsbad, CA, USA. <sup>45</sup>Biomedical Data Science, Department of Computer Science, University of Tübingen, Tübingen, Germany. <sup>46</sup>Ludwig institute for Cancer Research, University of Lausanne, Epalinges, Switzerland. <sup>47</sup>Core Facility Small Animal Imaging, German Cancer Research Center Heidelberg, Heidelberg, Germany. <sup>48</sup>Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany. <sup>49</sup>Department of General, Visceral and Transplantation Surgery, Tübingen University Hospital, Tübingen, Germany. <sup>50</sup>Institute of Pathology, RKH Hospital, Ludwigsburg, Germany. <sup>51</sup>Institute of Tissue Medicine and Pathology, University of Berne, Berne, Switzerland. <sup>52</sup>Signalling Research Centres BIOS and CIBSS, University of Freiburg, Freiburg, Germany. <sup>53</sup>Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>54</sup>German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center-University of Freiburg, Freiburg, Germany. <sup>55</sup>Department Internal Medicine I, University Hospital Tübingen, Tübingen, Germany. <sup>56</sup>Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany. <sup>57</sup>CIBSS Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany. <sup>58</sup>Center for Brain Research and Advancements in Neuroimmunology (BRAIN), Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>59</sup>Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland. <sup>60</sup>Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland. <sup>61</sup>Division of Genomics and Precision Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA. <sup>62</sup>Core Facility for Histopathology and Digital Pathology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>63</sup>Institute for Surgical Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. <sup>64</sup>DKFZ-Bayer Immunotherapeutic Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>65</sup>Core Facility Metabolomics, Medical Faculty University of Tübingen, Tübingen, Germany. <sup>66</sup>Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. <sup>67</sup>ZIEL Institute for Food and Health, Technische Universität München, Freising, Germany. <sup>68</sup>Cluster of Excellence EXC 2124 Controlling Microbes to Fight Infections, University of Tübingen, Tübingen, Germany. <sup>69</sup>These authors contributed equally: Xin Li, Cynthia Lebeaupin. <sup>70</sup>These authors jointly supervised this work: Randal J. Kaufman, Mathias Heikenwälder. <sup>69</sup>e-mail: cynthia.lebeaupin@gmail.com; dirk.haller@tum.de; rkaufman@sbpdiscovery.org; m.heikenwaelder@dkfz-heidelberg.de

## Methods

Key reagents and resource identifiers are provided in Supplementary Table 3.

## Human samples

Human HCC TMAs used in this study were obtained with informed patient consent from K.B. as described previously<sup>53</sup>. In brief, TMAs with formalin-fixed paraffin-embedded (FFPE) tissues ( $n = 731$ ) contained tumour-free/cirrhotic livers ( $n = 241$ ), premalignant dysplastic nodules ( $n = 14$ ) and HCCs ( $n = 473$ ; with G1 (87), G2 (311), G3 (75))<sup>20</sup>. Tissue cores had a diameter of 1 mm and slides had a thickness of 1–2  $\mu\text{m}$ . We complied with all relevant ethical regulations. The study was approved by the institutional ethics committee of the Medical Faculty of Heidelberg University (S-206/2005). Liver sections and snap-frozen tissue samples from healthy donors and patients with hepatitis were obtained from M.R. and N.R. with the approved institutional review board (IRB) protocol (2012-293N-MA) from the University Hospital Mannheim; from S. Roth with the approved ethical protocol S-629/2013; from A.W. with the approved application number KEK-ZH-Nr 2013-0382 by the local ethics committee (Kantonale Ethikkommission Zurich) in University Hospital Zurich. Human liver sections involved in spatial biology and IMC analysis were obtained from M. Hofmann, following the Declaration of Helsinki (1975), federal guidelines and local ethics committee regulations (Albert-Ludwigs-University, Freiburg, Germany, 20-1066). Detailed information is provided in the 'IMC analysis of human samples' section and Supplementary Table 2.

## Mice, diets, and treatments

The nomenclature and a description of ATF6 $\alpha$  mouse models are provided in Supplementary Table 1. The *nATF6<sup>fl/fl</sup>* (R26-LSL-nATF6-HA) mouse line was obtained by D. Haller<sup>15</sup>. *Alb-cre* mice and *Atf6<sup>fl/fl</sup>* mice were obtained from The Jackson Laboratory. *Pdcd1<sup>-/-</sup>* mice were provided by G. Tiegs and K. Neumann<sup>54</sup>. *Atf6<sup>-/-</sup>* mice were described previously by R.J.K.<sup>3</sup>. *MUP-uPA* mice were described previously<sup>37</sup>. The *nATF6<sup>fl/fl</sup>* mice were crossed with *Alb-cre* mice or intravenously injected with AAV8-cre (Vector Biolabs, VB1724 or VB1743 GFP control, 1E11VG/mouse) to generate hepatocyte-specific nATF6-HA-overexpressing heterozygous mice (*TG<sup>Alb-cre+</sup>* or *TG<sup>AAV-cre+</sup>*). Hepatocyte-specific nATF6-HA-overexpressing heterozygous mice (*TG<sup>Alb-cre+</sup>*) were bred with *Pdcd1<sup>-/-</sup>* mice to generate *TG:Pdcd1<sup>-/-</sup>* mice. Heterozygous R26-LSL-nATF6-HA mice (*nATF6<sup>fl/+</sup>*) were intravenously co-injected with AAV8-cre and AAV8-FBP1 or AAV8-FBP1<sup>E98A</sup> (plasmids were provided by M.K. and L.G.<sup>31</sup>; 1E11VG/mouse) to generate hepatocyte-specific FBP1-overexpressing mice (*TG<sup>AAV-cre/fbp1</sup>* or *TG<sup>AAV-cre/fbp1E98A</sup>*). *Atf6<sup>-/-</sup>* and littermate *Atf6<sup>+/-</sup>* mice were bred with *MUP-uPA* mice to generate *Atf6<sup>-/-</sup>:MUP-uPA* and *Atf6<sup>+/-</sup>:MUP-uPA* mice. The *Atf6<sup>fl/fl</sup>* mice were crossed with *Alb-cre* mice to generate hepatocyte-specific *Atf6*-knockout mice (*Atf6<sup>ΔHep</sup>*). All of the mouse lines were either on a pure C57BL/6J genetic background or crossed into it for at least ten generations.

Mice were housed under specific-pathogen-free (SPF) conditions at the German Cancer Research Center (DKFZ) or Sanford Burnham Prebys (SBP) at constant temperature of 20–24 °C and 45–65% humidity under a 12 h–12 h light–dark cycle. All control mice were age, gender and genetic-background matched. Where applicable, littermate controls were used to minimize the variation between mouse strains.

For mice receiving injections, the following protocols were used where applicable. *TG<sup>Alb-cre+</sup>* mice (aged 9 months) were treated with anti-PD-1 antibody (Bioxcell, BE0146) or isotype control (Bioxcell, BE0089) at an initial dose of 500  $\mu\text{g}$  i.p. followed by doses of 200  $\mu\text{g}$  i.p. bi-weekly for 12 weeks, as previously described<sup>55</sup>. Mice (aged 2 weeks) were i.p. injected once with DEN (Sigma-Aldrich, N0756, 25 mg per kg). GalNAc conjugation to ASOs against *Atf6* (GalNAc-ASO-*Atf6*; Gen 2.5 ASO (16-mer 3-10-3): GAATTTTTCAGCAAGG conjugated to GalNAc on the 5' end; Ionis Pharmaceuticals) or a scrambled nucleotide sequence

(GalNAc-ASO-scramble; Gen 2.5 ASO (16-mer 3-10-3): CGCCGATAAGG TACAC conjugated to GalNAc on the 5' end; Ionis Pharmaceuticals) were subcutaneously injected at 2.5 mg per kg once weekly at 4, 9 or 30 weeks of age (see the schematics in the figures). Oncogene *NRAS<sup>G12V</sup>* plasmid DNA (Addgene, 20205) was administered at 20  $\mu\text{g}$  transposon (*NRAS<sup>G12V</sup>*) combined with 10  $\mu\text{g}$  transposase (Sleeping Beauty (SB) 100, Addgene, 34879) in 2.5 ml by HDTV<sub>i</sub> per mouse at 8 weeks of age (see the schematics in the figures). The oncogene *KRAS<sup>G12D</sup>* (5  $\mu\text{g}$  per mouse, from D.T.), *MYC* (10  $\mu\text{g}$  per mouse, from D.T.) and sg-P53 (10  $\mu\text{g}$  per mouse in combination with *KRAS<sup>G12D</sup>*, 20  $\mu\text{g}$  per mouse in combination with *MYC*, Addgene, 59910) plasmid DNA were delivered together with SB transposase (transposon:transposase, 5:1; from D.T.) in 2 ml saline solution through HDTV<sub>i</sub> to the mouse liver. For HDTV<sub>i</sub> experiments, mice aged 8–12 weeks were used (see the schematics in the figures).

Dietary models started after 6 weeks of age (see the schematics in the figures) and included HFD (60% HFD; BioServ F3282 or Research Diets D12492i), CD-HFD (Research Diets D05010402) and WD (Research Diets D1602230i). Cholaemic mice were excluded from dietary experiments<sup>56</sup>. The i.p. glucose tolerance test and insulin tolerance test were performed as previously described<sup>57</sup>. The pyruvate tolerance test was performed in 16-h-fasted mice by measuring the blood glucose levels after a 2 g per kg pyruvate i.p. injection. Many treatment regimens, with experimental schemes with timelines shown in the figures, extended data figures and supplementary figures, used previously published reagents and standard experimental techniques<sup>55</sup>.

Housing and breeding of mice without interventions were performed in accordance with the approved protocols (A-23/17, EP-Z146102, G6/22 and G279/16) in the German Cancer Research Center (DKFZ). Mouse experiments were performed in accordance with German law and the governmental bodies, with approval from the Regierungspräsidium Karlsruhe (DKFZ 332, G6/22, G11/16, G129/16, G279/16, G7/17, G80/17, G70/18, G178/19, G141/19, G132-23 and G97/24) or National Institute of Health (NIH) guidelines of the United States, with approval from the SBP Institutional Animal Care and Use Committee (IACUC, AUF 23-027 (previously 20-030), AUF 23-045 (previously 20-056)). Tumour models used in this study were orthotopic hepatic tumour models; thus, direct calliper-based measurement of tumour size in living mice was not feasible. Animal monitoring and experimental procedures strictly adhered to the termination criteria outlined in the above-mentioned protocols (DKFZ 332, G6/22, G11/16, G129/16, G279/16, G7/17, G80/17, G70/18, G178/19, G141/19, G132-23 and G97/24 in DKFZ; IACUC, AUF 23-027 and AUF 23-045 in SBP). Each mouse was examined daily by trained animal care staff or research personnel. Animals exhibiting signs of distress, morbidity, clinical signs of pain or distress (including but not limited to cachexia, cyanosis, dyspnoea, ascites, or lack of mobility, food and water intake), or any abnormality meeting the predefined termination criteria were promptly euthanized, after which the biological materials were collected. These limits were not exceeded in any of the experiments. Mice that remained clinically normal and did not reach the termination criteria were maintained until the designated experimental endpoint, at which time they were euthanized, and the liver tumours were excised and measured.

## Measurements of serum parameters

Blood was drawn by cardiac puncture after dissection, and centrifugation was used to isolate serum using serum isolation gel tubes (Sarstedt, Z/1.1). The serology parameters were measured with commercially available FUJIFILM DRI-CHEM slides for ALT, AST, TCHO, TBIL, ALB and ALP on FUJIFILM DRI-CHEM NX500i or with Vetscan Mammalian Liver Profile rotors (Abaxis, 500-0040-12) with Vetscan VS2 Chemistry Analyzer. Fasting insulin levels were measured with 10  $\mu\text{l}$  of serum from 16 h fasted mice by ELISA, according to the manufacturer's guidelines (Mercodia, 10-1247-01) Serum lipids were measured using Infinity Reagents (Thermo Fisher Scientific, TR22421 triglycerides, TR13421 cholesterol).

## Cell lines and culture conditions

Cancer cell lines and viral studies were approved by the Institutional Biosafety Committees. The FL83B cells were purchased from ATCC. Colo800 and MART-1 T cells were obtained from R.C.<sup>58</sup>. The HLE cells originated from Japanese Collection of Research Bioresources Cell Bank (JCRB)<sup>59</sup>. The generation of nATF6-overexpression and *Atf6* knock-out (KO) cell lines was done in collaboration with J.K.

To generate nATF6-overexpression cells, the coding sequence encoding the activated form of mouse *Atf6* (*nAtf6*, amino acids 1–373) or human *ATF6* (nATF6, amino acids 1–386) and HA tag was cloned between the XhoI and EcoRI restriction sites of the retroviral plasmid MSCV-linker-IRES-GFP, resulting in the MSCV-nAtf6-IRES-GFP or MSCV-nATF6-IRES-GFP vector, respectively. nATF6 overexpressing (FL83B<sup>TC</sup>, HLE<sup>TC</sup> and Colo800<sup>TC</sup>) and control (FL83B<sup>WT</sup>, HLE<sup>WT</sup> and Colo800<sup>WT</sup>) cells were prepared by transduction of cells with retroviral particles containing MSCV-nAtf6-IRES-GFP or MSCV-nATF6-IRES-GFP and MSCV-linker-IRES-GFP construct, respectively. Viral particles were produced in Phoenix GP cells (ATCC CRL-3215) after transfection with either MSCV-nAtf6-IRES-GFP, or MSCV-nATF6-IRES-GFP or MSCV-linker-IRES-GFP vector together with VSV-G (Clontech) vector. Cells were expanded and sorted for GFP using the FACS Aria II (BD) system.

The FL83B *Atf6* KO cells were prepared by transfection (Lipofectamine 3000 Transfection Reagent, Thermo Fisher Scientific) of FL83B cells with vectors derived from pSpCas9(BB)–2A-Puro (PX459) V2.0<sup>60</sup> and following selection with puromycin (10 µg ml<sup>-1</sup>) for 3 days. The sequences for single guide RNAs (sgRNAs) and primers for verification of indel formation were designed using the CRISPOR.org webtool<sup>61</sup>. Control cells for FL83B *Atf6*-KO cells were transfected with PX459 V2.0 without any sgRNA cloned in. Indel formation was verified by TIDE assay<sup>62</sup>.

Cells were cultured in F12K Nut mix (FL83B cells, Invitrogen) or RPMI 1640 GlutaMax (Colo800 cells, HLE cells and MART-1 T cell, Invitrogen) containing 10% FBS (Invitrogen) and 1% penicillin–streptomycin (GIBCO).

## In vitro T cell killing assays

Colo800<sup>WT</sup> and Colo800<sup>TC</sup> cells were cultured overnight in 96-well ePlates (OMNI Life Science), followed by co-culture with or without MART-1 T cells in a ratio 1:5 for 3 days. The tumour cell growth rate was measured using the Agilent xCELLigence platform. For the rescue experiment, galloflavin (AOB1024-10, 200 µM) or AZD3965 (S7339, 1.6 nM) were used. The same protocol was applied to HLE<sup>WT</sup> and HLE<sup>TC</sup> cells but MelanA peptide was included at 25 ng ml<sup>-1</sup> in the culture medium to ensure proper antigen presentation.

## Metabolic flux analysis using the Seahorse bioanalyser

For extracellular acidification rate determination, the Agilent Seahorse XF Glycolysis Stress Test kit (Agilent, 103020-100) on the Seahorse Agilent XF96 platform was used according to the manufacturer's instructions. On Cell-Tak-coated (Corning, 354240) plates, 20k FL83B<sup>WT</sup>/FL83B<sup>TC</sup> cells or 100,000 MACS-purified primary TILs were seeded and crystal violet staining was performed after the assay for cell number normalization. The results were calculated with Agilent Wave Software v.2.6. At least three biological replicates, averaging up to eight technical replicates each, were used per experiment in quantifications.

## TEM analysis

TEM was performed in collaboration with M.P. Liver tissues were fixed with 2% paraformaldehyde and 2.5% of glutaraldehyde in 0.15 M sodium cacodylate buffer (SC buffer pH 7.4) for 48 h at 4 °C. The samples were placed in 1% osmium tetroxide in 0.15 M sodium cacodylate for 1–2 h on ice. The samples were washed five times for 10 min in 0.15 M SC buffer followed by rinsing in double-distilled H<sub>2</sub>O on ice and incubated in 2% of

uranyl acetate for 1–2 h at 4 °C. The samples were dehydrated in ethanol: 50%, 70%, 90%, twice at 100% for 10 min each on ice followed by dry acetone for 15 min at room temperature. Samples were incubated in 50:50 ETOH: Durcupan for at least 1 h at room temperature, followed by 100% Durcupan overnight. The next day, the samples were placed in fresh 100% Durcupan for half a day at room temperature. Tissues were embedded in Durcupan at 60 °C in an oven for 36–48 h. Ultrathin sections (60 nm) were cut on Leica microtome with Diamond knife followed by post-staining with both uranyl acetate and lead. Images were captured on JEOL 1400 plus TEM at 80KV with Gatan 4kx4k camera.

## Immune cell isolation and FACS

The isolation and staining of lymphocytes for flow cytometry followed a protocol described previously<sup>55</sup>. The mice were euthanized and the livers perfused with 0.9% NaCl buffer. Livers/tumours were collected, minced, digested with collagenase and DNase, and subsequently passed through a 100-µm filter. Hepatic lymphocytes were then purified by a two-step Percoll gradient. The spleens were passed through 100-µm mesh and washed to isolate splenic lymphocytes. The samples were treated with red blood cell lysis buffer for 5 min at room temperature, followed by a wash step. Magnetic-activated cell sorting (MACS)-based positive/negative selection (Miltenyi Biotec 130-090-101, Dead Cell Removal Kit; Miltenyi Biotec 130-117-044, CD8a (Ly-2) MicroBeads) was used to purify live TILs according to the manufacturer's instructions.

For lymphocyte stimulation, cells were cultured in RPMI 1640 supplemented with 2% (v/v) FBS. Cell activation cocktail with brefeldin A (BioLegend, 423304) and monensin solution (BioLegend, 420701) were diluted in the medium at 1:500 and 1:1,000, respectively. Antibody staining was done in the presence of Fc receptor blockade in FACS buffer. For live/dead cell discrimination, the ZombieDyeNIR was used according to the manufacturer's guidelines. After washing with FACS buffer and centrifugation (400g, 5 min, 4 °C), the cells were stained for 40 min at 4 °C with 25 µl of titrated antibody master mix and washed. Where applicable, the samples were sorted by FACS. eBioscience intracellular fixation buffer (00-8222-49) was used to fix samples for flow cytometry according to the manufacturer's guidelines. For samples requiring intracellular staining, eBioscience Perm buffer (00-8333-56) was used. The BD FACS Fortessa system was used to analyse the stained cells, and FlowJo was used to analyse data. In collaboration with the DKFZ FACS core facility, a FACS Aria II machine and a FACS Aria FUSION machine were used for sorting.

## Histological staining and in situ hybridization

The histology, IHC and scanning were performed as described previously<sup>57</sup>. Mice were euthanized and tissues were cryo-preserved or collected and fixed in 4% paraformaldehyde for 24 h. Paraformaldehyde-fixed tissues were paraffin-embedded, cut and stained in collaboration with the technical team from the Department of Chronic Inflammation and Cancer, DKFZ, Heidelberg or SBP Histology Core, San Diego.

For histological staining, FFPE tissues were cut to prepare 2-µm sections. These sections were stained with H&E or IHC with the antibodies listed in Supplementary Information on the Bond-MAX machine (Leica). The ATF6α IHC score in human liver was evaluated by a certified physician<sup>53</sup> based on intensity: 1, low/not detected; 2, moderate; 3, high; cytoplasm: 0, negative; 1, ≤33%; 2, 34–66%; 3, ≥67%; nuclear: 0, negative; 1, 1%; 2, 1–5%; 3, 6–20%; 4, ≥21%. For lipid droplet staining, 5-µm sections from cryo-preserved tissues were stained with Sudan Red (0.25% Sudan IV in ethanolic solution) or Oil Red O (0.5%, PolyScientific, K043). In situ hybridization was performed according to the manufacturer's instructions, the probe and reagents were purchased from Advanced Cell Diagnostics (ACD). 5-µm sections from mouse FFPE tissue were used. All stained slides were scanned with the Aperio AT2 DX System (Leica) and analysed by macro-based analysis by ImageJ (1.54g) or QuPath (v.0.5.1).

## Immunofluorescence

Immunofluorescence microscopy was performed in collaboration with D. Heide and J. Hetzer. In brief, mouse liver tissue was embedded in optimal cutting temperature (OCT) compound. Then, 25- $\mu$ m liver sections were permeabilized and blocked with 0.3% Triton X-100 (Sigma-Aldrich) and 10% FBS in PBS. CD3 (Invitrogen, MA1-90582), CD8 (BD, 553027) and PD-1 (R&D, AF1021) primary antibodies were used to stain the samples. Stained slides were covered with fluorescence mounting medium (DAKO) and scanned with the NanoZoomer S60 Digital slide scanner (Hamamatsu Photonics).

## NMR spectroscopy-based metabolomics

Nuclear magnetic resonance (NMR) spectroscopy-based metabolomics analysis was performed in collaboration with L.Z., D.B. and C.T. at the Werner Siemens Imaging Center (WSIC), Eberhard Karls University of Tübingen. In brief, liver pieces were cryogenically pulverized (Covaris cryoPREP CP02) and the powder was transferred to 2 ml adaptive focused acoustics glass tubes, where it was suspended in 300  $\mu$ l ultrapure methanol, 1000  $\mu$ l *tert*-butylmethyl ether and subjected to ultra-sonication-based 2-phase metabolite extraction procedures (Covaris E220 Evolution) using two consecutive sonication programs with vertical sample movement for maximum extraction yield. After ultrasonication, 250  $\mu$ l of molecular-biology-purity-grade water was added. The samples were centrifuged for phase separation at 12,000g for 10 min. The layers were then manually separated, aqueous phase was transferred to 1.5 ml tubes and evaporated overnight in a vacuum concentrator (Speedvac SPD300, Thermo Fisher Scientific).

Similarly, cell culture pellets collected in 1.2 ml ultrapure methanol were transferred to 2 ml adaptive focused acoustics glass tubes and subjected to a one-phase extraction procedure. Then, 110  $\mu$ l of chloroform and ultrapure water were added, and the mixtures were subjected to ultrasonication extraction. The mixtures were centrifuged to remove any potential solid particles, transferred to a clear glass vial and evaporated to dryness in the vacuum concentrator.

Dried metabolite pellets both from cell culture and liver tissue extracts were resuspended in deuterated phosphate buffer (pH 7.4, 1 M  $K_2HPO_4$ ,  $NaN_3$  containing 1 mM internal reference standard 3-(trimethylsilyl) propionic-2,2,3,3- $d_4$  acid sodium salt (TSP)) for quantification. The mixtures were again centrifuged at 30,000g for 30 min to separate undissolved substances. Clear supernatant was filled into 1.7 mm Bruker SampleJet-compatible NMR spectroscopy tubes. We acquired NMR spectra on a 600 MHz (proton frequency) spectrometer (Avance III HD, Bruker BioSpin) with a 1.7 mm room temperature microprobe at 298 K. A short proton ZG (zero go) experiment was recorded followed by a 7 min 1D NOESY (nuclear Overhauser effect) to assess offset the frequency and optimize water suppression. Carr–Purcell–Meiboom–Gill experiments were used for each polar extract sample to assign and quantify metabolites by suppressing residual background signals from remaining water and macromolecules (512 scans, 1 h for liver samples; 1,024 scans, 2 h for cell culture).

Spectra were preprocessed with Bruker TopSpin v.3.6.1, and annotated and quantified using ChenomX NMR suite v.8.5. The statistics were performed by MetaboAnalyst 5.0 online platform ([www.metaboanalyst.ca](http://www.metaboanalyst.ca)). In brief, we normalized the dataset by reference sample using probabilistic quotient normalization and performed a parametric analysis of variance (ANOVA) with an adjusted *P*-value (FDR) cut-off of 0.05 with Fisher's LSD post hoc analysis. For the heat maps, we used the Euclidean distance measure with Ward clustering algorithm.

## $^{13}C$ -lactate labelling and GC–MS

$TG^{AAV:gfip}$ ,  $TG^{AAV:cre}$  and  $TG^{AAV:cre/fbp1}$  mice at 13 weeks of age were fasted for 16 h overnight. The mice were injected intravenously with 0.25 mg per g sodium L-lactate ( $^{13}C_3$ ) three times at 15 min intervals before euthanasia.

Liver was collected and immediately snap-frozen in liquid nitrogen for metabolomic analysis.

The sample extraction methods were as follows: frozen liver samples (25–50 mg) were transferred to 2 ml tubes containing 2.8 mm ceramic beads (Omni International) and 0.45 ml ice-cold 50% methanol/20  $\mu$ M L-norvaline was added. The tubes were shaken (setting 5.5) for 30 s on the Bead Ruptor 12 (Omni International) system, quickly placed onto ice and frozen at  $-80^\circ C$  overnight. Thawed samples were centrifuged at 15,000g for 10 min at  $4^\circ C$ . The supernatant was then transferred to a new tube, mixed with 0.225 ml chloroform and centrifuged at 10,000g for 10 min at  $4^\circ C$ . This produced a two-phase separation. Portions (100  $\mu$ l) of the top phase were dried (Speedvac) for analyses of polar metabolites.

Metabolite derivatization and GC–MS run conditions: polar metabolites except for sugar phosphates were derivatized using isobutylhydroxylamine and MTBSTFA and analysed by GC–MS for  $^{13}C$  labelling and metabolite quantities as described previously<sup>63</sup>.

The samples were transferred to autosampler vials with inserts and analysed using the Rxi-5ms column (15 m  $\times$  0.25 mm inner diameter  $\times$  0.25  $\mu$ m, Restek) installed in a Shimadzu QP-2010 Plus gas chromatograph–mass spectrometer (GC–MS). The GC–MS was programmed with an injection temperature of  $250^\circ C$ , 1  $\mu$ l injection volume and split ratio 1/10. The GC oven temperature was initially  $130^\circ C$  for 4 min, rising to  $230^\circ C$  at  $6^\circ C\ min^{-1}$ , and to  $280^\circ C$  at  $60^\circ C\ min^{-1}$  with a final hold at this temperature for 2 min. The GC flow rate, with helium as the carrier gas, was  $50\ cm\ s^{-1}$ . The GC–MS interface temperature was  $300^\circ C$  and (electron impact) ion source temperature was  $200^\circ C$ , with 70 eV ionization voltage. The main glucose peak eluted at 13.7 min, and fragments of *m/z* 319 (contains 4 glucose carbons; overall formula  $C_{13}H_{31}O_3Si_3$ ) and *m/z* 205 (contains 2 glucose carbons; overall formula  $C_8H_{21}O_2Si_2$ ) were used to analyse  $^{13}C$ -glucose labelling as described previously<sup>63</sup>.

Samples for sugar-phosphate analysis were derivatized first with 30  $\mu$ l ethylhydroxylamine (Sigma-Aldrich)  $20\ mg\ ml^{-1}$  in pyridine for 20 min at  $80^\circ C$ , and secondarily with 30  $\mu$ l BSTFA (Thermo Fisher Scientific) for 60 min at  $80^\circ C$ . The samples were transferred to autosampler vials with inserts and analysed using an Rxi-5ms column (15 m  $\times$  0.25 mm inner diameter  $\times$  0.25  $\mu$ m, Restek) installed in a Shimadzu QP-2010 Plus GC–MS system. The GC–MS was programmed with an injection temperature of  $250^\circ C$ , 1.6  $\mu$ l injection volume and split ratio 1/10. The GC oven temperature was initially  $85^\circ C$  for 4 min, rising to  $115^\circ C$  at  $8^\circ C\ min^{-1}$ , to  $210^\circ C$  at  $20^\circ C\ min^{-1}$  and to  $280^\circ C$  at  $6^\circ C\ min^{-1}$  with a final hold at this temperature for 2 min. The GC flow rate, with helium as the carrier gas, was  $50\ cm\ s^{-1}$ . The GC–MS interface temperature was  $300^\circ C$  and (electron impact) the ion source temperature was  $200^\circ C$ , with 70 eV ionization voltage. Norvaline (internal standard) eluted at 6.7 min, glucose-1-phosphate at 15.7 min, the main fructose-6-phosphate peak at 16.1 min, and the main glucose-6-phosphate peak at 16.3 min. Fructose-6-phosphate was analysed for  $^{13}C$ -labelling using the fragment of *m/z* 459 containing three fructose carbons; the overall formula  $C_{15}H_{40}O_6Si_4P$ . Glucose-6-phosphate was analysed using the *m/z* 357 fragment ( $C_{11}H_{30}O_5Si_3P$ ) containing two glucose carbons and the *m/z* 471 fragment ( $C_{16}H_{40}O_6Si_4P$ ) containing four glucose carbons. Glucose-1-phosphate and glucose-6-phosphate were both quantified using *m/z* 315 and *m/z* 387 fragments; *m/z* 315 and 459 were used for quantifying fructose-6-phosphate, and the amounts were corrected for recovery of norvaline (*m/z* 144).

## Metabolomic analysis of liver tissue by LC–MS/MS

Metabolomic analysis of liver tissue by LC–MS/MS was performed in collaboration with L.M., N.M., S. Meckelmann and A.T. at University Hospital Essen and German Cancer Consortium, Essen. For metabolomic profiling using LC–MS/MS, 30–50 mg liver tissue was homogenized in ice-cold methanol using an electronic tissue disruptor (Qiagen). Metabolites were extracted following a two-step liquid method adapted from a previous study<sup>64</sup> with the addition of internal

standards ( $^{13}\text{C}_6$ -L-Arginine,  $^{13}\text{C}_5$ -L-Valine,  $^{13}\text{C}_2$ -citric acid,  $^2\text{H}_4$ -succinic acid and  $^{13}\text{C}_6$ -Fructose-6-phosphate). After homogenization, sonication and centrifugation, the supernatant was collected, dried and reconstituted.

Chromatography separation was performed on the Agilent 1290 Infinity II Bio LC system using the AdvanceBio MS Spent Media column (150 mm  $\times$  2.1 mm, 2.7  $\mu\text{m}$ ). A gradient elution was applied at 450  $\mu\text{l min}^{-1}$  with solvent A (10 mM ammonium acetate in water, pH 9) and solvent B (acetonitrile/water, 95:5, with 10 mM ammonium acetate). The gradient progressed from 100% B at 0 min, to 50% B at 6.5 min, reverting to 100% B at 7.01 min, with 1.1 min equilibration between runs. The column temperature was maintained at 70  $^\circ\text{C}$ , and 1  $\mu\text{l}$  of the sample was injected.

MS was conducted using a Thermo Orbitrap Q Exactive Plus, equipped with a HESI II ion source operating in both positive and negative modes. Full scans (70–1,050  $m/z$ ) were acquired at 35,000 resolution, while MS2 spectra were obtained at 17,500 resolution. Data analysis was performed using MS-Dial 4.9.2, enabling compound identification based on accurate mass and MS2 spectra, supported by an in-house retention time library.

### PET/CT and MRI

The positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) were done in collaboration with J.M. from the core facility of DKFZ. The PET/CT examinations were carried out on a special small animal scanner (Inveon PET/SPECT/CT, Siemens). The mice were injected with the F18 radioactively labelled tracer FDG through a tail catheter. The maximum injection quantity was 100  $\mu\text{l}$  and total activity applied between 3–8 MBq. Shortly before the examination, the animals were fasted for 4 h to ensure targeted absorption of the tracer into the tumours. The mice were anaesthetized (inhalation anaesthesia with sevoflurane (3–3.5% by volume) and air (0.5  $\text{l min}^{-1}$ )) before 0.1 ml of contrast medium (Prohance (Gadoteridol, Bracco), 0.5  $\text{mmol kg}^{-1}$  bodyweight, Bayer Schering Pharma) was i.p. injected. MRI examinations were carried out on a preclinical I T small-animal tomograph (ICON, Bruker).

### Protein extraction, western blotting and proteomics

The protocols for protein isolation and western blot analysis were described previously<sup>57</sup>. In brief, livers were homogenized (Fisherbrand Bead Mill 24, 15340163) and homogenate or cell lysis was prepared in RIPA buffer (Cell Signaling Technology 9806S) or T-PER buffer (Thermo Fisher Scientific, 78510), with protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, 78440). The lysates were centrifuged at 10,000g for 10 min at 4  $^\circ\text{C}$ . The protein concentration was quantified by Pierce BCA protein assay (Thermo Fisher Scientific, 23225). A total of 30–50  $\mu\text{g}$  of protein was denatured at 95  $^\circ\text{C}$  for 5 min in Laemmli buffer containing 5%  $\beta$ -mercaptoethanol and loaded in SDS gel for electrophoresis. Protein was then deposited onto PVDF membranes (Immobilon-P, Merck Millipore) or nitrocellulose membranes (Bio-Rad, 1704159) by semi-dry electroblotting (Trans-Blot Turbo Transfer, Bio-Rad, 1704150). The membranes were further incubated in 5% BSA or 5% skimmed milk solution for 1 h to overnight before primary antibody incubation. The primary antibodies listed in the Supplementary Information were incubated overnight on a shaker at 4  $^\circ\text{C}$ . After three 10 min washes with PBST or TBST, secondary antibodies were incubated with antibody solution for 1–2 h. Detection was accomplished using Clarity Western ECL Substrate (Bio-Rad) in conjunction with the ChemiDoc Touch imaging equipment (Bio-Rad). For IRDye (Licor) secondary antibody incubation protected from light, fluorescence was detected by Odyssey imaging system (Licor) combined with the acquisition software Image-Studio (Licor). Quantification of bands of interest in the linear range of exposure was performed by densitometry using ImageJ. Uncropped scans of blots are provided in the Supplementary Information. For any quantitative comparisons between samples or proteins on different gels/blots, the samples were derived from the

same experiment and the gels/blots were processed in parallel. Where applicable, consistent loading of proteins was further validated by Ponceau S staining solution (Thermo Fisher Scientific).

For MS, an equivalent amount of protein from mouse liver tissue was submitted to the proteomics core facility of the DKFZ and the protocols were described previously<sup>55</sup>. The raw intensity proteomics data were analysed using Maxquant<sup>65</sup> (v.2.4.3) with the default settings. Specifically, the UniProt *Mus musculus* reference proteome (UP000000589) was used as a reference for protein identification and quantification. The additional parameters were used run MaxQuant as follows: trypsin was used as enzyme digestion allowing two missed cleavages, carbamidomethyl was used for the fixed modification while the variable modifications were set to acetyl and oxidation, and the mass tolerances for the first and the main search were set to 20 and 4.5, respectively. Contamination proteins were removed from the identified proteins using the common contamination database. The normalized spectral protein intensity (LFQ) was used to calculate the protein abundance. Additional differential protein abundance was analysed using Persues R package using Welch's *t*-test and FDR-corrected *P* values. The proteomics data described in this article are available at the ProteomeXchange Consortium (Supplementary Information).

### RNA extraction, RT-qPCR and RNA-seq

According to the manufacturer's protocol, total RNA isolation from snap-frozen liver tissue or cultured cells was performed using the RNeasy Mini Kit (Qiagen, 74106). The on-column DNA digestion was carried out using an RNase-free DNase kit (Qiagen) or RNA samples were treated with TURBO DNase (Thermo Fisher Scientific, AM1907) according to the manufacturer's protocol to completely remove genomic DNA. RNA concentration and quality were determined by Nanodrop (Thermo Fisher Scientific) for quantitative PCR with reverse transcription (RT-qPCR) and by Qubit for RNA-seq. Then, 1  $\mu\text{g}$  of RNA was reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Thermo Fisher Scientific, 4374967) in a final volume of 20  $\mu\text{l}$  according to the manufacturer's instructions before RT-qPCR. In a 384-well plate, RT-qPCR was performed in duplicate using Fast Start SYBR Green Master Rox (Roche) or triplicate with iTaq Universal SYBR Green Supermix (Bio-Rad, 1725124). Eurofins, Millipore-Sigma or Integrated DNA Technologies (IDT) supplied custom-made primers using a 7900 HT RT-qPCR equipment (Applied Biosystems, Life Technologies) or CFX384 Real-time PCR system (Bio-Rad). RNA-seq was performed in collaboration with Genomics & Proteomics Core Facility in DKFZ or Genomics Core Facility after ScreenTape (Agilent) RNA quality control validation in SBP. The methodology is described in brief below and the accession numbers are listed in the Supplementary Information.

At the SBP Genomics Core, the RNA-seq assay was performed using the Illumina NextSeq 500 platform. In brief, poly(A) RNA was isolated using the NEBNext poly(A) mRNA magnetic isolation module and bar-coded libraries were made using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB). Libraries were pooled and single-end sequenced (1  $\times$  75) on the Illumina NextSeq 500 using the High output V2 kit (Illumina). Raw reads were preprocessed by trimming Illumina Truseq adapters, poly(A) and poly(T) sequences using cutadapt (v.2.3)<sup>66</sup> with the parameters 'cutadapt -j 4 -m 20 --interleaved -a AGATCGGAA GAGCACAGTCTGAACTCCAGTCAC -A AGATCGGAAGAGCGTCGT GTAGGG AAAGAGTGT Fastq1 Fastq2 | cutadapt --interleaved -j 4 -m 20 -a "A{100}" -A "A{100}" - | cutadapt -j 4 -m 20 -a "T{100}" -A "T{100}" -'. Trimmed reads were subsequently aligned to the mouse genome version mm10 using STAR aligner (v.2.7.0d\_0221)<sup>67</sup> with parameters according to ENCODE long RNA-seq pipeline (<https://github.com/ENCODE-DCC/long-rna-seq-pipeline>). Gene expression levels were quantified using RSEM (v.1.3.1)<sup>68</sup>. Ensembl v84 gene annotations were used for the alignment and quantification steps. RNA-seq sequence, alignment and quantification qualities were assessed using FastQC

# Article

(v.0.11.5) and MultiQC (v.1.8)<sup>69</sup>. Low-expressed genes were filtered out by retaining genes with estimated counts (from RSEM)  $\geq$  number of samples times five. Filtered estimated read counts from RSEM were used for differential expression comparisons using the Wald test implemented in the R Bioconductor package DESeq2 v.1.22.2 based on generalized linear model and negative binomial distribution<sup>70</sup>. Genes with Benjamini–Hochberg corrected  $P < 0.05$  and fold change  $\geq 2.0$  or  $\leq 2.0$  were selected as differentially expressed genes. Pathway analyses of differential expression comparisons were performed using IPA (Qiagen).

At the Genomics & Proteomics Core Facility in DKFZ, primary analysis of bulk RNA-seq data were performed using the nextflow pipeline nf-core/rnaseq (v.3.8) for the primary analysis of bulk RNA-seq data. Specifically, FastQC (v.0.11.9; <https://www.bioinformatics.babraham.ac.uk/projects/fastqc>) was used for quality control of the FastQ data followed by adapter trimming using Trim Galore (v.0.6.5) (<https://github.com/FelixKrueger/TrimGalore>). Reads were aligned to the mouse reference genome GRcm38.86 using STAR alinger<sup>67</sup> (v.2.7.10) and the subsequent read mapped to the genes were counted using featureCount module implemented in the subread R package<sup>71</sup> (v.1.6.4). Further quality control was performed using dupRader<sup>72</sup> and RSeQC<sup>73</sup> (v.2.6.4). Downstream analysis of the read counts matrix, including normalization (rlog and vst) and differential gene expression analysis was performed using DESeq2 R package<sup>70</sup> (v.1.40.2). A log-transformed fold change of 1 and FDR-corrected  $P$  value of 0.05 was used as a cut-off to identify differentially expressed genes. Sample distances were calculated using dist R (v.3.8) function using the entire gene expression. Pathway analysis of differentially expressed genes was carried out using the gProfiler2 R<sup>74</sup> (v.0.2.0) package.

## Gene signatures and database analyses

Two gene set signatures were used in this Article to represent ATF6 $\alpha$  activation:

(1) The human ATF6 $\alpha$ -activation signature was derived from the MSigDB ([www.msigdb.org](http://www.msigdb.org))<sup>17</sup> human gene set: ATF6\_TARGET\_GENES, including 1,081 ATF6 $\alpha$  transcription factor targets<sup>75</sup>.

To assess the human ATF6 $\alpha$ -activation signature in HCC tissue and non-tumour liver samples from patients with HCC shown in Fig. 1a, mRNA expression datasets were obtained from online repositories including the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium data portal. For datasets produced using Affymetrix whole-genome microarrays, raw .CEL files were processed using the SCAN (single-channel array normalization) method<sup>76</sup> and the SCAN.UPC R/Bioconductor package, and samples with median GNUSE quality scores<sup>77</sup> above 1.25 (computed with the frma Bioconductor package) were flagged for exclusion. For all of the other datasets, processed data provided by the original authors were used. Cases of fibrolamellar carcinoma were removed<sup>78</sup>. For all datasets, probe or gene IDs were mapped to Entrez gene identifiers. For microarray platforms containing multiple alternative probes or probesets per gene, the probe showing the great variance in expression among HCC samples was selected. The human ATF6 $\alpha$ -activation signature was used to quantify relative gene set enrichment scores across HCC and non-tumour samples in each dataset using the GSVA (gene set variation analysis) Bioconductor package<sup>79</sup>. Meta-analyses across datasets were computed with the metafor R package<sup>80</sup> using a random-effects model and the DerSimonian–Laird estimator. The same datasets were used to assess mRNA expression of *ATF6* and *FBP1* in HCC tissue and non-tumour liver samples from patients with HCC shown in Supplementary Fig. 1e and Extended Data Fig. 6b. To evaluate the correlation between the expression levels of genes and gene signatures in human HCC shown in Extended Data Fig. 6a, 15 datasets with extensive whole-genome RNA expression data were chosen (TCGA-LIHC<sup>81</sup>: GSE65485, GSE50579, GSE45436, GSE62232, GSE9843; iCOD<sup>82</sup>: GSE63898, GSE64041, GSE76297, GSE16757), and gene expression values were batch-adjusted using the ComBat method<sup>83</sup> as

implemented by the sva R package. The Pearson correlation coefficient was computed, as well as the odds ratio and  $P$  value based on a cut-off of +1 s.d. from the mean using Fisher's exact test.

To analyse the role of ATF6 $\alpha$  in determining response to anti-PD-1 monotherapy in patients with HCC, we used a cohort of 83 patients<sup>25</sup>. In Fig. 1r, mRNA expression levels of ATF6 $\alpha$ -related genes were plotted for ATF6 $\alpha^{\text{hi}}$  and ATF6 $\alpha^{\text{low}}$  samples with enrichment scores for the human ATF6 $\alpha$ -activation signature generated by ssGSEA (see below).

Signature profiles shown in Extended Data Fig. 1a–c were assessed in two cohorts of patients with HCC ( $n = 171$  (ref. 19) and  $n = 228$ <sup>18,84</sup>), with samples distributed by high to low enrichment of the human ATF6 $\alpha$ -activation signature. For Extended Data Fig. 1a,b, the following signatures were used: proliferation subclass<sup>85</sup>; S2 subclass<sup>86</sup>; EPCAM<sup>87</sup>; CK19\_1 (ref. 18); CK19\_2 (ref. 88); Notch<sup>18</sup>; Vascular Invasion<sup>89</sup>; MET<sup>90</sup>; mTOR signalling<sup>91</sup>; IGF signalling<sup>92</sup>; TGF $\beta$  late<sup>93</sup>.

For Kaplan–Meier plots, the median of the human-derived ATF6 $\alpha$ -activation signature described above (Fig. 1b) or MSigDB REACTOME\_UNFOLDED\_PROTEIN\_RESPONSE\_UPR (Fig. 1c) was used to divide TCGA-LIHC samples by median split into high and low groups and produce Kaplan–Meier plots, which visualize survival probability over time<sup>94</sup>. The same ssGSEA method applied to Supplementary Fig. 1g where TCGA BLCA, COAD-READ, BRCA, GBM, LUAD and SKCM samples were divided by the median split of human ATF6 $\alpha$ -activation signature and visualized for survival probability over time. Finally, TCGA-LIHC samples were divided by the median split into high and low groups according to the expression of UPR-related gene mRNA or MSigDB Human Gene Sets (ATF4\_Q2; CHOP\_Q1; XBP1\_Q1). In Fig. 1b,c and Supplementary Fig. 1g, patients who had events recorded after 60 months (180 days) were treated as alive at the 60-month timepoint. Statistical significance for differences between the high and low enrichment groups was assessed using the Mantel–Cox log-rank test. The Kaplan–Meier survival analysis was performed in the Python programming language using the lifelines package<sup>95</sup> and visualized using matplotlib (<https://doi.org/10.5281/zenodo.592536>). The TCGA expression data were from TCGA PANCAN data freeze 1.1 (19 August 2015).

(2) The mouse ATF6 $\alpha$ -activation signature and ssGSEA enrichment scores generation were generated using mouse-derived differentially expressed genes in liver tissue of DEN/HFD-treated *TG<sup>AAV-cre</sup>* versus *TG<sup>AAV-egfp</sup>* mice using RNA-seq. Statistically significant genes ( $\text{Abs}(\log_2[\text{FC}]) \geq 1$  BHP  $< 0.05$ ) included 888 upregulated and 266 downregulated genes to define the up and down gene sets representing mouse-derived ATF6 $\alpha$ -activation in liver. ssGSEA was used to provide ATF6 $\alpha$ -activation ssGSEA\_UP and ssGSEA\_DN enrichment scores for each of the TCGA-LIHC samples. Each ssGSEA enrichment score represents the degree to which the genes in a particular gene set are coordinately upregulated or downregulated within a sample. In this manner, ssGSEA projects a single sample's gene expression profile from the space of single genes onto the space of gene sets. The UP and DN enrichment scores are then combined into one signature by subtracting the DN score from the UP score:  $\text{ssGSEA}_{\text{combined}} = \text{ssGSEA}_{\text{UP}} - \text{ssGSEA}_{\text{DN}}$ . For more details on ssGSEA, see the original references<sup>27,96</sup> and the documentation of the single-sample GSEA module in GenePattern ([www.genepattern.org/modules/docs/ssGSEAProjection/4/](http://www.genepattern.org/modules/docs/ssGSEAProjection/4/)). To quantify the degree of association of single gene mRNA and gene set ssGSEA profiles, we used the IC<sup>97</sup> a mutual information measure of correlation similar to the Pearson correlation coefficient, but better for detecting non-linear associations. An empirical permutation test was used to assess statistical significance and compute  $P$  values and false-discovery rates (FDR). The  $\text{ssGSEA}_{\text{combined}}$  scores represent the activation of the mouse-derived ATF6 $\alpha$ -activation signature and are shown at the top of Fig. 3q, correlated with human gene sets from the MSigDB ([www.msigdb.org](http://www.msigdb.org))<sup>17</sup>.

ER stress: ATF6\_TARGET\_GENES (same as the ATF6 $\alpha$ -activation signature used above); REACTOME\_UNFOLDED\_PROTEIN\_RESPONSE\_UPR; DDIT3 (mRNA); REACTOME ASPARAGINE\_N\_LINKED\_GLYCOSYLATION.

Metabolism: FBPI (mRNA); Q1\_HYPOXIA\_TARGETS\_OF\_HIF1A\_AND\_FOXA2; HALLMARK\_OXIDATIVE\_PHOSPHORYLATION.

Oncogenesis: NRF2\_01; ROS\_AND\_RNS\_PRODUCTION\_IN\_PHAGOCYTES; HALLMARK\_PI3K\_AKT\_MTOR\_SIGNALING; REACTOME\_SIGNALING\_BY\_WNT; REACTOME\_SIGNALING\_BY\_TGFB\_FAMILY\_MEMBERS; LEE\_LIVER\_CANCER\_MYC\_E2F\_UP.

Immunosuppression: CTLA4; PD-1; GSE26495\_PD1HIGH\_VS\_PD1LOW\_CD8\_TCELL\_UP; GSE9650\_EFFECTOR\_VS\_EXHAUSTED\_CD8\_TCELL\_UP; GSE9650\_EFFECTOR\_VS\_EXHAUSTED\_CD8\_TCELL\_DN.

For the heat map of immune features and signatures related to ICB response in HCC (Extended Data Fig. 9b), human patient tumour samples ( $n = 171$ )<sup>49</sup> were divided into two groups by high and low enrichment of the mouse-derived ATF6 $\alpha$ -activation signature. Human patient tumour samples were defined as high or low using the nearest template prediction (NTP) module from Gene Pattern<sup>98</sup> and the mouse-ATF6 $\alpha$ -activation signature described above. Positivity for the immune, IFNAP and poor prognosis signatures (Figs. 1r and 5a and Extended Data Fig. 9b) was similarly defined by NTP module from Gene Pattern<sup>98</sup> as previously described<sup>25</sup>, and a significant prediction was defined using an FDR < 0.05.

### scRNA-seq

Single-cell 3' RNA (gene expression) libraries were generated according to the 'Chromium Single Cell 3' Reagents Kits User Guide (v3.1 Chemistry)' (CG000204, 10x Genomics). For each sample, CD45<sup>+</sup> cells from a complete liver were loaded into individual wells of the Chromium Chip G (Chromium Next GEM Chip G Single Kit, 1000127). GEM generation, reverse transcription, cDNA amplification and library preparation were performed using the Chromium Next GEM Single Cell 3' GEM, Library and Gel Bead Kit v3.1 (1000121) according to the standard protocol. Size selection was performed using AMPure XP beads (A63881, Beckman Coulter). cDNA concentration was determined using the D5000 reagent kit (5067-5589, Agilent Technologies) and the library PCR cycle number was adjusted accordingly. The libraries were uniquely indexed using single-index primers from separate wells of the Single Index Kit T Set A plate (3000431). Quality control and molarity calculations of the final libraries were performed with the Qubit 3.0 Fluorometer (Q33216, Invitrogen) and the 4200 TapeStation system (Agilent Technologies). Libraries were pooled in a single 10 nM reaction for sequencing at the NGS Core Facility at the DKFZ according to Chromium Single Cell 3' Reagents Kits User Guide v3.1 Chemistry (CG000204, 10x Genomics). Library pools were sequenced on two lanes of the NovaSeq 6000 system (v1.5 Reagent Kit). Sequencing was performed in a paired-end manner with a sequencing depth of at least 20,000 reads per cell and the read 1 sequenced for 28 cycles, i7 index for 8 cycles and read 2 for 91 cycles.

The 10x Genomics scRNA-seq data were processed using the qbic-pipelines/cellranger pipeline (v.1.01), which functions as a wrapper for the 10x Genomics cellranger-count pipeline (v.5.0.1) based on the nf-core framework<sup>99</sup>. The quality of the FastQ files was first assessed using FastQC (v.0.11.8) and aggregated for visualization using MultiQC<sup>69</sup> (v.1.7; <http://multiqc.info/>). Raw reads were filtered and aligned to the reference mouse genome (UCSC mm10) to generate feature-barcode matrices for each sample. The UMI count matrix underwent preprocessing utilizing the Scanpy package (v.1.9.2) and the Seurat R package (v.2.4.3). After filtering out low-quality cells, defined as those expressing fewer than 200 genes or exhibiting a mitochondrial genome transcript ratio exceeding 0.2, a total of 19,690 cells was retained for subsequent analysis. Library size normalization was performed using Scanpy on the filtered matrix to obtain the normalized count. PCA was applied to the normalized expression matrix, focusing on highly variable genes. Cell clustering was performed using the graph-based Leiden clustering approach in Scanpy, and the results were visualized in two dimensions using UMAP. To interpret the developmental trajectory of CD8 T cells, we used the monocle package (v.2.24.0) using the DDRTree method. The GSVA package (v.1.48.3) was used to compute the

pathway enrichment scores for individual cells. The gene sets used for this analysis included: HALLMARK-OXIDATIVE-PHOSPHORYLATION, WP-FATTY-ACID-BETAOXIDATION, WP-PURINE-METABOLISM, WP-AEROBIC-GLYCOLYSIS, KEGG-ARGININE-AND-PROLINE-METABOLISM, GOBP-ARGININE-CATABOLIC-PROCESS, KEGG-CITRATE-CYCLE-TCA-CYCLE, WP-FATTY-ACID-BIOSYNTHESIS, GOBP-FATTY-ACID-ELONGATION, WP-PENTOSE-PHOSPHATE-METABOLISM, KEGG-TRYPTOPHAN-METABOLISM, KEGG-PYRUVATE-METABOLISM, KEGG-N-GLYCAN-BIOSYNTHESIS, KEGG-GLYCOLYSIS-GLUCONEOGENESIS, GOBP-FATTY-ACID-BETA-OXIDATION, GOBP-FATTY-ACID-BIOSYNTHETIC-PROCESS, GOBP-ARGININE-METABOLIC-PROCESS.

### IMC analysis of human samples

The initial cohort comprised FFPE liver tissue of non-tumour ( $n = 4$ ), tumour margin ( $n = 16$ ) and tumour regions ( $n = 4$ ) from patients with HCC (aetiology metabolic dysfunction- and alcohol-associated liver disease (MetALD),  $n = 2$ ; MASH,  $n = 9$ ; chronic hepatitis B virus infection (cHBV),  $n = 2$ ; chronic hepatitis C virus infection (cHCV),  $n = 6$ ; unknown,  $n = 3$ ) and liver cirrhosis ( $n = 2$ ) (prepared as a tissue microarray (TMA; diameter, 2 mm; thickness, 2  $\mu$ m). The validation cohort consisted of FFPE slides obtained from non-tumour, margin and tumour regions from patients with HCC (non-tumour,  $n = 10$ ; margin,  $n = 7$ ; tumour,  $n = 10$ ; aetiology: MetALD,  $n = 1$ ; MASH,  $n = 1$ ; cHBV,  $n = 1$ ; cHCV,  $n = 4$ ; unknown,  $n = 3$ ; thickness, 2  $\mu$ m). Written informed consent was obtained in all cases and the study was conducted according to the Declaration of Helsinki (1975), federal guidelines and local ethics committee regulations (Albert-Ludwigs-University, Freiburg, Germany, 20-1066).

Antibodies were labelled with the chosen metals according to the protocol of the Maxpar antibody labelling kit. Antibody staining was performed as described previously<sup>100</sup>. In brief, the slide was baked at 60 °C for 2 h and deparaffinization was performed in two ROTI Histol baths for 5 min followed by rehydration for 5 min each in a graded ethanol series (ethanol:deionized water 100:0, 100:0, 95:5, 80:20). The slide was washed in TBS pH 7.6. Heat-induced epitope retrieval was performed in a pressure cooker at 95 °C for 30 min in DACO EnVisionFlex target retrieval solution. After cooling the slide to room temperature in retrieval solution, it was washed in TBS for 10 min and blocked 45 min at room temperature with SuperBlock blocking buffer. Staining was performed with the antibody mix diluted in TBS containing 5% BSA and incubated overnight at 4 °C in a hydration chamber. The slide was next washed twice in TBS containing 0.2% Tween-20 for 5 min. Ir-intercalator for nuclear staining was added for 30 min at room temperature and the slide was washed three times with TBS, rinsed with ultrapure water, left to dry and was stored at room temperature until acquisition. For acquisition, a Helios time-of-flight mass cytometer (CyTOF) coupled to a Hyperion Imaging System (Fluidigm) was used. Tissue sections were laser-ablated spot-by-spot at 200 Hz for a total area of 1.5  $\mu$ m  $\times$  0.75  $\mu$ m. ROIs were determined using an ATF6 $\alpha$  IHC and H&E staining of sequential tissue sections.

Correction for signal spillover of the metal isotopes was compensated using the Catalyst package in R; the script is available at GitHub (<https://github.com/NiklasVesper/ImagingCytometryTools>).

To analyse subcellular localization of antigens in the IMC data, a segmentation and analysis pipeline was developed. First, single-cell data for each individual cell was generated by image segmentation followed by detailed analysis of the segmented dataset. Cellular segmentation was performed with CellProfiler using the Cellpose 2.0 TissueNet segmentation model. The image overlay required for cellular segmentation was performed with the following proteins: CD4, CD8, CD15, CD20, CD68, SMA, E-cadherin and beta-catenin. For nuclear segmentation, Cellpose 2.0 CP segmentation model was used. Cytoplasmic segmentation was derived by subtracting the nuclear segmentation from the cellular (Supplementary Fig. 2a,b). The CellProfiler Cellpose 2.0 plugin was installed as described at GitHub (<https://github.com/>

# Article

CellProfiler/CellProfiler-plugins). As a final step, all necessary data for further analysis from the segmented dataset was exported as a .csv file. The full CellProfiler pipeline for image segmentation with detailed settings and structure can be found on request at GitHub (<https://github.com/NiklasVesper/ImagingCytometryTools>).

For data analysis, a newly designed algorithm maps subcellular compartments (nuclei and cytoplasm) to corresponding cells by extracting the area of a cell and checking if there is a corresponding nucleus and cytoplasm within this area by matching the most central *xy*-coordinates of nuclei or cytoplasm, respectively (Supplementary Fig. 2c). Marker expression on the whole-cell or subcellular compartments was determined by gating on positive and negative cells/subcellular compartments in a histogram and image-based verification. Next, tumours and corresponding tissue were classified into ATF6 $\alpha^{\text{hi}}$  and ATF6 $\alpha^{\text{low}}$  tissue (Supplementary Fig. 2d,e). Further analysis was performed by OMIQ (<https://www.omiq.ai/>). Neighbourhood analysis was performed by setting an area of interest (radius = 1.5  $\times$  average cell diameter) around the cells and checking for the phenotype of the neighbouring cells. Next, the frequency of the lineage of the neighbouring cells were compared. All scripts for this analysis are available on request (<https://github.com/NiklasVesper/ImagingCytometryTools>).

## GeoMx DSP analysis of human samples

Manual slide preparation for GeoMx-NGS RNA was conducted according to the manufacturer's guidelines (Bruker Spatial Biology). In brief, human HCC tissue FFPE microarrays (see the 'Human samples' section) were baked at 60 °C for 1 h before deparaffinization in CitriSolv and rehydration. The samples were incubated in target retrieval Tris EDTA solution at 99 °C for 15 min, RNA targets were exposed by permeabilization with proteinase K solution at 37 °C for 15 min and the samples were post-fixed in 10% formalin. In situ hybridization with RNA detection probes for the Cancer Transcriptome Atlas was done at 37 °C overnight before stringent washing, blocking and morphology marker staining for Syto13 (DNA dye), pan-CK and CD45 at room temperature for 1 h in a humidified chamber. The slides were loaded into the GeoMx Digital Spatial Profiler (DSP) to select ROIs for instrument cycling and ROI collection per well into a 96-well plate. After data collection, the samples were amplified by PCR, pooled and assessed for RNA quality control before sequencing on the NextSeq 500 (Illumina) system at the SBP Genomics core. FastQ files were transferred back to the GeoMx DSP for data analysis that included quality control, scaling and normalization, visualizations and statistical tests.

## CUT&RUN, ATAC-seq and data analysis

The CUT&RUN, ATAC-seq and related data analysis were done in collaboration with M.M. and B.G.R. as previously described<sup>101</sup>. In brief, livers from mice were collected and directly processed for nucleus isolation using liver swelling buffer (10 mM Tris pH 7.5, 2 mM MgCl<sub>2</sub>, 3 mM CaCl<sub>2</sub>) with a douncer. Liver homogenates were passed through a 70- $\mu$ m strainer, centrifuged (400g, 5 min, 4 °C) and the pellets were resuspended in lysis buffer. The samples were centrifuged (400g, 5 min, 4 °C) and the pellets washed twice in PBS. Nucleus numbers were counted and ready for OMICS sample preparation.

For CUT&RUN, 500,000 nuclei from livers of *TG<sup>Alb-cre+</sup>* mice were used following standard protocol<sup>101</sup>. Primary antibody (rabbit anti-ATF6 $\alpha$ , SAB biotech 32008 or rabbit anti-HA, Abcam, ab9110) or control (mouse IgG) was used (5  $\mu$ g for target antibody and 1  $\mu$ g for IgG). Libraries were sequenced using NextSeq 2000 P3 Reagents (50 Cycles) v3 (Illumina, 20046810) on the NextSeq 2000 platform (Illumina). Data were analysed using the *nf-core/cutandrun* pipeline v.3.2.2 with Nextflow v.24.04.2, using the default parameters and following software dependencies: *bedtools* (v.2.30.0), *bowtie* (v.2.4.4), *deeptools* (v.3.5.1), *fastqc* (v.0.12.1), *picard* (v.3.1.0), *Python* (v.3.9.12), *samtools* (v.1.17), *Genrich* (v.0.6.1), *TrimGalore* (v.0.6.6), *ucsc* (v.377). CUT&RUN analysis identified direct target genes by using the HOMER's *annotatePeaks.pl* tool

on the final peak set and selecting genes with a peak located within  $\pm 1$  kb of their transcription start site.

For ATAC-seq, 50,000 nuclei from livers of *TG<sup>Alb-cre-</sup>* or *TG<sup>Alb-cre+</sup>* mice were used. Libraries were sequenced on the NextSeq 2000 platform (Illumina). ATAC-seq data were analysed using the *nf-core/atacseq* pipeline v.2.1.2 with Nextflow v.24.0.2 using the default parameters<sup>101</sup>.

## MIBI analysis

Tissue sections (4  $\mu$ m) were cut from mouse liver/tumour FFPE tissue blocks and subjected to MIBI. Staining, acquisition and data analysis were performed in collaboration with F.J.H. as previously described<sup>43</sup>.

Tissue slides were deparaffinized by incubation at 70 °C for 20 min, followed by three xylene washes. Rehydration was done by graded ethanol series (twice with 100% ethanol; twice with 95% ethanol; once with 80% ethanol; once with 70% ethanol) followed by a wash with distilled water. Antigen retrieval used epitope retrieval buffer (pH 9) with slides incubated at 97 °C for 40 min and cooled to 65 °C using the Lab Vision PT Module (Thermo Fisher Scientific). The slides were washed with MIBI wash buffer, composed of low-barium PBS-based IHC Tween buffer supplemented with 0.1% BSA. Tissues were blocked for 1 h with 1 $\times$  TBS IHC wash buffer with Tween-20, 2% donkey serum, 0.1% cold fish skin gelatin, 0.1% Triton X-100 and 0.05% sodium azide. Primary antibodies were diluted in 3% donkey serum TBS IHC wash buffer and filtered through a 0.1  $\mu$ m PVDF membrane before staining. The slides were incubated with primary antibodies overnight at 4 °C. The slides were washed twice with MIBI wash buffer and fixed for 5 min in 2% glutaraldehyde in low-barium PBS. Finally, the slides were dehydrated through three washes in Tris buffer (0.1 M, pH 8.5) and two washes in distilled water followed by a graded ethanol series (once with 70%; once with 80%; twice with 95%; and twice with 100%). The slides were stored in a vacuum chamber until imaging.

Images were acquired using the MIBI in coarse mode, capturing fields of view of 800  $\mu$ m  $\times$  800  $\mu$ m per sample. Regions enriched in CD8<sup>+</sup> T cells were selected based on visual inspection of corresponding IHC images. After image acquisition, raw ion count data were processed into multiplexed images using the toffy package for noise filtering, intensity normalization and channel compensation.

Cell segmentation was performed using Cellpose 2.0 with the 'TN2' model Python package for pretrained neural network segmentation. Single-cell marker intensities were calculated by marker expression average across all pixels within each segmented cell mask. Cells beyond the acceptable range were excluded (<71 pixels (0.1 percentile) or >3,318 pixels (99.5 percentile), nuclear sum intensity below 9.21 a.u., or nuclear proportion outside the range of 0.3% to 99.8%). Marker expression values were normalized and capped at the 99.9 percentile across all retained cells, multiplied by a factor of 10 and arcsinh-transformed. CD8<sup>+</sup> T cells were identified using FlowSOM, based on CD45, CD3 and CD8 expression. FlowSOM clustering was implemented using the Python version of the algorithm. LDH expression was visualized at the single-cell level using contour plots, with cells from treatment and control groups colour-coded in blue and red, respectively. Statistical significance was assessed using the Mann-Whitney *U*-tests. Moreover, the distribution of LDH expression was visualized using overlaid kernel density estimation plots, comparing four experimental conditions. Differences in cumulative distributions were evaluated using the Kolmogorov-Smirnov test. Low-level processing is available at GitHub (<https://github.com/a-ngelolab/toffy>) and the cell segmentation pipeline available at GitHub (<https://github.com/mouseland/cellpose>).

## Statistical analyses

Pilot experiments and previously published results were used to estimate the sample size, such that appropriate statistical tests could yield significant results. No further statistical methods were used to predetermine sample size. Measurements were taken from distinct biological samples, unless otherwise indicated. Mice were randomly

allocated into different groups to make sure that the phenotype was homogeneous across groups, and were then fed with appropriate diet and/or administered their respective treatment regimens. Randomization of human patients was not applicable as no prospective trial/study was performed and human samples evaluated were obtained from pre-existing human patient cohorts/databases, adhering to ethical guidelines. Investigators were blinded to group allocation for all experiments in which blinding was technically feasible. Blinding was not possible for studies comparing preclinical liver cancer mouse models in which features were visually distinguishable (for example, normal chow pellets were brown, HFD pellets were blue; obese versus lean phenotypes; liver tumours inherently visible during dissection). Human patient data underwent pseudonymisation and were blinded to the analyser.

Data were collected in Microsoft Excel. Unless otherwise indicated, data are presented as mean  $\pm$  s.e.m. (for example, scatter dot plot data). Violin plot data are presented showing all points with a dotted line at the median. Box and whisker plot data are presented with boxes spanning the 25th to 75th percentiles, with a line at the median, and whiskers from the minimum to maximum value. Statistical analysis was performed using GraphPad Prism software v.9.3.1 and v.10.0.3 (GraphPad Software). The normality assumption of the data distribution was verified using the Shapiro–Wilk test before performing the suitable statistical tests. For two-group comparisons, normally distributed data were analysed using two-tailed unpaired *t*-tests, and non-normal data were analysed using two-tailed unpaired Mann–Whitney *U*-tests. For comparisons of more than two groups, data were analysed using one-way or two-way ANOVA and corrected for multiple comparisons using statistical hypothesis testing (Tukey's post hoc test), where applicable. Tumour incidence was analysed by  $\chi^2$  test for contingency. Kaplan–Meier survival curves were analysed by a log-rank (Mantel–Cox) test. Where appropriate, false-discovery rate (FDR) corrections for multiple-hypothesis testing were performed. Exact *P* values between 0.0001 and 0.05 are reported. Sample sizes and statistical tests used are indicated in the legends or in the subsection below.

### Sample sizes, biological replicates and statistical tests

For Fig. 1b,c, ATF6 $\alpha^{\text{hi}}$ , *n* = 185 patients; ATF6 $\alpha^{\text{low}}$ , *n* = 185 patients; data were obtained from the TCGA-LIHC database. For Fig. 1d,e, *n* = 473 patients, with *n* = 120 (ATF6 $\alpha^{\text{hi}}$ ) and *n* = 353 (ATF6 $\alpha^{\text{low}}$ ) patients; ATF6 $\alpha^{\text{low}}$ , *n* = 130, with *n* = 46 (G1) and *n* = 84 (G2) patients; ATF6 $\alpha^{\text{hi}}$ , *n* = 223 with *n* = 22 (G1), *n* = 139 (G2), *n* = 58 (G3) and *n* = 4 (undefined) patients. For Fig. 1g, *n* = 7 patients each with NT (non-tumour) or T (tumour) samples. For Fig. 1i, non-tumour (*n* = 32), tumour margin (*n* = 34), tumour (*n* = 32). For Fig. 1k, ATF6 $\alpha^{\text{low}}$ , *n* = 8 ROIs; ATF6 $\alpha^{\text{hi}}$ , *n* = 16 ROIs. For Fig. 1o–q, *n* = 10 patients. For Fig. 1r, *n* = 83 patients. Scatter dot plot data are presented as mean  $\pm$  s.e.m. Violin plot data are presented showing all points with a dotted line at the median. Box and whisker plot data are presented with boxes spanning the 25th to 75th percentiles, with a line at the median, and whiskers from the minimum to maximum values. Data in Fig. 1a were analysed using Pearson correlation coefficient with Fisher's exact test. Data in Fig. 1b,c were analysed using median split and log-rank test. Data in Fig. 1g were analysed using two-way ANOVA. Data in Fig. 1i were analysed using one-way ANOVA with Geisser–Greenhouse correction with Tukey's post hoc test. D'Agostino–Pearson, Shapiro–Wilk and Kolmogorov–Smirnov tests were performed to test for normal distribution. Data in Fig. 1p were analysed using two-tailed Mann–Whitney *U*-tests. Data in Fig. 1q were analysed using Wilcoxon tests and Mann–Whitney *U*-tests. Data in Fig. 1r were analysed using Wilcoxon tests.

For Fig. 2b,c, 3-month-old *TG<sup>Alb-cre-</sup>* mice: *n* = 8, 5 male and 3 female mice; 6-month-old *TG<sup>Alb-cre-</sup>* mice: *n* = 14, 9 male and 5 female mice; 3-month-old *TG<sup>Alb-cre+</sup>* mice: *n* = 10, 7 male and 3 female mice; 6-month-old *TG<sup>Alb-cre+</sup>* mice: *n* = 18, 10 male and 8 female mice. For Fig. 2e,g,h, *TG<sup>Alb-cre-</sup>* mice: *n* = 5; *TG<sup>Alb-cre+</sup>* mice: *n* = 7. For Fig. 2i, *n* = 6 mice per group. For Fig. 2j, CUT&RUN: *TG<sup>Alb-cre+</sup>* mice: *n* = 5; ATAC-seq:

*TG<sup>Alb-cre-</sup>* mice: *n* = 4; *TG<sup>Alb-cre+</sup>* mice: *n* = 5. For Fig. 2l,m, *TG<sup>AAV-gfp</sup>* mice: *n* = 12; *TG<sup>AAV-cre</sup>* mice: *n* = 9; and *TG<sup>AAV-cre/fbp1</sup>* mice: *n* = 8. For Fig. 2n, *n* = 3 mice per group. For Fig. 2p, *n* = 4 mice per group. Scatter dot plot data are presented as mean  $\pm$  s.e.m. Data in Fig. 2b,c were analysed using two-tailed unpaired *t*-tests between age-matched *TG<sup>Alb-cre-</sup>* and *TG<sup>Alb-cre+</sup>* mice at the designated timepoint. Data in Fig. 2l,m were analysed using one-way ANOVA.

For Fig. 3a, *TG<sup>Alb-cre-</sup>* mice: *n* = 17, 8 male and 9 female mice; *TG<sup>Alb-cre+</sup>* mice: *n* = 43, 17 male and 26 female mice. For Fig. 3b, *TG<sup>Alb-cre-</sup>* mice: *n* = 35, 20 male and 15 female mice; *TG<sup>Alb-cre+</sup>* mice: *n* = 30, 11 male and 19 female mice. For Fig. 3d,e,h, 9-month-old *TG<sup>Alb-cre-</sup>* mice: *n* = 20, 10 male and 10 female mice; 9-month-old *TG<sup>Alb-cre+</sup>* mice: *n* = 33, 13 male and 20 female mice; 12-month-old *TG<sup>Alb-cre-</sup>* mice: *n* = 29, 12 male and 17 female mice; 12-month-old *TG<sup>Alb-cre+</sup>* mice: *n* = 49, 25 male and 24 female mice. For Fig. 3i, 12-month-old *TG<sup>Alb-cre+</sup>* mice: *n* = 6; samples from patients with HCC, 151. For Fig. 3k–o, *TG<sup>AAV-gfp</sup>* mice: *n* = 11, 6 male and 5 female mice; *TG<sup>AAV-cre</sup>* mice: *n* = 12, 7 male and 5 female mice. For Fig. 3p, *TG<sup>AAV-gfp</sup>* mice: *n* = 3; *TG<sup>AAV-cre</sup>* mice: *n* = 5. For Fig. 3q, *n* = 371 patients, data were obtained from the TCGA-LIHC database. Scatter dot plot data and line graph data are presented as mean  $\pm$  s.e.m. Data in Fig. 3a were analysed using the log-rank (Mantel–Cox) test. Data in Fig. 3b were calculated for the area under the curve and analysed using two-tailed Student's *t*-tests. Data in Fig. 3d,e,l,m were analysed using Mann–Whitney *U*-tests. Data in Fig. 3k,n were analysed using two-tailed unpaired *t*-tests. Data in Fig. 3h,o were analysed using  $\chi^2$  tests for contingency. Data in Fig. 3i syntenic mouse–human cancer genome copy-number alteration (CNA) concordance was calculated by mapping mouse CNA-positive regions to their human homologues, determining for each pair whether the same CNA type exceeded a 5% frequency threshold in human samples, and summarizing all regions of a given CNA type into a contingency table analysed using two-tailed Fisher's exact test. Data in Fig. 3q were analysed using empirical permutation and correlation measured by IC as further described in Methods: Gene signatures and database analyses.

For Fig. 4b,c, *Atf6<sup>+/-</sup>* mice: *n* = 9; *Atf6<sup>-/-</sup>* mice: *n* = 14. For Fig. 4f, *n* = 3 mice per group. For Fig. 4h,i, *Atf6<sup>fl/fl</sup>* mice: *n* = 11; *Atf6<sup>ΔHep</sup>* mice: *n* = 12. For Fig. 4k, *Atf6<sup>fl/fl</sup>* mice: *n* = 6; *Atf6<sup>ΔHep</sup>* mice: *n* = 5. Fig. 4l: *n* = 9 mice per group. For Fig. 4n, *n* = 10 mice per group. For Fig. 4t: untreated, *n* = 9 mice; GalNac-ASO-scramble: *n* = 7 mice; GalNac-ASO-*Atf6*: *n* = 6 mice. For Fig. 4w, GalNac-ASO-scramble: *n* = 8 mice; GalNac-ASO-*Atf6*: *n* = 12 mice. Scatter dot plot data are presented as mean  $\pm$  s.e.m. Data in Fig. 4c,i,l,n,w were analysed using two-tailed unpaired *t*-tests or Mann–Whitney *U*-tests based on data normality distribution. Data in Fig. 4b,h were analysed using  $\chi^2$  tests for contingency. Data in Fig. 4t were analysed using one-way ANOVA.

For Fig. 5a, 3-month-old *TG<sup>Alb-cre-</sup>* mice: *n* = 5; *TG<sup>Alb-cre+</sup>* mice: *n* = 7; 3-month-old *TG<sup>AAV-cre</sup>* and *TG<sup>AAV-cre/fbp1</sup>* mice: *n* = 4 mice per group; 30-week-old DEN/HFD-treated *TG<sup>AAV-gfp</sup>* mice: *n* = 3; and *TG<sup>AAV-cre</sup>* mice: *n* = 5 with pair-matched non-tumour and tumour samples; 38-week-old DEN/HFD-treated *Atf6<sup>+/-</sup>* and *Atf6<sup>-/-</sup>* mice: *n* = 3 mice per group. For Fig. 5b,c, *TG<sup>Alb-cre-</sup>* mice: *n* = 6; *TG<sup>Alb-cre+</sup>* mice: *n* = 7. For Fig. 5e–h, *n* = 4 mice per group. For Fig. 5j, anti-IgG: *n* = 8 mice; anti-PD-1: *n* = 10 mice. For Fig. 5l, *n* = 3 mice per group. For Fig. 5n: *TG<sup>Alb-cre+</sup>* mice: *n* = 19, 9 male and 10 female; *TG:Pdcd1<sup>-/-</sup>* mice: *n* = 18, 8 male and 10 female. For Fig. 5p, *TG<sup>Alb-cre+</sup>* mice: *n* = 43; *TG:Pdcd1<sup>-/-</sup>* mice: *n* = 53. Scatter dot plot data are presented as mean  $\pm$  s.e.m. Data in Fig. 5a were analysed using non-parametric Wilcoxon and Kruskal–Wallis tests. Data in Fig. 5b,c,j were analysed using two-tailed unpaired *t*-tests. The distribution of LDH expression in Fig. 5l was visualized using overlaid KDE plots. Differences in cumulative distributions were evaluated using the Kolmogorov–Smirnov tests. Data in Fig. 5n were analysed using two-tailed unpaired Mann–Whitney *U*-tests. Data in Fig. 5p were analysed using the log-rank (Mantel–Cox) test.

Mouse icons used in Figs. 2–5 were created using BioRender (Heikenwalder, M. (2026); <https://BioRender.com/lgjsny9>).

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

The proteomics data are available at ProteomeXchange Consortium through the PRIDE database under project accession PXD045903. The bulk RNA-seq data are available under GEO SuperSeries GSE244344 (GSE244341: *TG<sup>AAV-gfp</sup>*, *TG<sup>AAV-cre</sup>* and *TG<sup>AAV-cre/fbp1</sup>*, GSE244342: *TG<sup>AAV-gfp</sup>* and *TG<sup>AAV-cre</sup>* + DEN/HFD; GSE244343: *Atf6<sup>+/+</sup>* and *Atf6<sup>-/-</sup>* DEN/HFD), and GSE244212 (3M *TG<sup>Alb-cre-</sup>* and *TG<sup>Alb-cre+</sup>*), GSE244213 (6M *TG<sup>Alb-cre-</sup>* and *TG<sup>Alb-cre+</sup>*) and GSE285265 (*Atf6<sup>fl/fl</sup>* and *Atf6<sup>ΔHep</sup>* mice + CD-HFD). The scRNA-seq data are available under GEO GSE243826 and GSE285366. The CUT&RUN data are available under GEO GSE285262. The ATAC-seq data are available under GEO GSE285261. The array of CGH data is available under GEO GSE242831. The NMR-based metabolomics data and LC-MS/MS metabolic analysis are available at the Metabolights database through the study MTBLS13241. The results here are in part based on data generated by the TCGA Research Network (<https://www.cancer.gov/tcga>). Databases used in this Article included MSigDB ([www.broadinstitute.org/msigdb](http://www.broadinstitute.org/msigdb)). Source data are provided with this paper.

53. Tang, Y. et al. alpha-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. *Cell Commun. Signal.* **21**, 162 (2023).
54. Neumann, K. et al. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. *Sci. Rep.* **9**, 2038 (2019).
55. Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature* **592**, 450–456 (2021).
56. Gallage, S. et al. Spontaneous cholelithiasis in C57BL/6 mice predisposes to liver cancer in NASH. *Cell. Mol. Gastroenterol. Hepatol.* **13**, 875–878 (2022).
57. Malehmir, M. et al. Platelet GPIIb is a mediator and potential interventional target for NASH and subsequent liver cancer. *Nat. Med.* **25**, 641–655 (2019).
58. Kober, C. et al. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. *J. Immunother. Cancer* **11**, e007495 (2023).
59. Scherer, D. et al. RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling. *Cancers* **12**, 2510 (2020).
60. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013).
61. Concordet, J.-P. & Haussler, M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. *Nucleic Acids Res.* **46**, W242–W245 (2018).
62. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res.* **42**, e168 (2014).
63. Scott, D. A. Analysis of melanoma cell glutamine metabolism by stable isotope tracing and gas chromatography-mass spectrometry. *Methods Mol. Biol.* **2265**, 91–110 (2021).
64. Sellick, C. A., Hansen, R., Stephens, G. M., Goodacre, R. & Dickson, A. J. Metabolite extraction from suspension-cultured mammalian cells for global metabolite profiling. *Nat. Protoc.* **6**, 1241–1249 (2011).
65. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372 (2008).
66. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* **17**, 10–12 (2011).
67. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
68. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
69. Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).
70. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
71. Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res.* **47**, e47 (2019).
72. Sayols, S., Scherzinger, D. & Klein, H. dupRad: a Bioconductor package for the assessment of PCR artifacts in RNA-seq data. *BMC Bioinformatics* **17**, 428 (2016).
73. Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. *Bioinformatics* **28**, 2184–2185 (2012).
74. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2—an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res* <https://doi.org/10.12688/f1000res.24956.2> (2020).
75. Yevshin, I., Sharipov, R., Kolmykov, S., Kondrakhin, Y. & Kolpakov, F. GTRD: a database on gene transcription regulation—2019 update. *Nucleic Acids Res.* **47**, D100–D105 (2019).
76. Piccolo, S. R. et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. *Genomics* **100**, 337–344 (2012).
77. McCall, M. N., Murakami, P. N., Lukk, M., Huber, W. & Irizarry, R. A. Assessing affymetrix GeneChip microarray quality. *BMC Bioinformatics* **12**, 137 (2011).

78. Dinh, T. A. et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. *Sci. Rep.* **7**, 44653 (2017).
79. Hänzelmann, S., Castelo, R. & Guinney, J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* **14**, 7 (2013).
80. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. *J. Stat. Softw.* **36**, 1–48 (2010).
81. Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. *Cell* **169**, 1327–1341 (2017).
82. Shimokawa, K. et al. iCOD: an integrated clinical omics database based on the systems-pathology view of disease. *BMC Genomics* **11**, S19 (2010).
83. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
84. Villanueva, A. Hepatocellular carcinoma. *N. Engl. J. Med.* **380**, 1450–1462 (2019).
85. Chiang, D. Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res.* **68**, 6779–6788 (2008).
86. Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Res.* **69**, 7385–7392 (2009).
87. Yamashita, T. et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. *Gastroenterology* **136**, 1012–1024 (2009).
88. Andersen, J. B. et al. Progenitor-derived hepatocellular carcinoma model in the rat. *Hepatology* **51**, 1401–1409 (2010).
89. Minguez, B. et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. *J. Hepatol.* **55**, 1325–1331 (2011).
90. Kaposi-Novak, P. et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. *J. Clin. Invest.* **116**, 1582–1595 (2006).
91. Villanueva, A. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. *Gastroenterology* **135**, 1972–1983 (2008).
92. Tovar, V. et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockade. *J. Hepatol.* **52**, 550–559 (2010).
93. Coulouarn, C., Factor, V. M. & Thorgeirsson, S. S. Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. *Hepatology* **47**, 2059–2067 (2008).
94. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **53**, 457–481 (1958).
95. Davidson-Pilon, C. lifelines: survival analysis in Python. *J. Open Source Softw.* <https://doi.org/10.21105/joss.01317> (2019).
96. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* **462**, 108–112 (2009).
97. Kim, J. W. et al. Characterizing genomic alterations in cancer by complementary associations. *Nat. Biotechnol.* **34**, 539–546 (2016).
98. Reich, M. et al. GenePattern 2.0. *Nat. Genet.* **38**, 500–501 (2006).
99. Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat. Biotechnol.* **38**, 276–278 (2020).
100. Salié, H. et al. Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma. *Gut* **74**, 451–466 (2024).
101. Lim, B. et al. Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis. *Nat. Genet.* **57**, 668–679 (2025).

**Acknowledgements** We thank the members of the Core Facility Small Animal Imaging Center, the Core Facility Flow Cytometry, the NGS Core Facility, Mass Spectrometry based Protein Analysis Unit, Single-cell Open Lab (scOpenLab) and DKFZ-Bayer Immunotherapeutic Lab for their technical support; L. Beideck, V. Eichwald, F. Blum, F. Müller, A. L. Eck, H. Stammer, M. Owczorz and L. Wüst for technical support; Y. Miao for support in bioinformatics analysis and data uploading; D. Herebian for supporting bile-acid characterization; D. Scott (NCI Cancer Center NIH grant); and the staff at University of California, San Diego, Cellular and Molecular Medicine Electron Microscopy Core (UCSD-CMM-EM Core, RRID: SCR\_022039) for equipment access and technical assistance. M. Heikenwälder was supported by an European Research Council (ERC) Consolidator grant (HepatoMetaboPath), SFBTR179 project ID 272983813, SFB/TR 209 project ID 314905040, SFBTR1335 project ID 360372040, SFB 1479 (project ID: 441891347), the research unit FOR5889 “dangerhep”, the Wilhelm Sander-Stiftung, the Research Foundation Flanders (FWO) under grant 30826052 (EOS Convention MODEL-IDI), Deutsche Krebshilfe projects 70113166 and 70113167, German-Israeli Cooperation in Cancer Research (DKFZ-MOST) and the Helmholtz-Gemeinschaft, Zukunftsthema ‘Immunology and Inflammation’ (ZT-0027). M. Heikenwälder was also supported by seed funding from HI-TRON, by Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, by Cluster of Excellence CMFI EXC 2124 and by an ERC Synergy grant “Hepamodulator”. M. Heikenwälder, M.P., M. Hofmann, X.L. and R.Z. were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (project ID 441891347 SFB 1479). M.B. was supported by DFG within the CRC 1160 (project ID 256073931-Z02 to M.B.), CRC/TRR 167 (project ID 259373024-Z01), CRC 1453 (project ID 431984000-S1), TRR 359 (project ID 491676693-Z01), CRC/TRR 353/1 (project ID 471011418-SP02), FOR 5476 UcarE (project ID 493802833-P7) and SATURN3 (01KD2206L-AP8). We acknowledge funding from the German Federal Ministry of Education and Research (BMBF) within the Medical Informatics Funding Scheme PM4Onco-FKZ 01ZZ2322A (M.B.) and EkoEstMed-FKZ 01ZZ2015 (G.A.). M. Heikenwälder and D. Haller were supported by the DFG CRC 1335 Aberrant immune signals in cancer (360372040). M. Heikenwälder and J.M.L. are supported by a grant from the European Commission (Horizon Mission on Cancer, THRIVE, Ref. 101136622). This study was supported by the Rainer Hoeng Stiftung and by the DFG (TRR 412/1, 535081457). J.M.L. is further supported by grants from the Samuel Waxman Cancer Research Foundation; the Spanish National Health Institute (MICINN, PID2022-139365OB-I00); the NIH (R01 DK128289-01 and 1R01CA273932-01A1); through a partnership between Cancer Research UK (CRUK), Fondazione AIRC per la Ricerca sul Cancro and Fundación Científica de la Asociación Española Contra el Cáncer (FAECC) (Accelerator Award, HUNTER, C9380/A26813); by the Acadèmia de

Ciències Mèdiques i de la Salut de Catalunya i Balears; the Fundació Científica de la Asociación Española Contra el Cáncer (FAECC; PRYGN223117LLOV); Fundació Científica de la Asociación Española Contra el Cáncer, FAECC, Reto AECC 70% Supervivencia (RETOS245779LLOV), the Generalitat de Catalunya (AGAUR, 2021-SGR 01347), AECC Excellence Program (EPAEC246711CLIN) and from “la Caixa” Foundation under agreement LCF/PR/SP23/52950009. R.P. is supported by the Fundació de Recerca Clínic Barcelona-IDIBAPS and by a grant from the Spanish National Health Institute (MICINN, PID2022-139365OB-I00). A portion of this work was supported by NIH grants R01AGO62190, P01HL160472 and P01CA281819 (R.J.K.) and R01DK120714, R01DK133448 and R01CA234128 (M.K.). C.L. was supported by NIH training grant T32DK007494 and Fishman Fund Fellowship. National Cancer Institute (NCI) grants T32CA009140 to L.C.K. and R35CA220483 to M.C.S. L.C.K. was also supported by the American Cancer Society Postdoctoral Fellowship PF-23-1034739-01-TBE. S. Roth was supported by German Research Foundation (DFG) project ID 314905040, 469332207 and 493697503 and German Cancer Aid (Deutsche Krebshilfe), project no. 70113922. Swiss National Science Foundation (SNSF) project fund to A.W. (grant no. SNF320030\_182764). We acknowledge the members of the SBP Animal Facility, specifically B. Charbono and A. Charbono; the Histology Core, specifically G. Garcia and M. Sevilla; and the Genomics and Bioinformatics Shared Resource Cores and the NCI Cancer Center NIH Support Grant P30 CA030199, with Spatial Omics instrumentation supported by S10OD030285. S.G. is supported by a Max-Eder Junior Research Group Program of the Deutsche Krebshilfe (German Cancer Aid, project ID 70116308). The UCSD-CMM-EM Core is supported in part by the National Institutes of Health Award number S10OD023527. Work by T.V.P. and P.T. was supported by NIH grants R01CA154480, R01CA121941, R01CA247551, U01CA176058, R01DE026870, U24CA220341, U24CA248457, R01CA226803, U01CA217885, P30CA023100 and R01CA109467, and a State of California Initiative to Advance Precision Medicine award (OPR18112).

**Author contributions** All of the authors made substantial contributions to the manuscript. X.L., C.L., D. Haller, R.J.K. and M. Heikenwälder participated in the conception and design of the work. All of the authors participated in the acquisition, analysis or interpretation of data as follows. Design of the study: X.L., C.L., D. Haller, R.J.K. and M. Heikenwälder. Mouse permission documentation, housing and handling: X.L., C.L., A.K., C.D.-C., L.L., A.D., U.R., T.M., V.P.R. and M.F.-V. Acquisition and analysis of metabolic cage experiments: A.A., S.G. and X.L. qPCR/immunoblots and data analysis: X.L., C.L., A.K., C.D.-C., L.L., J. Hanselmann, M.V., Z.C., I.J. and O.I.C. Histological staining and analyses of mouse liver tissue: D. Heide, J. Hetzer, X.L., C.L., A.K. and L.L. Histological staining and analyses of human liver tissue: C.R., M. Hofmann, D. Heide, J. Hetzer and X.L. Acquisition and analysis of human HCC TMA data: Y.T., K.B. and C.L. Acquisition and analysis of human HCC IMC data: N.V., M. Hofmann and B.B. Pathological analysis of human and mouse liver tissue: J.S., B.G., D.T., S. Roessler and A.W. Acquisition and

analysis of flow cytometry data: C.F., P.R., X.L., L.L., A.K., P. Shen., N.T.-B. and R.Z. Acquisition and analysis of MIBI data: M.C. and F.J.H. Acquisition and analysis of aCGH data: M.S. and K.U. Acquisition and analysis of PET/CT and MRT data: M.J., X.L. and L.L. Acquisition and analysis of TEM data: M.P., X.L., C.L. and C.D.-C. Bioinformatic analysis of human liver cancer databases: J.H.-P., L.F., J.M.L., R.P., A.G.-O., M.P.-G., T.V.P., P.T., Y.H., A. Sun., G.A. and M.B. CUT&RUN, ATAC-seq and analyses: B.G.R., M.M., R.S.P., S.D.P. and D.T.O. NMR-based metabolome and analyses: L.Z., D.B. and C.T. LC-MS-based metabolome and analyses: L.M.N.M., J.R., S.W.M., A.T., L.S. and A. Schulze. Acquisition and analysis of scRNA-seq data: P. Sant, J.-P.M., M.Q., C.Z., D.Y., P.Z., J.-H.L., S.N. and S. Roth. Acquisition and analysis of bulk RNA-seq/proteome data: X.L., C.L., P. Baskaran, X.B., T.V.P. and P.T. Acquisition and analysis of metabolic flux assay and T-cell-killing assay data: A.K., A.B., P.-C.H., R.C. and C.L. Generation of genetically modified cell lines: J.K. and X.L. GalNac-ASO compounds and scientific input: S. M. FBP1 AAV8 vectors and critical FBP1-related scientific input: L.C.K., M.C.S., L.G. and M.K. R26-LSL-nATF6 $\alpha$ -HA transgenic mice and scientific input: O.I.C. and D. Haller. Additional key materials, human tissue samples and scientific input: P. Schirmacher, M.R., N.R., S. Roth, O.I.C., A.W., R.Z., M.P., T.L., N.P.M., P. Bronsert, K.K. and R.T. Acquisition of directly relevant funding: C.L., R.J.K., M. Heikenwälder and M.K. Draft and substantial revision of manuscript: X.L., C.L., R.J.K. and M. Heikenwälder.

**Funding** Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ).

**Competing interests** J.M.L. has received research support from Bayer Pharmaceuticals, Eisai, Bristol-Myers Squibb and Ipsen. He has also received consultancy fees from Bayer HealthCare Pharmaceuticals, Eisai, Merck, Bristol-Myers Squibb, Eli Lilly, Roche, Genentech, Ipsen, Glycotest, AstraZeneca, Omega Therapeutics, Mina Alpha, Boston Scientific, Exelixis, Bluejay, Abbvie, Moderna and Captor Therapeutics. The ASO compounds targeted to mouse *Atf6* were provided to SBP through a material transfer agreement with Ionis Pharmaceuticals. R.J.K. is consulting with Metagenomi Phar. C.L. is currently an employee at Pfizer. L.Z. is currently an employee at Dr. Falk Pharma. The other authors declare no competing interests.


#### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-025-10036-8>.

**Correspondence and requests for materials** should be addressed to Cynthia Lebeaupin, Dirk Haller, Randal J. Kaufman or Mathias Heikenwälder.

**Peer review information** *Nature* thanks Juan Cubillos-Ruiz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


**Reprints and permissions information** is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | See next page for caption.

**Extended Data Fig. 1 | High levels of ATF6 $\alpha$  activation are associated with aggressive HCC subtypes and *Fbp1* downregulation in humans, Related to Fig. 1. (a-b)** Heatmap of HCC molecular subtype, hepatic progenitor and poor prognosis gene signatures in 228 HCC tumours<sup>18</sup> (a) and 171 HCC tumours<sup>19</sup> (b) distributed by high to low enrichment of human ATF6 $\alpha$ -activation signature (MSigDB<sup>17</sup> Human Gene Set: ATF6\_Target\_Genes<sup>75</sup>). (c) Heatmap of metabolism, cell cycle, or oncogenesis MSigDB Hallmark gene sets of tumour samples<sup>18,19</sup> in 228 HCC tumours<sup>18</sup> (left) and 171 HCC tumours<sup>19</sup> (right) distributed by high to low enrichment of human ATF6 $\alpha$ -activation signature. (d) Tumour grade distribution of ATF6 $\alpha$ -negative and ATF6 $\alpha$ -positive (high and low) HCC samples from human HCC tissue microarrays (TMAs) (n = 473; ATF6 $\alpha$ -: n = 120 and ATF6 $\alpha$ + : n = 353 patients (low: n = 130; high: n = 223)). Compared to ATF6 $\alpha$ -negative samples (IHC score=0, 25.4%), the remaining 74.6% ATF6 $\alpha$ -positive samples were binned into distinct groups based on ATF6 $\alpha$  activation: (i) low (IHC score 1-2; 27.5% of total) or (ii) high (IHC score  $\geq$ 3; 47.1% of total). (e-f) Heatmap of nATF6 $\alpha$  target protein expression (e) regrouped by signalling pathway (f) in non-tumour liver (NT) or paired tumour (T) tissue from the Chinese Human Proteome Project HCC patients of increasingly aggressive S-I, S-II, and S-III subtypes<sup>21</sup> (n = 101; S-I, n = 36; S-II, n = 32; S-III, n = 33). (g) Percentage of cells with inactive (cytoplasmic) ATF6 $\alpha$  expression in non-tumour tissue (n = 32), tumour margin (n = 34) or tumour (n = 32) based on IHC of ATF6 $\alpha$  in HCC patients. (h) Percentage of cells with active (nuclear) ATF6 $\alpha$  expression distributed by viral (n = 12 non-tumour, 11 tumour margin, 10 tumour) or non-


viral (n = 17 non-tumour, 19 tumour margin, 18 tumour) hepatitis HCC patients. (i) DSP workflow, adapted from user's manual (image provided by Bruker Spatial Biology). Representative DSP immunofluorescence staining in liver tissue of HCC patient as technical control (below). Red arrows indicate CD45+ (immune) cells and green arrows indicate PanCK+ (biliary) cells. (j) Heatmap of unsupervised hierarchical clustering of nearly 1200 genes from the Cancer Transcriptome Atlas panel revealing distinct high-ATF6 $\alpha$  versus low-ATF6 $\alpha$  HCC ROIs. (k) Volcano plot of significantly downregulated (blue) and upregulated (red) transcripts in high-ATF6 $\alpha$  versus low-ATF6 $\alpha$  ROIs. (l) DSP Pathway Analysis of differentially expressed genes in high-ATF6 $\alpha$  versus low-ATF6 $\alpha$  HCC ROIs. (m) Kaplan-Meier survival curves for TCGA-LIHC patients divided into two groups by median split based on high (n = 185) or low *FBP1* (n = 185) mRNA expression. Scatter dot plot data are presented as mean values  $\pm$  SEM. Box and whisker plot data are presented with boxes spanning 25th to 75th percentiles, with a line at the median, and whiskers from min to max. Data in 1a-c with continuous variables were analysed by Pearson correlation, while categorical variables were compared by Wilcoxon test. Data in 1e were mined and re-processed for analysis by Wilcoxon rank sum test. Data in 1g-h were analysed by one-way ANOVA with Geisser-Greenhouse correction, Tukey multiple comparison correction. D'Agostino-Pearson, Shapiro-Wilk, and Kolmogorov-Smirnov tests were performed to assess for normal distribution. Lognormally distributed cohorts were log-transformed prior to testing. Data in 1m were analysed by median split and log-rank test.



Extended Data Fig. 2 | See next page for caption.

**Extended Data Fig. 2 | Persistent ATF6 $\alpha$  activation causes ER stress-driven liver injury in 3-month-old mice, Related to Fig. 2.** (a-b) Scheme (top) of *nAtf6<sup>fl+</sup>* mice injected with AAV8-*gfp* (n = 3) or AAV8-*cre* (n = 3), the latter inducing heterozygous expression of nATF6-HA in hepatocytes, with representative liver IHC for HA (bottom, a; scale bar = 200  $\mu$ m) and related quantification (b). (c) Representative immunoblot analysis to validate ATF6 $\alpha$  and HA expression in livers of *TG<sup>AAV-cre</sup>* mice, and GFP expression in livers of *TG<sup>AAV:gfp</sup>* mice. VINCULIN as loading control, ran on GFP blot. kDa: kilodalton. (d) Representative liver macroscopy of female *TG<sup>Alb-cre-</sup>* and *TG<sup>Alb-cre+</sup>* mice sacrificed at 3 months of age. (e-f) Serum alkaline phosphatase (ALP, e) levels of *TG<sup>Alb-cre-</sup>* (n = 8) and *TG<sup>Alb-cre+</sup>* (n = 9) mice and cholesterol (f) levels of *TG<sup>Alb-cre-</sup>* (n = 8) and *TG<sup>Alb-cre+</sup>* (n = 10) mice. (g) ER width quantification of TEM images shown in Fig. 2d from livers of *TG<sup>Alb-cre-</sup>* (n = 28 fields of view (FOV), 2 mice) and *TG<sup>Alb-cre+</sup>* (n = 40 FOV, 4 mice).


(h) qRT-PCR analysis of indicated mRNAs from livers of *TG<sup>Alb-cre-</sup>* (n = 5) and *TG<sup>Alb-cre+</sup>* (n = 7) mice. Bold labelling depicts significant genes. (i) Quantification of immunoblot analysis in Fig. 2e from livers of *TG<sup>Alb-cre-</sup>* (n = 5) and *TG<sup>Alb-cre+</sup>* (n = 7) mice. (j) Quantification of IHC in Fig. 2f from livers of *TG<sup>Alb-cre-</sup>* (n = 5) and *TG<sup>Alb-cre+</sup>* (n = 7) mice. (k-l) Representative H&E staining and IHC (k; scale bar = 100  $\mu$ m) with quantification (l) for HA, Ki67, 53BP1, p62, CK19, and CD44v6 from livers of 3-month-old *TG<sup>Alb-cre-</sup>* (n = 4 for 53BP1, n = 5 for the rest) and *TG<sup>Alb-cre+</sup>* (n = 4 for 53BP1, n = 7 for the rest) mice. (m) PCA of RNA-seq data from livers of 3-month-old *TG<sup>Alb-cre-</sup>* (n = 5) and *TG<sup>Alb-cre+</sup>* (n = 7) mice, showing unsupervised clustering of liver transcriptome. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 2b,e-j,l were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Mouse icon was created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/lgjnsy9>.



Extended Data Fig. 3 | See next page for caption.


**Extended Data Fig. 3 | Catalytically functional FBPI in hepatocytes mitigates ATF6 $\alpha$ -activation-driven dysregulation of glucose- and lipid-metabolism, ER stress, and liver injury, Related to Fig. 2.** (a) Glucose tolerance test of 16h-fasted  $TG^{AAV:gfp}$ ,  $TG^{AAV:cre}$ , and  $TG^{AAV:cre/fbpl}$  mice (n = 6/group). (b) Pyruvate tolerance test and excursion of 16h-fasted  $TG^{AAV:gfp}$  (n = 6),  $TG^{AAV:cre}$  (n = 5), and  $TG^{AAV:cre/fbpl}$  (n = 5) mice. (c) Insulin levels of 16h-fasted  $TG^{AAV:gfp}$  (n = 8),  $TG^{AAV:cre}$  (n = 8), and  $TG^{AAV:cre/fbpl}$  (n = 7) mice measured by ELISA. (d) Quantification of immunoblot analysis from livers of  $TG^{AAV:gfp}$ ,  $TG^{AAV:cre}$ , and  $TG^{AAV:cre/fbpl}$  mice in Fig. 2n (n = 5/group). (e) Quantification of IHC in Fig. 2o from livers of  $TG^{AAV:cre}$  and  $TG^{AAV:cre/fbpl}$  mice (n = 7/group). (f-g) IHC of Ki67 (f; scale bar = 100  $\mu$ m) with related quantification (g) from livers of  $TG^{AAV:cre}$  and  $TG^{AAV:cre/fbpl}$  mice (n = 7/group). (h) NMR metabolomics partial least squares discriminant analysis (PLS – DA) of liver samples from  $TG^{AAV:gfp}$ ,  $TG^{AAV:cre}$ , and  $TG^{AAV:cre/fbpl}$  mice (n = 5/group) with coloured 95% confidence intervals illustrating individual group separation. (i) Top 15 NMR metabolite concentration changes and their VIP score based on the PLS – DA regression model. (j) [ $^{13}$ C]-labelled lactate uptake measured by GC-MS analysis from livers of  $TG^{AAV:gfp}$  (n = 5),  $TG^{AAV:cre}$  (n = 6), and  $TG^{AAV:cre/fbpl}$  (n = 6) mice. (k) Representative liver tissue showing similar PAS staining and

IHC of BiP and CHOP expression in  $TG^{AAV:cre}$  and hepatocyte-specific FBPI-catalytically dead mutant  $TG^{AAV:cre/fbplE98A}$  mice. Scale bar = 100  $\mu$ m. (l-m) Representative immunoblot analysis (l) and quantification (m) of indicated proteins from livers of  $TG^{AAV:gfp}$  (n = 2) and  $TG^{AAV:cre/fbplE98A}$  (n = 5) mice. VINCULIN as loading control, ran on FBPI blot. kDa: kilodalton. (n) qRT-PCR analysis of indicated mRNAs from livers of  $TG^{AAV:gfp}$  (n = 9),  $TG^{AAV:cre}$  (n = 9),  $TG^{AAV:cre/fbpl}$  (n = 7), and  $TG^{AAV:cre/fbplE98A}$  (n = 5) mice. Bold labelling depicts significant genes. (o) Representative liver Oil Red O staining for lipid accumulation from  $TG^{AAV:cre}$ ,  $TG^{AAV:cre/fbpl}$ , and  $TG^{AAV:cre/fbplE98A}$  mice (scale bar = 100  $\mu$ m). (p) Total cholesterol or triglyceride levels measured in sera (left) or livers (right) of  $TG^{AAV:cre}$  (n = 9),  $TG^{AAV:cre/fbpl}$  (n = 8), and  $TG^{AAV:cre/fbplE98A}$  (n = 5) mice. (q) Schematic by which ATF6 $\alpha$  activation causes dysregulated glucose metabolism through FBPI downregulation that perpetuates ER stress in a feed-forward loop. Scatter dot plot data and line graph data are presented as mean values  $\pm$  SEM. Data in 3a-d,j,p were analysed by one-way ANOVA. Data in 3e,g were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 3n were analysed by two-way ANOVA.



**Extended Data Fig. 4 | ATF6 $\alpha$  activation spontaneously drives hepatocarcinogenesis, related to Fig. 3. (a)** Scheme of  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice sacrificed at 9 or 12 months old (top) with representative liver macroscopy of 12-month-old female mice (bottom). **(b-d)** Serum ALP **(b)**, cholesterol **(c)**, and albumin **(d)** levels (9 M:  $TG^{Alb-cre-}$  n = 20 (10 males, 10 females);  $TG^{Alb-cre+}$  n = 33 (13 males, 20 females). 12 M:  $TG^{Alb-cre-}$  n = 29 (12 males, 17 females);  $TG^{Alb-cre+}$  n = 49 (25 males, 24 females)). **(e)** Genomic aberrations detected by aCGH of representative 12-month-old  $TG^{Alb-cre-}$  mouse livers and  $TG^{Alb-cre+}$  mouse tumour tissue. **(f-g)** Representative immunoblot analysis **(f)** and quantification **(g)** of HA-nATF6 $\alpha$  in paired non-tumour liver (N) and tumour (T) lysates of  $TG^{Alb-cre-}$  (n = 5) and  $TG^{Alb-cre+}$  (n = 4) mice. VINCULIN as loading control, ran on a

separate blot, processed in parallel. kDa: kilodalton. **(h-i)** Representative immunoblot analysis **(h)** and quantification **(i)** of nATF6 $\alpha$  in paired non-tumour (NT) liver and tumour (T) lysates of wild-type (WT) mice injected with diethylnitrosamine (DEN; 25 mg/kg) at two weeks of age prior to high-fat diet (HFD) feeding and sacrificed at 38 weeks of age (n = 5 mice/group). VINCULIN as loading control, ran on nATF6 $\alpha$  blot. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 4b-d,i were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 4g were analysed by one-way ANOVA. Mouse icon was created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/Igjnsy9>.




Extended Data Fig. 5 | See next page for caption.

# Article


**Extended Data Fig. 5 | ATF6 $\alpha$  activation accelerates hepatocarcinogenesis in a carcinogen and dietary preclinical model, related to Fig. 3. (a)** Scheme of *nAtf6<sup>fl/fl</sup>* mice intraperitoneally injected with diethylnitrosamine (DEN; 25 mg/kg) prior to AAV8-*gfp* or AAV8-*cre* injection at the start of 60% high-fat diet (HFD) feeding and sacrificed at 30 weeks of age (top). Representative liver macroscopy of 30-week-old female mice (bottom). **(b)** Body weight gain of DEN/HFD-treated *TG<sup>AAV-gfp</sup>* mice (n = 11; 6 males, 5 females) and *TG<sup>AAV-cre</sup>* mice (n = 12; 7 males, 5 females). **(c-e)** Serum cholesterol **(c)**, bile acids **(d)**, and albumin **(e)** levels of DEN/HFD-treated *TG<sup>AAV-gfp</sup>* (n = 11) and *TG<sup>AAV-cre</sup>* (n = 12) mice. **(f-g)** Representative tumour (T) and non-tumour (NT) H&E staining and IHC for AFP, HA, BiP **(f)**; scale bar = 300  $\mu$ m), with quantification **(g)** from livers of *TG<sup>AAV-gfp</sup>* (n = 3) and *TG<sup>AAV-cre</sup>* (n = 4) mice. **(h-i)** Representative immunoblot analysis **(h)** and quantification **(i)** of indicated proteins from non-tumour (N) or tumour (T) liver lysates of *TG<sup>AAV-gfp</sup>* (n = 11NT, with 4 T) and *TG<sup>AAV-cre</sup>* mice (n = 12NT, with 31 T). VINCULIN as loading control, ran on a separate blot, processed in parallel. kDa:

kilodalton. **(j-k)** Representative tumour (T) and non-tumour (NT) liver IHC of cl-Caspase 3 and CHOP **(j)**; scale bar = 300  $\mu$ m), with quantification **(k)** in *TG<sup>AAV-gfp</sup>* (n = 3) and *TG<sup>AAV-cre</sup>* (n = 4) mice. **(l)** GSEA of RNA-seq data shows negatively and positively enriched pathways in tumour (T) versus non-tumour (NT) livers of *TG<sup>AAV-cre</sup>* mice (n = 5/group). **(m)** Volcano plot of RNA-seq data in tumour (T) versus paired non-tumour (NT) livers of *TG<sup>AAV-cre</sup>* mice (n = 5/group). Purple, red, blue, and black dots represent ER-stress-related, immune-related, metabolic, and oncogenic genes, respectively. **(n)** Quantification of IHC in Fig. 3r from tumour tissue of *TG<sup>AAV-gfp</sup>* and *TG<sup>AAV-cre</sup>* mice (n = 3/group). Scatter dot plot data and line graph data are presented as mean values  $\pm$  SEM. Data in 5c-e, g, n were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 5g, i, k were analysed by two-way ANOVA. Data in 5l were analysed by GSEA based on the Kolmogorov-Smirnov test. Mouse icon was created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/lgjnsy9>.



**Extended Data Fig. 6 | ATF6 $\alpha$  activation in HCC is associated with downregulated FBP1, while restoring FBP1 reduces tumour burden and immunosuppression in mice, related to Fig. 3. (a) Correlation analysis and regression line of *FBP1* mRNA to the human ATF6 $\alpha$ -activation signature (ATF6\_Target\_Genes) in 15 publicly available datasets. (b) Forest plot of *FBP1* mRNA expression in human HCC in relation to non-tumour liver tissue in 22 publicly available datasets. (c) Scheme (top) of DEN/HFD-treated *TG<sup>AAV-cre</sup>* ( $n = 10$ ) and *TG<sup>AAV-cre/fbp1</sup>* ( $n = 11$ ) mice, with representative macroscopic liver images at 30 weeks of age (bottom). (d-e) Liver-to-body weight (d), tumour number (e, left) and area (e, right, cm<sup>2</sup>) per liver of DEN/HFD-treated *TG<sup>AAV-cre</sup>***


( $n = 10$ ) and *TG<sup>AAV-cre/fbp1</sup>* ( $n = 11$ ) mice. (f-g) Representative liver H&E staining and IHC for CD8 and PD1 (f) with quantification (g) in tumour (T) versus paired non-tumour (NT) livers from DEN/HFD-treated *TG<sup>AAV-cre</sup>* ( $n = 10$ ) and *TG<sup>AAV-cre/fbp1</sup>* ( $n = 11$ ) mice. H&E: scale bar = 3 mm; IHC: scale bar = 300  $\mu$ m. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 6a,b were computed by Pearson correlation coefficient and p-value based on a cut-off of +1 standard deviation from the mean using Fisher's exact test. Data in 6d,e were analysed by two-tailed unpaired *t*-test based on data normality distribution. Data in 6g were analysed by two-way ANOVA. Mouse icon was created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/Igjsny9>.



Extended Data Fig. 7 | See next page for caption.

**Extended Data Fig. 7 | Targeting ATF6 $\alpha$  activation protects against MASH-HCC hallmarks, Related to Fig. 4.** (a) Body weight gain during HFD-feeding of *Atf6*<sup>+/+</sup> (n = 9; 3 males, 6 females) and *Atf6*<sup>-/-</sup> (n = 14; 9 males, 5 females) mice injected with diethylnitrosamine (DEN; 25 mg/kg) at 2 weeks of age and sacrificed at 38 weeks of age. (b) Liver-to-body weight of DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 9) and *Atf6*<sup>-/-</sup> (n = 14) mice. (c) Serum ALT levels of DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 9) and *Atf6*<sup>-/-</sup> (n = 14) mice. (d-e) Representative IHC (d, scale bar = 500  $\mu$ m) and quantification (e) of BiP in liver tumour from DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 5) and *Atf6*<sup>-/-</sup> (n = 6) mice. (f-g) Representative H&E staining and IHC for Ki67, 4HNE, CD8, and PDI (f; scale bar = 100  $\mu$ m) in tumour (T) and non-tumour liver (NT) of DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 5) and *Atf6*<sup>-/-</sup> (n = 6) mice with intratumoral quantification (g). (h) TEM images and quantification of tumour tissue from DEN/HFD-treated *Atf6*<sup>+/+</sup> or *Atf6*<sup>-/-</sup> mice, as in Fig. 4e, with cellular structures denoted as: C, collagen; ER, endoplasmic reticulum; L, lipid droplets; M, mitochondria; N, nucleus (scale bar = 1  $\mu$ m). ER width: n = 21 fields of view

(FOV), 2 *Atf6*<sup>+/+</sup> mice or n = 22 FOV, 2 *Atf6*<sup>-/-</sup> mice; lipid droplets: n = 18 FOV, 2 *Atf6*<sup>+/+</sup> mice or n = 19 FOV, 2 *Atf6*<sup>-/-</sup> mice. (i-j) Quantification (i) of immunoblot analysis (j, representative) from DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 7NT, with 8 T) and *Atf6*<sup>-/-</sup> (n = 8NT) mouse liver lysates. VINCULIN as loading control, ran on FBPI blot. kDa: kilodalton. (k-l) Volcano plot (k) of RNA-seq data with GSEA enrichment plots (l) from livers of DEN/HFD-treated *Atf6*<sup>-/-</sup> versus *Atf6*<sup>+/+</sup> mice (n = 3/group). Purple, red, blue, and black dots indicate ER stress, immune-related, metabolic and oncogenic genes, respectively. (m) qRT-PCR analysis of indicated mRNAs from livers/tumours of DEN/HFD-treated *Atf6*<sup>+/+</sup> (n = 9NT, 9 T) and *Atf6*<sup>-/-</sup> mice (n = 8NT, 4 T). Bold labelling depicts significant genes. Scatter dot plot data and line graph data are presented as mean values  $\pm$  SEM. Data in 7b-c, e, g, h, m were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 7i were analysed by one-way ANOVA.




Extended Data Fig. 8 | See next page for caption.

**Extended Data Fig. 8 | Targeting ATF6 $\alpha$  activation by ASOs reduces ER-stress-related liver injury and HCC tumour burden in mice, Related to Fig. 4.**

(a) Scheme of wild-type (WT) or *MUP-uPA* mice receiving GalNac-conjugated ASO-Scramble or ASO-*Atf6* (2.5 mg/kg/week) for 3 weeks (top), with representative macroscopic liver images of WT mice (bottom). (b-c) Liver-to-body weight (b), and serum ALT levels (c) from livers of ASO-Scramble- or ASO-*Atf6*-treated WT mice (n = 8,3) or *MUP-uPA* mice (n = 8,7). (d) qRT-PCR analysis of indicated mRNAs from livers of ASO-Scramble- or ASO-*Atf6*-treated WT mice (n = 7,3) or *MUP-uPA* mice (n = 8,7). Bold labelling in genes depicts significant genes. (e) Quantification of IHC in Fig. 4r from livers of ASO-Scramble- (n = 5) or ASO-*Atf6*-treated (n = 4) *MUP-uPA* mice. (f-g) Quantification of ER width (f) and additional TEM images (g) from livers of ASO-Scramble-treated WT mice (n = 20 fields of view (FOV), 2 mice) and ASO-Scramble- (n = 30 FOV, 2 mice) or ASO-*Atf6*-treated (n = 33 FOV, 3 mice) *MUP-uPA* mice, as in Fig. 4q, with cellular structures denoted as: C, collagen; ER, endoplasmic reticulum; L, lipid droplets; M, mitochondria; N, nucleus (scale bar left to right = 2  $\mu$ m, 1  $\mu$ m, 500 nm). (h-i) Representative IHC of Ki67 and cl-Caspase 3 (h; scale bar = 100  $\mu$ m), with quantification (i) from livers of ASO-Scramble- or ASO-*Atf6*-treated *MUP-uPA* mice (n = 5,4). (j) Scheme of *MUP-uPA* mice or WT mice fed a HFD and sacrificed at 30 weeks of age. Representative liver macroscopy of 30-week-old male mice

(bottom). (k-l) Liver-to-body weight (k) and tumour incidence (l) of HFD-fed WT (n = 5) or *MUP-uPA* (n = 9) mice. (m) Representative H&E staining (scale bar = 2 mm) of livers from HFD-fed WT or *MUP-uPA* mice. (n) Scheme of *MUP-uPA* or WT mice administered GalNac-conjugated ASO-Scramble or ASO-*Atf6* during the last 10 weeks of HFD-feeding (top) with representative macroscopic liver images of WT mice (bottom). (o-p) Liver-to-body weight (o) and serum ALT levels (p) of ASO-Scramble- or ASO-*Atf6*-treated WT mice (n = 3,4) or *MUP-uPA* mice (n = 7,6) under HFD-feeding. (q-r) Representative *in-situ* hybridization (ISH) (q, scale bar = 50  $\mu$ m) with quantification of *Atf6* mRNA intensity per field (r) in non-tumour (NT) liver, tumour border and tumour (T) of ASO-Scramble (n = 8) or ASO-*Atf6*-treated (n = 6) *MUP-uPA* mice under HFD-feeding. (s) qRT-PCR analysis of indicated mRNAs from livers of ASO-Scramble (n = 6) or ASO-*Atf6* (n = 5) treated *MUP-uPA* mice under HFD-feeding. Log<sub>2</sub>(Fold change) normalized to ASO-Scramble-treated WT mice. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 8b,c,o,p,r were analysed by two-way ANOVA. Data in 8d,e,k,s were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 8f were analysed by one-way ANOVA. Data in 8l were analysed by Chi-square test for contingency. Mouse icons were created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/lgjsny9>.




Extended Data Fig. 9 | See next page for caption.

**Extended Data Fig. 9 | Prolonged ATF6 $\alpha$  activation in hepatocytes is associated with an immunosuppressive liver microenvironment in mice, Related to Fig. 5.**

**(a)** Gene signatures predicting poor survival and Immune-mediated Cancer Field (ICF) signature analysed in livers of 3-month-old  $TG^{Alb-cre-}$  (n = 5) and  $TG^{Alb-cre+}$  (n = 7) mice, as shown in Fig. 5a. **(b)** Heatmap of immune features and signatures related to immune checkpoint blockade (ICB) response in HCC patients (n = 171<sup>19</sup>) divided into two groups by high and low enrichment of the mouse-derived ATF6 $\alpha$ -activation signature established from RNA-seq data of DEN/HFD-treated  $TG^{AAV-cre}$  and  $TG^{AAV-gfp}$  mice (see Methods). **(c)** Representative immunoblot analysis and quantification of PD-L1 expression from livers of 6-month-old  $TG^{Alb-cre-}$  (n = 4) and  $TG^{Alb-cre+}$  (n = 9) mice. GAPDH as loading control, ran on PD-L1 blot. kDa: kilodalton. **(d-e)** Representative IHC **(d;** scale bar = 100  $\mu$ m) with quantification **(e)** from livers of 6-month-old  $TG^{Alb-cre-}$  (n = 6) and  $TG^{Alb-cre+}$  (n = 7) mice. **(f)** Liver CD45<sup>+</sup> lymphocytes count (per gram of liver) in 6-month-old  $TG^{Alb-cre-}$  (n = 6) and  $TG^{Alb-cre+}$  (n = 7) mice by

FACS. **(g-h)** The proportion of CD4<sup>+</sup> T-cells **(g)** and macrophages, monocytes, monocytic- or polymorphonuclear myeloid-derived suppressor cells (M/PMN-MDSC, **h**) in livers of  $TG^{Alb-cre-}$  (n = 6) and  $TG^{Alb-cre+}$  (n = 7) mice. **(i)** Quantification of immunofluorescence staining in Fig. 5d of livers from  $TG^{Alb-cre-}$  (n = 3) and  $TG^{Alb-cre+}$  (n = 4) mice. **(j-k)** scRNA-seq UMAP representations of immune cell populations from FACS-sorted CD45<sup>+</sup> cells **(j)** and respective cell-type distribution **(k)** from livers of 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice (n = 4/group). **(l)** scRNA-seq cell-type distribution of subclustered CD8<sup>+</sup> T-cells (Fig. 5e) from livers of 6-month-old  $TG^{Alb-cre-}$  and  $TG^{Alb-cre+}$  mice (n = 4/group). Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 9a were analysed using the nonparametric Wilcoxon and Kruskal-Wallis tests. Data in 9b with continuous variables were analysed by two-tailed Student's *t*-test, and categorical variables were analysed by Fisher's exact test. Data in 9c,e-i were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution.




Extended Data Fig. 10 | See next page for caption.

**Extended Data Fig. 10 | ATF6 $\alpha$  activation metabolically renders**

**cancer cells resistant to T-cell-mediated cytotoxicity, Related to Fig. 5.**

**(a-b)** Metabolic flux analysis **(a)** for extracellular acidification rates (ECAR) of FL83B<sup>WT</sup> (n = 3) or FL83B<sup>TG</sup> (n = 3) hepatocytes, with quantification **(b)** for glycolysis and glycolytic capacity. **(c)** Glucose consumption in FL83B<sup>WT</sup> or FL83B<sup>TG</sup> hepatocytes cultured for 48 h (n = 6/group). **(d)** qRT-PCR analysis of glucose-related metabolic genes in FL83B<sup>WT</sup> or FL83B<sup>TG</sup> cells (n = 6/group). Bold labelling depicts significant genes. **(e)** NMR spectroscopy-based metabolomics analysis of lactate concentration in FL83B cells with ATF6 $\alpha$  expression (FL83B<sup>TG</sup>) or deletion (FL83B<sup>KO</sup>), normalized to respective controls (n = 6/group). **(f)** NMR metabolomics PLS – DA with coloured 95% confidence intervals illustrating the clear group separation in metabolic profile between FL83B<sup>WT</sup> and FL83B<sup>TG</sup> cells (n = 6/group). **(g)** qRT-PCR analysis of primary hepatocytes harvested from livers of 3-month-old *TG<sup>Alb-cre-</sup>* (n = 4) and *TG<sup>Alb-cre+</sup>* (n = 6) mice. Bold labelling depicts significant genes. **(h)** qRT-PCR analysis of primary hepatocytes harvested from livers of CD-HFD-fed *Atf6<sup>liver</sup>* (n = 6) and *Atf6<sup>liver</sup>* (n = 6) mice. Bold labelling depicts significant genes. **(i)** Scheme of HCC cancer cell line (HLE) stably transfected with control vector (HLE<sup>WT</sup>) or nATF6 $\alpha$ -expressing (HLE<sup>TG</sup>) plasmid and co-cultured with or without cytotoxic MART-1 T-cells to assess immune attack by a real-time cell analyzer (xCELLigence). **(j)** HLE<sup>WT</sup> or HLE<sup>TG</sup> cancer cell growth over time with quantification on the right panel (n = 3/group). **(k)** Killing assay and quantification for HLE<sup>WT</sup> or HLE<sup>TG</sup> cancer cell growth in co-culture conditions with cytotoxic MART-1 T-cells (n = 3/group).


**(l)** Scheme of Colo800 tumour cells stably transfected with control (Colo800<sup>WT</sup>) or nATF6 $\alpha$ -expressing (Colo800<sup>TG</sup>) plasmid and co-cultured with cytotoxic MART-1-specific T-cells to assess immune attack in a real-time cell analyzer (xCELLigence). **(m)** Killing assay of Colo800<sup>WT</sup> or Colo800<sup>TG</sup> tumour cells in co-culture conditions with cytotoxic MART-1-specific T-cells (n = 3/group) in the presence or absence of the lactate dehydrogenase inhibitor galloflavin. **(n)** Killing assay for Colo800<sup>WT</sup> or Colo800<sup>TG</sup> tumour cell growth in co-culture conditions with cytotoxic MART-1 T-cells (n = 4/group) in the presence or absence of the lactate efflux inhibitor AZD3965. **(o)** Glucose consumption of Colo800<sup>WT</sup> and Colo800<sup>TG</sup> cells cultured for 48 h (n = 6/group). **(p)** qRT-PCR analysis of indicated mRNAs from Colo800<sup>WT</sup> and Colo800<sup>TG</sup> cells (n = 6/group). Bold labelling depicts significant genes. **(q)** NMR metabolomics PLS – DA with coloured 95% confidence intervals illustrating the clear group separation in metabolic profile between Colo800<sup>WT</sup> (n = 5) and Colo800<sup>TG</sup> (n = 6) cells. **(r)** Top 15 metabolites and their VIP score based on the PLS – DA regression model. Scatter dot plot data are presented as mean values  $\pm$  SEM. Line graph data are presented as mean values  $\pm$  SEM (10a) or mean values  $\pm$  SD (10j-k, m-n). Data in 10b-d,g,h,o,p were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 10e were analysed by one-way ANOVA. Data in 10j,k were calculated for the area under the curve and analysed by two-tailed Student's *t*-test. Data in 10m,n were calculated for the area under the curve and analysed by one-way ANOVA. In vitro co-culture schematics were created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/lgjnsy9>.



Extended Data Fig. 11 | See next page for caption.

**Extended Data Fig. 11 | Anti-PD1 immune checkpoint blockade enhances T-cell-mediated anti-tumour immunosurveillance in livers with ATF6 $\alpha$  activation, Related to Fig. 5.** (a) Liver-to-body weight of 9-month-old *TG<sup>Alb-cre+</sup>* mice treated with  $\alpha$ -IgG (n = 8) or  $\alpha$ -PD1 (n = 10) antibody. (b) IHC quantification for CD8<sup>+</sup> and PD1<sup>+</sup> cells in Fig. 5k from livers of *TG<sup>AAV-cre</sup>* mice treated with  $\alpha$ -IgG (n = 6) or  $\alpha$ -PD1 (n = 5) monotherapy. (c-d) Representative liver tumour (T) IHC (c) and quantification (d) of HA, CHOP, BiP, and AFP (scale bar = 100  $\mu$ m) from *TG<sup>Alb-cre+</sup>* mice treated with  $\alpha$ -IgG (n = 6) or  $\alpha$ -PD1 (n = 5) monotherapy. (e) Contour plot for LDH expression in CD8<sup>+</sup> TILs in  $\alpha$ -IgG/PD1-treated *TG<sup>Alb-cre+</sup>* mice by MIB1 (n = 3/group). (f) Experimental scheme (top), and qRT-PCR analysis of *Atf6* or *Hspa5* mRNA expression in non-tumour liver (NT) or tumour (T) samples from C57BL6/J (WT) mice after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA (n = 4/group). (g) Scheme depicts C57BL6/J mice treated with  $\alpha$ -IgG or  $\alpha$ -PD1 monotherapy after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA (top) with representative, macroscopic liver images at sacrifice (bottom). (h) Tumour number (left) and area (right, cm<sup>2</sup>) per liver of  $\alpha$ -IgG/PD1-treated C57BL6/J (WT) mice (n = 4/group). (i) Representative H&E staining (low magnification) of livers from  $\alpha$ -IgG/PD1-treated C57BL6/J (WT) mice. Scale bar = 3 mm. (j) Scheme of *nATF6<sup>fl/+</sup>* mice administered AAV8-*gfp* or AAV8-*cre* and sacrificed 5 days after injection, with representative liver HA IHC (bottom,

scale bar = 100  $\mu$ m). (k) Scheme (top) with representative, macroscopic liver images (bottom left) and liver IHC for HA (bottom right) from *nATF6<sup>fl/+</sup>* mice administered AAV8-*cre* (*TG<sup>AAV-cre</sup>*) and treated with  $\alpha$ -IgG/PD1 monotherapy after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA, scale bar = 100  $\mu$ m. (l-m) Liver-to-body weight (l), tumour number and area (m, cm<sup>2</sup>) of *TG<sup>AAV-cre</sup>* mice treated with  $\alpha$ -IgG (n = 6) or  $\alpha$ -PD1 (n = 9) monotherapy after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA. (n) Representative H&E staining and IHC for Collagen IV and HNF4 $\alpha$  from livers of *TG<sup>AAV-cre</sup>* mice treated with  $\alpha$ -IgG/PD1 after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA, scale bar = 200  $\mu$ m for IHC. (o-p) Representative H&E staining (low magnification) and IHC for CD8 and PD1 (o) with quantification (p) in livers of *TG<sup>AAV-cre</sup>* mice treated with  $\alpha$ -IgG (n = 6) or  $\alpha$ -PD1 (n = 9) monotherapy after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA. (q) Scheme (top) and Kaplan-Meier survival curves (bottom) of *TG<sup>AAV-cre</sup>* mice treated with  $\alpha$ -IgG (n = 5) or  $\alpha$ -PD1 (n = 4) monotherapy after HDTV of MYC:TP53<sup>KO</sup> plasmid DNA. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 11a,b,d,f,h,l,m were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 11e were analysed by Mann-Whitney test. Data in 11p were analysed by two-way ANOVA. Data in 11q were analysed by log-rank (Mantel-Cox) test. NT: non-tumour, T: tumour, SP: spleen. Mouse icons were created in BioRender. Heikenwalder, M. (2026) <https://BioRender.com/lgjnsy9>.



Extended Data Fig. 12 | See next page for caption.

**Extended Data Fig. 12 | *Pdcd1* deletion enhances anti-tumour**

**immunosurveillance in livers of  $TG^{Alb-cre+}$  mice, Related to Fig. 5.** (a) Breeding strategy of  $TG:Pdcd1^{-/-}$  mice (top) and representative FACS scatter plot showing PDI-knockout efficiency (bottom). (b) Liver-to-body weight of 9-month-old  $TG^{Alb-cre+}$  (n = 19; 9 males, 10 females) and  $TG:Pdcd1^{-/-}$  mice (n = 18; 8 males, 10 females). (c) Serological parameters (c, ALT, AST, ALP and cholesterol) of 9-month-old  $TG^{Alb-cre+}$  (n = 19; 9 males, 10 females) and  $TG:Pdcd1^{-/-}$  mice (n = 16; 7 males, 9 females). (d) NMR metabolomics PLS – DA with coloured 95% confidence intervals, showing no distinct separation in metabolic profile between livers of 9-month-old  $TG^{Alb-cre+}$  and  $TG:Pdcd1^{-/-}$  mice (n = 5/group). (e) NMR-based metabolic analysis of lactate or glucose levels in livers of 9-month-old  $TG^{Alb-cre+}$  versus  $TG:Pdcd1^{-/-}$  mice (n = 5/group). (f-g) Representative PAS staining and IHC for BiP, CHOP, Ki67,  $\gamma$ -H2AX, and cl-Caspase 3 (f; scale bar = 100  $\mu$ m), with quantification (g) in non-tumour livers from  $TG^{Alb-cre+}$  (n = 5) and  $TG:Pdcd1^{-/-}$  (n = 6) mice. (h) Representative IHC for HA (scale bar = 200  $\mu$ m) in tumour (T) and non-tumour (NT) liver of  $TG^{Alb-cre+}$  and  $TG:Pdcd1^{-/-}$  mice. (i) Representative *in-situ* hybridization of *Tmf* mRNA (left; scale bar = 100  $\mu$ m) and related quantification (right) in livers from  $TG^{Alb-cre+}$  (n = 3) and  $TG:Pdcd1^{-/-}$  (n = 4) mice. Arrowheads indicate immune cell clusters. (j) IHC quantification for intratumoral CD8<sup>+</sup> and PDI<sup>+</sup> cells in Fig. 5o from livers of  $TG^{Alb-cre+}$  (n = 5) and

$TG:Pdcd1^{-/-}$  (n = 6) mice. (k-m) Liver immune cells were isolated and stimulated (with PMA and ionomycin) for cytokine production, cytokine-secreting CD8<sup>+</sup> T-cells (k), CD4<sup>+</sup> T-cells (l) and NKT cells (m) were measured by flow cytometry in 9-month-old  $TG^{Alb-cre+}$  (n = 4) and  $TG:Pdcd1^{-/-}$  mice (n = 4). (n-p) Liver immune cells isolated from 9-month-old  $TG^{Alb-cre+}$  (n = 4) and  $TG:Pdcd1^{-/-}$  (n = 4) mice with naïve (n), CD8<sup>+</sup>PDI<sup>+</sup> (o), and effector (p) CD8<sup>+</sup> T-cell populations measured by FACS. (q-r) Contour plot (q) and KDE plot (r) for LDH expression in CD8<sup>+</sup> TILs from livers of 9-month-old  $TG^{Alb-cre+}$  and  $TG:Pdcd1^{-/-}$  mice by MIBI (n = 3/group). (s) Schematic depiction of prolonged ATF6 $\alpha$  activation driving early liver injury and DNA damage through cellular stress and metabolic reprogramming that dampens immunosurveillance efficacy, perpetuating oncogenic signalling for progression to HCC in mice and humans. Scatter dot plot data are presented as mean values  $\pm$  SEM. Data in 12b,c,e,g,i,j-p were analysed by two-tailed unpaired *t*-test or Mann-Whitney test based on data normality distribution. Data in 12q were analysed by Mann-Whitney test. The distribution of LDH expression in 12r was visualized using overlaid KDE plots. Differences in cumulative distributions were evaluated using the Kolmogorov-Smirnov test. Mouse icons and schematic depiction were created in BioRender.

Heikenwalder, M. (2026) <https://BioRender.com/lgjnsy9>.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Data were collected with Microsoft Excel, Office 2019 (v16).

Data analysis All relevant data analysis have been described in detail in the Methods section of the manuscript.

For softwares:

GraphPad Prism software (version 9.3.1 or 10.0.3) was used for statistical analysis (generally presented as mean  $\pm$ SEM). Sample sizes and statistical tests used are indicated in the legends. Exact p-values over  $p < 0.0001$  are reported.

FlowJo (version 10) was used to analyze FACS data obtained from BD FACSFortessa machine.

Data from Metabolic Flux Analysis (Seahorse bioanalyzer) were calculated with Agilent Wave Software V2.6.

Histological staining and in-situ hybridization slides were analyzed by macro-based analysis by ImageJ (1.54g) or QuPath (v0.5.1).

10x Genomics cellranger-count pipeline (v5.0.1), FastQC (version v0.11.8), MultiQC (v1.7), the Scanpy package (v1.9.2), the Seurat R package (v2.4.3), the monocle package (v2.24.0) and the GSVA package (v1.48.3) was utilized to proceed and analyze the mouse 10x Genomics single-cell RNA sequencing data.

For Western blot analysis, quantification of bands of interest in the linear range of exposure was performed by densitometry using imageJ (1.53k).

The Maxquant9 (V2.4.3) and Persues R package were used to analyze the proteomics data.

Cutadapt v2.3, STAR aligner v2.7.0d\_022111, RSEM v1.3.1, Ensembl v84 gene annotations, FastQC v0.11.5, MultiQC v1.8, the R Bioconductor package DESeq2 v1.22.2, the Ingenuity Pathway Analysis (Qiagen, Redwood City, USA) were used to proceed and analyze bulk RNA-seq data at the SBP Genomics Core.

FastQC (v0.11.9), Trim Galore (v0.6.5), STAR aligner (V2.7.10), the subread R package (v1.6.4), dupRader, RSeQC(V2.6.4), the DESeq2 R package (V1.40.2), the dist R (V3.8), and the gProfiler2 R (V0.2.0) package were used to proceed and analyze bulk RNA-seq data at the Genomics & Proteomics Core Facility in DKFZ.

The Catalyst R package, the Cellprofiler Cellpose 2.0 plugin and OMIQ (<https://www.omiq.ai/>) platform were used to analyze data obtained from imaging mass cytometry.

NMR-based metabolomic data were proceed and analyzed with Bruker TopSpin 3.6.1 software, ChenomX NMR suite 8.5 software and the MetaboAnalyst 5.0 online platform ([www.metaboanalyst.ca](http://www.metaboanalyst.ca)).

LC-MS metabolic data analysis was performed using MS-Dial 4.9.2, enabling compound identification based on accurate mass and MS2 spectra, supported by an in-house retention time library.

The “SCAN.UPC” R/Bioconductor package, the “GSVA” (Gene Set Variation Analysis) Bioconductor package, the “metafor” R package, and the “sva” R package were used for analyzing the human ATF6 $\alpha$ -activation signature in different databases. The Kaplan-Meier survival analysis was performed in the Python using the lifelines package and visualized using matplotlib.

CUT&RUN data were analyzed using the nf-core/cutandrun pipeline v3.2.2 with Nextflow version 24.04.2, keeping default parameters and following software dependencies: bedtools (v2.30.0), bowtie (v2.4.4), deeptools (v3.5.1), fastqc (v0.12.1), picard (v3.1.0), python (v3.9.12), samtools (v1.17), Genrich (v0.6.1), TrimGalore (v0.6.6), ucsc (v377). CUT&RUN analysis identified direct target genes by using the HOMER’s annotatePeaks.pl tool.

ATAC-Seq data were analyzed using the nf-core/atacseq pipeline v2.1.2 with Nextflow version 24.0.2, using default parameters.

Pipelines and code used in data analysis are listed below:

Multiplexed ion beam imaging (MIBI): Low level processing is available at <https://github.com/a-ngelolab/toffy> and cell segmentation pipeline available at <https://github.com/mouseland/cellpose>.

Bulk RNA-seq: ENCODE long RNA-seq pipeline (<https://github.com/ENCODE-DCC/long-rna-seq-pipeline>) and Trim Galore (v0.6.5) (<https://github.com/FelixKrueger/TrimGalore>).

IMC: Correction for signal spillover of the metal isotopes were compensated using the Catalyst package in R with the script available at <https://github.com/NiklasVesper/ImagingCytometryTools>. The full CellProfiler pipeline for image segmentation with detailed settings and structure can be found upon request under: <https://github.com/NiklasVesper/ImagingCytometryTools>. All scripts for Neighborhood analysis are available upon request at: <https://github.com/NiklasVesper/ImagingCytometryTools>.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

For data-sets generated in this study:

The proteomics data are available at ProteomeXchange Consortium via the PRIDE database, under the Project accession: PXD045903. The bulk-RNA-seq data are available at SuperSeries GSE244344 (GSE244341 = TGA AV-gfp, TGA AV-cre or TGA AV-cre/fbp1; GSE244342 = TGA AV-gfp or TGA AV-cre + DEN/HFD; GSE244343 = Atf6+/+ or Atf6-/- DEN/HFD), and GSE244212 (3M TGA lbcre- or TGA lbcre+), GSE244213 (6M TGA lbcre- or TGA lbcre+), GSE285265 (Atf6fl/fl or Atf6 $\Delta$ Hep mice + CD-HFD). Raw reads were aligned to the reference mouse genome: Mus musculus (house mouse) genome assembly GRCh38 (mm10) from Genome Reference Consortium [GCA\_000001635.2 GCF\_000001635.20]. The single-cell RNA-seq data are available at GEO Submission (GSE243826) and GEO Submission (GSE285366). The single-cell RNA-seq data are available at GEO Submission (GSE243826) and GEO Submission (GSE285366). The CUT&RUN data are available at GEO Submission (GSE285262). The ATAC-seq data are available at GEO Submission (GSE285261). The array of comparative genomic hybridization data is available at GEO Submission (GSE242831). The NMR-based metabolomics data and LC-MS/MS metabolic analysis are available at the Metabolights database, via the study MTBLS13241.

For previously published datasets:

The human ATF6 $\alpha$ -activation signature was derived from the Molecular Signatures Database (MSigDB, [www.msigdb.org](http://www.msigdb.org)) Human Gene Set: ATF6\_TARGET\_GENES. 22 datasets with extensive whole-genome RNA expression data were chosen (TCGA-LIHC, GSE77314, LIRI-JP, GSE56545, GSE77509, GSE54236, GSE17856, GSE47197, GSE14520, GSE45436, GSE63898, GSE84005, GSE64041, GSE76297, GSE25097, GSE45114, GSE76427, GSE36376, GSE39791, GSE36411, GSE57957, GSE84598) to evaluate the correlation between the expression levels of genes and gene signatures in human HCC. The results here are in part based upon data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>. We also used data-sets from the following publications: Villanueva et al., 2015 (<https://doi.org/10.1002/hep.27732>); Montironi et al., 2023 (<https://doi.org/10.1136/gutjnl-2021-325918>); Haber et al., 2023 (<https://doi.org/10.1053/>

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	The respective sex and gender information are reported in Supplementary Information Table 2.
Reporting on race, ethnicity, or other socially relevant groupings	No further information about race, ethnicity, or other socially relevant groupings are reported.
Population characteristics	Human characteristics are reported in Supplementary Information Table 2.
Recruitment	No active recruitment of human participants was done in the frame of this study. The clinical samples and data we used—including tissue microarrays from HCC patients and their control group, as well as liver tissue sections and frozen samples from patients with liver disease or HCC—were all obtained from existing patient samples provided by collaborating hospitals or related institutions, in strict accordance with their relevant ethical regulations. The authors and collaborators of this study conducted research and analyses on the acquired samples and data, all accessible samples were analyzed, and there was no self-selection. The transcriptomic and proteomic data used in this study for liver cancer patients were all from previously published datasets.
Ethics oversight	<p>The respective ethics committee is listed in the Methods section.</p> <p>Human HCC tissue microarrays (TMAs) used in this study were obtained with informed patient consent from Prof. Kai Breuhahn as described by him previously (<a href="https://doi.org/10.1186/s12964-023-01169-2">https://doi.org/10.1186/s12964-023-01169-2</a>). The use of these TMAs in current study is approved by the institutional ethics committee of the Medical Faculty of Heidelberg University (S-206/2005).</p> <p>Liver sections and snap-frozen tissue samples from healthy donors and patients with hepatitis were obtained from Dr. Mohammad Rahbari and Dr. Nuh Rahbari with the approved institutional review board (IRB) protocol (2012-293N-MA) from the University Hospital Mannheim; from Dr. Susanne Roth in Department of Surgery at Heidelberg University Hospital with the approved ethical protocol S-629/2013; from Dr. Achim Weber with the approved application number KEK-ZH-Nr. 2013-0382 by the local ethics committee (Kantonale Ethikkommission Zurich) in University Hospital Zurich.</p> <p>Human liver sections involved in Spatial Biology and Imaging Mass Cytometry analysis were obtained from Dr. Maïke Hofmann. Written informed consent was obtained in all cases and the study was conducted according to the Declaration of Helsinki (1975), federal guidelines and local ethics committee regulations (Albert-Ludwigs-University, Freiburg, Germany, approvals 20-1066).</p>

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Plot experiments and previously published results (e.g. Pfister et al, Nature 2021; Dudek et al, Nature 2021) were used to estimate the sample size, such that appropriate statistical tests could yield significant results. No further statistical methods were used to predetermine sample size. The sample size and exact 'n' numbers are indicated in the Methods and Figure Legends.
Data exclusions	No data exclusion of human data. Mice with obvious cholemic phenotype were excluded from dietary experiment.
Replication	All experiments presented were conducted with sufficient mouse numbers to ensure statistical significance could be reached, particularly for experiments involving tumor studies. Biochemical or image based data were reproduced in multiple mice: e.g., Weight analysis of mice measuring transaminase levels, liver tumor development characterization, flow cytometry analyses, immunohistochemical staining, confocal analysis. Mouse in vivo and in vitro experiments were repeated at least three times. All attempts of replicating data were successful.
Randomization	Mice were randomly allocated into different groups to make sure the phenotype was homogeneous across groups, and were then fed with appropriate diet and/or administered their respective treatment regimens. Randomization of human patients was not applicable as no prospective trial/study was performed (no active recruitment of human patients, as indicated above) and human samples evaluated were obtained from pre-existing human patient cohorts/databases, adhering to ethical guidelines.
Blinding	Investigators were blinded to group allocation for all experiments in which blinding was technically feasible. Experiments of mice with

## Blinding

different genotypes on the same diet were blinded. Quantitative analyses, including serum transaminase measurements, IC/IF quantification, immunoblot densitometry, and flow cytometry (FACS) analysis, were conducted using sample code labeling. Blinding was not possible for studies comparing preclinical liver cancer mouse models in which features were visually distinguishable (e.g., normal chow pellets were brown, high-fat diet pellets were blue; obese vs. lean phenotypes; liver tumors inherently visible during dissection). Human patient data underwent pseudonymisation and was blinded to the analyzer.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

#### Antibodies

Primary antibodies: (Antibody dilutions followed manufacturer's guidelines)

4HNE Abcam ab48506  
 AFP R&D AF5369  
 APC anti-mouse IFN- $\gamma$  Antibody BioLegend 505810  
 ATF4 Cell Signalling 11815  
 ATF6 $\alpha$  Enzo ADI-905-729-100  
 ATF6 $\alpha$  OriGene TA336753  
 ATF6 $\alpha$  n-ATF6 $\alpha$  Signalway Antibody 32008  
 ATF6 $\alpha$  n-ATF6 $\alpha$ -Human reactivity Novus Biologicals 40256  
 ATF6 $\alpha$ -Human reactivity Abnova H00022926  
 B220 BD 553084  
 BiP Cell Signaling Technology 3177  
 CCL2-FITC ThermoFisher 11-7076-81  
 CCL5-PE BioLegend 149103  
 CD11b-BV650 BioLegend 101239  
 CD11b-BV711 BioLegend 101242  
 CD11c-BV421 BioLegend 117343  
 CD11c-PE.Dazzle BioLegend 117348  
 CD19-BV421 BioLegend 115527  
 CD19-FITC BioLegend 115505  
 CD1d-PE BioLegend 123509  
 CD200r3-PE BioLegend 142205  
 CD206 Proteintech 18704-I-AP  
 CD206-PE.Dazzle BioLegend 141731  
 CD3 Invitrogen MA1-90582  
 CD4 eBioscience 14-9766  
 CD4-AlexaFluor700 BioLegend 100536  
 CD4-PE BioLegend 100512  
 CD44-APC BioLegend 103012  
 CD44-PE.Cy7 BioLegend 103029  
 CD45-BV510 BioLegend 103138  
 CD62L-PE.Dazzle BioLegend 104448  
 CD62L-BV421 BioLegend 104436  
 CD8 Invitrogen 14-0808-82  
 CD86-AlexaFluor700 BioLegend 105023  
 CD8 $\alpha$ -PerCP.Cy5 BioLegend 100734  
 CHOP Cell Signaling Technology 5554  
 CHOP/GADD153 Santa Cruz sc-7351  
 CK19 Developmental Studies Hybridoma Bank TROMA-III AB\_2133570  
 cCASP3 Cell Signaling Technology 9661  
 CLEC4F R&D AF2784-SP  
 Coll-IV Cedarlane CL50451AP-1  
 CyclinD1 Cell Signaling Technology 2978  
 Eif2 $\alpha$ -Mouse Cell Signaling Technology 9722

F4/80-Mouse Linaris T-2006  
 F480-PE.Cy7 BioLegend 123114  
 FBP1 Sigma HPA005857  
 GAPDH Cell Signaling Technology 2118  
 GFP Novus Biologicals NB600-308  
 GP73 Santa Cruz sc-48011  
 Granzyme B Monoclonal Antibody (NGZB) - PE eBioscience 12-8898-82  
 GS Abcam ab16802  
 HA Abcam 9110  
 HIF-1 alpha Novus Biologicals NB100-105  
 IRE1 $\alpha$  Cell Signaling Technology 3294  
 IFN- $\gamma$  - APC BioLegend 505810  
 KDEL ER marker Santa Cruz sc-58774  
 Ki67 Thermo Scientific RM-9106-S1  
 Ki67-BV711 BD 563755  
 Ly6C- FITC BioLegend 128006  
 Ly6G-BV605 BioLegend 127639  
 MHCII- PerCP.Cy5 BioLegend 107625  
 Nk1.1- PE.Cy7 BioLegend 108713  
 NK1.1- BV421 BioLegend 108741  
 p-Eif2 $\alpha$  Cell Signaling Technology 3868  
 p-IRE1 $\alpha$  This paper This paper  
 p21 Abcam ab188224  
 p62 Biozol Diagnostica MBL-PM045  
 PARP Cell Signaling Technology 9532  
 pcJUN Cell Signaling Technology 3270  
 PCNA Cell Signaling Technology 13110  
 PD1 R&D AF1021  
 PD1-BV605 BioLegend 135220  
 PD-L1 Cell Signaling Technology 64988  
 PE/Dazzle™ 594 anti-mouse TNF- $\alpha$  Antibody BioLegend 506346  
 SiglecF-APC BioLegend 155507  
 TCR $\beta$ -BV650 BD 742483  
 TNF $\alpha$ - PerCP.Cy5 BD 506322  
 TNF- $\alpha$  -PE/Dazzle BioLegend 506346  
 TRAP $\alpha$  Abcam ab133238  
 TXNIP Cell Signaling Technology 14715  
 VINCULIN Sigma V9131  
 VINCULIN Santa Cruz sc-73614  
 XBP-1 Santa Cruz sc-8015  
 $\alpha$ -PD1 BioCell BE-0146  
 $\alpha$ -IgG BioCell BE-0090  
 $\gamma$ -H2AX Novus Biologicals NB100-2280

Secondary antibodies:

IRDye 680RD Donkey anti-Rabbit IgG Licor 926-68073  
 IRDye® 800CW Donkey anti-Rabbit IgG Licor 926-32213  
 IRDye 680RD Goat anti-Mouse IgG Licor 926-68070  
 IRDye® 800CW Goat anti-Mouse IgG Licor 926-32210  
 anti-rabbit-HRP Cell Signaling Technology 7074  
 anti-mouse-HRP Cell Signaling Technology 7076  
 anti-rat-HRP Cell Signaling Technology 7077  
 anti-goat-HRP Santa Cruz Biotechnology sc-2354  
 anti-goat DAKO P 0449  
 anti-mouse Abcam ab125904  
 anti-rat Jackson Immuno Research 312-005-045

Antibodies (used in IMC analysis)

CD45 Cell Signaling Technology 13917BF  
 CD68 BioLegend 916104  
 HLA-DR abcam ab176408  
 SMA fluidigm 3141017D  
 CD15 BioLegend 301902  
 CD3 Cell Signaling Technology 85061BF  
 CD39 abcam ab236038  
 CD163 fluidigm 3147021D  
 CD11c abcam ab52632  
 CXCR5 Cell Signaling Technology 721725  
 ATF-6 Abnova H00022926\_M03  
 TCF1 Cell Signaling Technology 2203BF  
 TOX abcam ab237009  
 FoxP3 Thermo fisher 14-4777-82  
 CD4 abcam ab181724  
 TCRgd abcam ab185753  
 E-cadherin Cell Signaling Technology 3195BF  
 b-Catenin Cell Signaling Technology Cat#33893

CD20 BD 555677  
 CD8a BioLegend 372902  
 PD-1 Cell Signaling Technology 86163BF  
 CD204 invitrogen 14-9054-82  
 GranzymeB fluidigm 3167021D  
 Collagen fluidigm 3169023D  
 CD45RO BioLegend 304202  
 CD34 abcam ab198395  
 HH3 Cell Signaling Technology 4499BF

Opal 520 Reagent Pack Akoya Biosciences, Inc. FP1487001KT  
 Opal 540 Reagent Pack Akoya Biosciences, Inc. FP1494001KT  
 Opal 570 Reagent Pack Akoya Biosciences, Inc. FP1488001KT  
 Opal 620 Reagent Pack Akoya Biosciences, Inc. FP1495001KT  
 Opal 650 Reagent Pack Akoya Biosciences, Inc. FP1496001KT

Antibodies (used in animal treatments)  
 InVivoMAB rat IgG2a isotype control Bio X Cell BXC-BE0089-100MG  
 InVivoMAB anti-mouse PD-1 (CD279) Bio X Cell BXC-BE0146-100MG

#### Validation

Validation of commercial antibodies was done on a regular quality control of each lot by the manufacturer (e.g. Biolegend "The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions"; "Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis."; "Every lot of product is quality tested against a "gold standard" reference lot. A new lot is only released based on our defined QC specifications to ensure lot to lot reproducibility and reliability. Biolegend guarantees the stability and performance of all our products shipped at room temperature. Wherever possible, knock-out validated antibodies were used. At CST, "we validate all of the antibodies we sell in-house using rigorous, application-specific testing". At Abcam "Biophysical QC enables confirmation of antibody identity at a molecular level, delivering robust, reproducible results for the best lot-to-lot consistency". "We can use this data to validate subsequent batches guaranteeing the highest specificity, sensitivity and consistency every time".

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

#### Cell line source(s)

Col0800: Kind gift from Dr. Rafael Carretero  
 FL83B: ATCC CRL-2390  
 HLE: Riken BRC Cell Bank

#### Authentication

FL83B were authenticated with purchase from ATCC (STR profiling for the cell line verifies its authenticity). HLE and Colos00 cells were not authenticated beyond in-house cell morphology validation.

#### Mycoplasma contamination

All cell lines are tested negative for mycoplasma contamination by ATCC and by Microbiological diagnostics DKFZ.

#### Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used in this study.

## Animals and other research organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

#### Laboratory animals

All animals in this study were described in Methods and Supplementary information. All mouse lines were either on a pure C57BL/6J background or crossed into in for at least 10 generations. Experimental schemes with timelines for treatment regimens are shown in corresponding Figures. Specifically, where indicated, DEN injections were done at 2 weeks old, special diets were started after 6 weeks old, AAV/oncogene injections were done between 6-10 weeks old, ASO injections were started at 4, 9 or 30 weeks old. Anti-IgG/PD1 treatment were done on 9-month-old Transgenic mice.

#### Wild animals

not used

#### Reporting on sex

All mice used in this study were age, gender, and genetic background matched. Detailed sex information of experimental animals were provided in respective figure legend or methods.

#### Field-collected samples

not used

#### Ethics oversight

Regierungspräsidium Karlsruhe, Karlsruhe, Germany, or National Institute of Health (NIH) guidelines of the United States, with approval from the Sanford Burnham Prebys Institutional Animal Care and Use Committee (IACUC), San Diego, CA, USA.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	This study was not performed in active clinical trials.
Study protocol	This study was not performed in active clinical trials.
Data collection	The respective data collection (fresh/retrospective cohort analysis/analyses of published data) process is listed in the Methods section.
Outcomes	This study was not performed in active clinical trials.

## Plants

Seed stocks	No plant material used in this study.
Novel plant genotypes	No plant material used in this study.
Authentication	No plant material used in this study.

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	<p>Please see Methods and Supplementary Information.</p> <p>The isolation and staining of lymphocytes for flow cytometry followed the protocol described in Methods. Animals were sacrificed and livers perfused with 0.9% NaCl buffer. Livers were collected, minced, digested with Collagenase and DNase, and subsequently passed through a 100µm filter. Hepatic lymphocytes were then purified by a 2-step Percoll gradient. Spleens were passed through 100µm mesh and washed to isolate splenic lymphocytes. The samples were treated with red blood cell lysis buffer for 5 minutes at RT, followed by a washing step.</p> <p>For lymphocyte stimulation, cells were cultured in RPMI 1640 supplemented with 2%(v/v) FBS. Cell Activation Cocktail with Brefeldin A (Biolegend #423304) and Monensin Solution (Biolegend #420701) were diluted in the medium at the rate of 1:500 and 1:1000, respectively. Antibody staining was done in the presence of Fc receptor blockade in flow cytometry-activated cell sorting (FACS) buffer. For live/dead cell discrimination, the ZombieDyeNIR dye was used according to the manufacturer's guidelines. After washing with FACS buffer and centrifugation (400g, 5min, 4°C), cells were stained for 40min at 4°C with 25µl of titrated antibody master mix and then washed. For sorting experiments, the samples were then sorted using FACS. eBioscience IC fixation (#00-8222-49) was used to fix samples for samples requiring only surface staining for flow cytometry, as directed by the manufacturer's guidelines. For samples requiring intracellular staining, eBioscience Perm buffer (#00-8333-56) was used. BD FACSFortessa was used to analyze the stained cells, and FlowJo was used to analyze data. In collaboration with the DKFZ FACS core facility, a FACS Aria II machine and a FACS Aria FUSION machine were employed for sorting.</p>
Instrument	Cells were analyzed using BD FACSFortessa or BD FACSSymphony. For sorting, a FACS Aria II and a FACS Aria FUSION in collaboration with the DKFZ FACS core facility were used.
Software	Collected data was analyzed by FlowJo V10.2.
Cell population abundance	Absolute quantification by using CountBright™ Absolute Counting Beads.
Gating strategy	Gating strategy were provided in Supplementary Figure.

Gating strategy

Debris exclusion by FSC-A/SSC-A. Doublets were excluded by using FSC-A/FSC-H and SSC-A/SSC-H gates. Life/Dead exclusion was performed. Remaining cells were analyzed according to displayed markers.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.